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Abstract  
Acute pancreatitis is an important disease in companion animal medicine, and 
diagnostic methodology available to veterinary practitioners is often limited. Evidence 
based principles for the management of this common disease are also lacking. This 
thesis explores the current diagnostics of canine pancreatitis and management of this 
condition, reviewing the literature across both the veterinary and human medical fields. 
 Assessment of the specificity of canine pancreatic-specific lipase (cPL) was 
made in a post-mortem study and calculated to be 82-92%, with a correlating 
sensitivity of 45-55%. A multi-centre study of dogs presenting with clinical signs 
consistent with acute pancreatitis to assess a new laboratory test, serum canine 
pancreatic elastase-1 (cPE-1) was also performed. This test had a sensitivity ranging 
from 66-79%, with a specificity of 92%. The sensitivity of both laboratory tests was 
greater in dogs with severe disease.  
To assess potential treatment options, a clinical severity score was established, 
with gut health, respiratory complications, cardiac complications, and blood pressure 
determining the final score. Retrospectively, plasma administration did not appear to be 
associated with treatment success, but this conclusion was limited by the retrospective 
nature of the study and small numbers of dogs. Out of the other factors, fasting for 3 or 
more days was the one most significantly associated with mortality. To begin 
assessment of nutritional modalities, pancreatic responses in healthy dogs to varying 
dietary fat composition (ranging from 4%DW to 16% DW) was assessed, with no 
statistical difference determined. On the basis of this, a pilot study of 10 dogs with 
severe pancreatitis was undertaken, with 5 dogs fed enterally and another 5 dogs were 
given total parenteral nutrition (TPN). No differences in mortality or days of 
hospitalisation between the two were found, but there were significantly less episodes 
of vomiting or regurgitation in the dogs given food (p < 0.001). There were also more 4 
 
severe complications (4/5) in the TPN group compared to the enteral feeding group 
(2/5).   
In all, this thesis supports the new premise of enteral feeding of dogs with acute 
pancreatitis early in the course of disease, determines the sensitivity and specificity of 
two diagnostic tests and has established an objective marker of disease severity.  
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Introduction 
Pancreatitis is an important disease of dogs. Acute pancreatitis can cause 
profuse vomiting with resultant dehydration and hypovolaemia (Simpson, 1993; 
Williams and Steiner, 2005). There is a high mortality rate associated with systemic 
effects of the disease, and dogs often require intensive treatment and hospitalisation 
(Ruaux and Atwell, 1998b).  
Predicting which animals will develop severe complications is difficult, 
although there is a significant association between fatality and existence of concurrent 
diseases such as diabetes mellitus, hyperadrenocorticism, and epilepsy (Cook et al., 
1993; Hess et al., 1998; Ruaux and Atwell, 1998b). Traditional biochemical methods of 
diagnosing pancreatitis such as elevation of serum amylase and lipase concentrations 
are poor predictors of mortality (Mansfield et al., 2003). Despite an increase in the 
number of studies in the past decade addressing the diagnostic difficulties faced in 
canine pancreatitis, it is still unclear how sensitive and specific the currently used 
diagnostic modalities are. Part of this difficulty is a lack of a true gold standard, as 
pancreatic histopathology is seldom performed in severely unwell dogs with 
pancreatitis. It is also uncertain as to how the pancreatic inflammation seen 
histologically correlates to clinical severity, or indeed if it is the primary reason for 
presentation of the animal.  
Treatment of acute pancreatitis is non-specific and aimed at correcting 
secondary consequences of the disease (such as hypovolaemia or pain for example) 
rather than directly treating the pancreatic inflammation. There is a lack of controlled 
studies in treatment of this condition, and most recommendations are extrapolated from 
animal experimental models and human gastroenterology. An important aspect of 
developing any prospective treatment trials is to ensure that animals of equal clinical 12 
 
severity are compared in studies, in order to ensure that any benefits are due to the 
treatment intervention rather than the study population.  
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Purpose 
 
This body of work aims to answer the following questions 
-  In a cohort of dogs who display clinical signs that could be consistent with 
canine pancreatitis, what is the specificity and sensitivity of serum canine 
pancreatic-elastase 1, a potentially new diagnostic test? 
-  In a sufficiently large cohort of dogs with diseases of similar severity to acute 
pancreatitis, what is the clinical specificity and sensitivity of canine pancreatic 
lipase?  
-  Is there an effective and robust way to characterise the clinical severity of 
canine pancreatitis to aid in the development of future research into 
optimisation of treatment strategies?  
-  Does the administration of plasma or minimal enteral nutrition have any 
potential benefits in the treatment of acute pancreatitis? 
-  Does differing fat content of diet cause differing responses of the canine 
pancreas, and necessitate specific nutritional strategies? 
-   Is early interventional enteral nutrition delivered proximal to the pylorus well 
tolerated by dogs with acute pancreatitis? 
-  Is there evidence that early interventional enteral nutrition may be of benefit in 
treating dogs with severe acute pancreatitis?  
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Chapter 1:  Literature Review 
1.1 Normal anatomy and physiology of the canine pancreas 
 
In order to fully understand the potential complications of pancreatitis in dogs and 
devise treatment options, it is important to be cognisant of the role and location of the 
pancreas. The anatomical location and control of exocrine pancreatic functions are 
directly relevant when considering the aetiologies of pancreatitis, as well as the 
resultant clinical signs and optimal treatments. 
1.1.1 Normal Canine Pancreatic Anatomy 
 
The pancreas is composed of a left and right lobe, joined in a small central body 
(Williams, 1996). Embryologically, the right lobe is formed from the ventral 
primordium (bud) and contains a majority of polypeptide-producing cells (Evans and 
Christensen, 1979; Williams, 1996). The left lobe develops from the dorsal bud, and 
predominantly contains glucagon secreting cells (Evans and Christensen, 1979; 
Williams, 1996). In the dog there are usually two pancreatic ducts leading to the small 
intestine. The duct that originates from the ventral bud is the pancreatic, or Wirsung’s, 
duct and opens adjacent to the bile duct on the major duodenal papilla (Evans and 
Christensen, 1979; Williams, 1996). The accessory, or Santorini, duct originating from 
the left lobe opens distally to this at the minor duodenal papilla (Evans and Christensen, 
1979; Williams, 1996). In some dogs only one duct (generally the accessory as it is the 
largest), is present and so all pancreatic juice enters the intestine through the minor 
duodenal papilla (Evans and Christensen, 1979; Williams, 1996). This differs from 
people, who normally have one duct only and are predisposed to obstructions of this 
duct (Al Mofleh, 2008).  
The pancreas is situated in the cranial part of the abdomen (Figure 1.1). The 
body follows along the mesenteric surface of the duodenum, curving at the first 17 
 
duodenal flexure (Evans and Christensen, 1979; Williams, 1996). The right lobe then 
travels alongside the duodenum, and may reach the caecum. The left lobe is deeper in 
the mesentery, and sits adjacent to the pylorus. This results in the pancreas having 
direct physical contact with the liver, transverse colon, left kidney and spleen, as well 
as the surrounding omentum (Evans and Christensen, 1979; Williams, 1996). 
Inflammation surrounding the pancreas therefore has the potential to directly affect 
multiple organs within the abdomen.  
 
Figure 1.1 An in situ representation of the anatomical location of the pancreas, and the 
organ’s close proximity to other abdominal structures.   
 
The functional units of the exocrine pancreas are acinar cells. The bulk of the 
exocrine function is performed by the central acinar cells, with an extensive duct 
system allowing complex communication between the exocrine and endocrine cells of 
Gall bladder 
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the pancreas. The endocrine function, which will not be discussed in detail in this 
thesis, is performed by the islets of Langerhans, which are scattered throughout the 
tissue. There is close communication between the exocrine and endocrine cells, 
ensuring coordination of digestion and the production of endocrine hormones such as 
insulin (Charles, 2007; Evans and Christensen, 1979; Williams, 1996)..  
The blood supply to the pancreas originates from the coeliac and cranial 
mesenteric arteries. They branch off to form the cranial and caudal pancreatico-
duodenal arteries respectively, and enter the right limb of the pancreas (Evans and 
Christensen, 1979; Williams, 1996). The splenic artery, which itself arises from the 
coeliac artery, supplies the left limb. There are parallel venous systems that drain into 
the portal vein (Evans and Christensen, 1979; Williams, 1996). The pancreatic lobule is 
supplied by a single arterial branch, and the acinar cells are supplied by a continuous 
network of capillaries (Charels, 2007; Evans and Christensen, 1979). The artery often 
supplies islets first and therefore bathes the acinar cell in relevant hormones, or the so-
called ‘insuloacinar’ portal system’ (Charles, 2007; Cuthbertson and Christophi, 2006). 
The downstream supply to acinar cells makes them uniquely susceptible to poor 
perfusion and hypotension, an important factor in the development of pancreatitis, to be 
discussed in section 1.2.2.4.  
The nervous supply to the pancreas is not discretely localised, but rather forms a 
large web of nerve fibres, with many nerve trunks throughout the parenchyma of the 
pancreas (Evans and Christensen, 1979; Williams, 1996).. This nervous supply 
originates from the vagus and splanchnic nerves, which travel alongside the coeliac and 
caudal mesenteric arteries (Evans and Christensen, 1979; Williams, 1996).. The 
neurogenic supply is also intricately involved in the exocrine function of the pancreas.  19 
 
1.1.2 Normal pancreatic physiology 
The pancreas has a number of exocrine functions. The pancreas is responsible 
for secreting enzymes into the small intestine to assist in degradation of proteins, fats 
and carbohydrates. To protect itself from the digestive nature of these enzymes the 
pancreatic enzymes are stored as zymogens within the pancreatic acinar cells. 
Zymogens are catalytically inactive precursors of digestive enzymes that are secreted 
into the lumen of the small intestine in response to food. Enterokinase, a peptide 
produced by small intestinal mucosal cells, activates trypsin. Trypsin subsequently 
activates an enzyme cascade, cleaving the activation peptides from other digestive 
zymogens, as shown in Figure 1.2 (Rinderknecht, 1986). 
                                                 Trypsinogen 
 
Trypsinogen Activation Peptide 
Enterokinase 
 
 
Trypsin 
 
Chymotrypsinogen              Chymotrypsin 
Proelastase                Elastase 
Kallikreinogen                Kallikrein 
Procarboxypeptidase A              Carboxypeptidase A 
Procarboxypeptidase B              Carboxypeptidase B 
Prophospholipase A              Phospholipase A 
 
Figure 1.2: Diagrammatic representation of trypsin activating the pancreatic cascade 
within the duodenum 
   
  The pancreas is able to protect itself from auto-digestion in a number of ways. As 
already mentioned, firstly the digestive enzymes are stored in the acinar cells as inert 
zymogens, and theoretically are only activated within the lumen of the duodenum. 
Secondly, within the acinar cell the zymogen granules are kept separately from the 
lysosomal granules enclosed in membrane bound organelles (Steer and Meldolesi, 
1988). Lysosomal enzymes are produced in the ribosomes attached to the rough 
endoplasmic reticulum, in the same manner that zymogens are, but are additionally 
glycosolated and phosphorylated as they pass through the Golgi complex (Frossard and 20 
 
Pastor, 2002; Steer and Meldolesi, 1988). Studies have shown that these two enzyme 
groups are kept physically apart throughout all stages of their production (Scheele, 
1980). Thirdly, location of pancreatic secretory trypsin inhibitor (PSTI) within the 
acinar cells allows for immediate inhibition of trypsin should it be prematurely 
activated within the acinar cells. PSTI is produced and stored in the same location as 
the digestive enzymes (Laskowski and Kato, 1980; Rinderknecht, 1986). Finally, 
should any activated trypsin reach the circulation, larger anti-proteases in the blood 
have the capacity to deactivate some circulating trypsin (Rinderknecht, 1986; Williams, 
1996).  
1.1.2.1 Control of exocrine function 
The control of exocrine secretion is an important aspect in considering 
nutritional management of pancreatitis. There are four phases of pancreatic secretion: 
basal, cephalic, gastric and intestinal (Abou-Assi and O'Keefe, 2001). The basal rate is 
slow and present during fasting; the cephalic is vagally mediated and stimulated by 
sight, smell and taste; the gastric is stimulated by the stomach distending with food 
causing gastrin release; and the intestinal phase occurs when chyme enters the 
duodenum, via secretin and cholecystokinin (CCK) production. It would appear that 
secretin stimulates production of the aqueous component of pancreatic secretion in the 
ducts, whilst CCK stimulates production of digestive enzymes in the acinar cells 
(Frossard and Pastor, 2002). There is also a pathway not controlled by CCK that 
stimulates pancreatic secretion when food is in the duodenal lumen. The amount of 
digestive enzymes contained in pancreatic secretions increases relative to the amount of 
bicarbonate 1-2 hours following a meal, with a second peak 8-11 hours later comprising 
a larger volume and containing a greater amount of bicarbonate (Williams, 1996). 
There are other substances that can also stimulate secretion, such as acetylcholine, 21 
 
gastrin, substance P, and vasoactive peptide (VIP); but their complete role is not yet 
fully understood (Abou-Assi and O'Keefe, 2001). 
The enteropancreatic pathway has been studied a lot in rodent models, and to 
some extent in people, but very little in dogs. One early experimental study (utilizing a 
fistula model in 4 dogs) measured pancreatic secretion and quantified proteins and 
bicarbonates in those secretions (Konturek et al., 1979). They found that there was an 
increase in pancreatic protein secretion when amino acids and fat were delivered both 
intravenously and directly into the duodenum. This response seemed to be particularly 
triggered by L-tryptophan and L-phenylalanine. This suggested that end-products of 
protein digestion may be more potent stimulants than protein as a whole. In dogs 
therefore, there could also be an enterohepatic reflex that stimulates pancreatic 
secretory function after absorption of L-isomers of amino acids from the gut.  
One canine experimental study also assessed the interaction of various 
substances on pancreatic secretion (Beglinger et al., 1984). They determined that in 
dogs, CCK alone did not increase pancreatic protease or bicarbonate secretion, but 
when given with secretin there was an increase. This didn’t change when atropine was 
administered, except in the presence of phenylalanine, suggesting the cholinergic 
control of pancreatic secretion is probably not present in dogs. This has some clinical 
relevance, as it is thought that the cephalic (or anticipation) phase of pancreatic 
secretion is vagally mediated. If vagal (cholinergic) mediation doesn’t occur in dogs, 
then exposure to smells and sight of food may have little effect on pancreatic secretion. 
In a landmark study that helped to shape the nutritional management of acute 
pancreatitis for decades, the effects of diet and anatomical location of food delivery 
were assessed in healthy dogs (Ragins et al., 1973). It was concluded that maximal 
pancreatic stimulation occurred in dogs when an acidic fluid containing amino acids 22 
 
was delivered to the duodenum, but not when delivered to the jejunum. This led to the 
avoidance of feeding methods that resulted in food being present in the duodenum.  
Further, the concept of an ‘ileal brake’ has been proposed. This is when 
nutrients reach the distal ileum or colon there is negative feedback on a wide range of 
intestinal functions. In a canine experimental study this was demonstrated when a 
complete human liquid convalescent diet was infused into the colon and ileum (Wen et 
al., 1995). This delayed phase 3 of the migrating motor complex (MMC) in the 
duodenum and adjacent ileum and increased the release of inhibitory substances on 
pancreatic secretion. These substances in the dog also inhibit gastric secretions, gastric 
emptying and the normal fasting motility of the stomach. The ileal brake concept was 
proven in another canine experimental model, and appeared to be most strongly 
stimulated by tryptophan (Niebergall-Roth et al., 2000). This suggests that although 
food within the intestine may initially cause increased pancreatic secretions, once it 
reaches the distal ileum or colon, there is negative feedback on the pancreas, perhaps 
ameliorating any adverse effects.  
1.2 Pancreatitis: The Disease 
1.2.1 Animal experimental models 
In order to fully evaluate the advances made in understanding the 
pathophysiology of pancreatitis it is important to have an understanding of the 
experimental models used, and how they may relate to canine pancreatitis as it naturally 
occurs. These methods were well summarised by Su et al in 2006, and are reviewed 
briefly here, with both invasive and non-invasive methods for inducing pancreatitis (Su 
et al., 2006). The most commonly applied non-invasive method is administration of a 
CCK analogue (cerulein) intravenously, subcutaneously or into the peritoneum. It has 
been applied to a number of species, including dogs (Simpson et al., 1995). This results 
in a mild, self-limiting form of pancreatitis that is useful for studying lung-associated 23 
 
pathology, and so is likely reflective of only a small proportion of dogs seen in 
veterinary practice. A dietary model feeding a choline-deficient diet with ethionine 
(CDE diet) is simple and highly reproducible, and causes a severe, necrotizing form of 
pancreatitis (Lombardi et al., 1975). This correlates well with the severe acute 
pancreatitis seen in dogs, as it results in hypovolaemia, hypoxia, pancreatic necrosis 
and acidosis. This model is very useful for assessing interventions that might reduce 
mortality, but to date is considered species-specific and sex-specific, as it only affects 
young female mice (Niederau et al., 1992). Other non-invasive methods such as ethanol 
administration, gene knockout or immune modulation are difficult to reproduce and 
costly to perform, so are seldom undertaken unless studying a specific genetic 
abnormality or pharmacological intervention, and are typically limited to rodents. A 
newer developed protocol in mice is the administration of high-dose arginine, which 
results in dose-dependent pancreatic necrosis (Hegyi et al., 2004). Long-term 
administration results in chronic pancreatitis, which may also be of benefit in canine 
medicine as it could allow for evaluation of the insulin-acinar axis (Weaver et al., 
1994). 
Invasive methods of inducing pancreatitis are probably more applicable for 
relating to gallstone induced disease in people, but there may be some relevancy to 
dogs. Invasive methods have been performed in a range of species, including dogs and 
cats. These invasive methods include a closed duodenal loop model that closes off the 
pancreatic duct and diverts bile to the jejunum (Pfeffer et al., 1957). This model 
induces necrosis rather than inflammation and carries a high mortality rate. If the loop 
is temporarily closed and trypsin along with sodium taurocholate is injected into the 
duodenum, the pancreatitis is milder and interventions are easier to study (Orda et al., 
1980). It is unknown how much of a role duodenal reflux has in causing pancreatitis in 
dogs, and so this may not be a valid method for comparative studies. Perhaps the most 24 
 
promising methodology for canine disease is combined hypersecretion (injection of 
CCK) and low-dose infusion of glycodeoxycholic acid into the pancreatic ducts 
(GDOC) (Schmidt et al., 1992). This method is perhaps the most appropriate for 
comparative purposes as it causes widespread necrosis and inflammation of the organ; 
however it poses some technical challenges. Other invasive methodologies are 
technically complex, such as antegrade pancreatic duct perfusion, duct ligation, 
ischaemia-perfusion models or biliopancreatic duct injections of taurocholate, and all of 
which produce severe pancreatitis.  
1.2.2 Pathophysiology of pancreatitis 
  
There has been a considerable amount of work elucidating the cellular events 
that initiate pancreatitis and the resultant inflammatory cascades over the past three 
decades. These investigations have been on experimental rodent models (unless 
otherwise stated), with a resultant extrapolation to naturally occurring disease that may 
not always be appropriate (Su et al., 2006).  
1.2.2.1 Initiating cellular events 
Pancreatitis develops when there is excessive activation of trypsin and other 
pancreatic proteases within the pancreas, which overwhelm the safeguards of both PSTI 
within the acinar cell and anti-proteases in the circulation (Lasson and Ohlsson, 1984). 
The local and distant inflammatory effects of pancreatitis are mediated by a range of 
inflammatory pathways, and severe disease is perpetuated by splanchnic circulatory 
failure, as discussed further in this section.  
The earliest event in pancreatitis occurs when there is activation of trypsinogen 
to trypsin within the acinar cell, as confirmed by electron microscopy and 
ultrastructural studies (Lerch et al., 1992; Rinderknecht, 1986; Saluja et al., 1997; Steer 
and Meldolesi, 1988). A secretory (or apical) block develops, where zymogen granules 25 
 
are not secreted into the intestinal lumen as normally for degradation by enterokinase 
(Saluja and Steer, 1999). This block is likely due to microtubular dysfunction, and may 
result from oxidative stress in some cases (Windsor and Hammodat, 2000). 
As a result of this block, co-localisation of zymogen granules and lysosomal 
proteases develops, where trypsinogen is activated to trypsin by lysosomal proteases 
(Rinderknecht, 1986; Steer and Meldolesi, 1988). This is depicted in Figure 1.3, and 
has become widely accepted as the main initiating step in pancreatitis. As discussed in 
section 1.1.2, lysosomes are normally kept physically separated from zymogen granules 
within the acinar cell. Trypsin has been shown to be activated by cathepsin B, a 
lysosomal protease (Rinderknecht, 1986). Although concurrent administration of a 
cathepsin B inhibitor significantly reduced the development of pancreatitis in one 
study, it didn’t completely prevent it (Saluja et al., 1997). It is likely the inhibitor used 
in this experiment was only a partial antagonist, as confirmed later in an in vitro model 
(Saluja and Steer, 1999).  There may also be other mechanisms involved, as cathepsin-
B deficient mice can also develop pancreatitis, albeit to a lesser severity than mice 
without that deficiency (Halangk et al., 2000). Additionally, hypotension has been 
shown to cause trypsin activation prior to the appearance of proteases, suggesting there 
are other cellular mechanisms that have not been fully elucidated that lead to this 
premature trypsin activation (Mithofer et al., 1995; Rinderknecht, 1986). Co-
localisation may also occur due to a dysfunction of the normally coded separation of 
the two components (Steer et al., 1984). 
The role of inappropriate trypsin activation in initiating pancreatitis is 
exemplified by a mutation in the cationic trypsinogen gene that is linked to recurrent 
pancreatitis in people (Whitcomb et al., 1996). It is suspected that this mutation results 
in failure of the protective mechanism against activation, and so prematurely activated 
trypsin accumulates in the acinar cell (Bhatia et al., 2000). 26 
 
Experimental models have shown that the pH of the acinar cell is very 
important in determining the likelihood of the lysosomal and zymogen granules co-
localising (Bhoomagoud et al., 2009; Noble et al., 2008; Sherwood et al., 2007). The 
most recent of these studies showed that low acinar pH alone did not lead to the 
development of pancreatitis, but it did heighten zymogen activation following cerulein 
stimulation. Trypsinogen activation also appears to require the presence of intra-
cytosolic calcium in some in vitro experiments (Kruger et al., 2000; Mooren et al., 
2003). It is proposed that Ca
2+ located in the zymogen granules has a protective 
function against activation of trypsin, but within the cytosol acts in conjunction with 
CCK as an intra-cellular messenger for the release of lysosomal proteases (Kruger et 
al., 2000). In fact, blockade of the calcium signalling system within the cells stops 
production of trypsinogen activation peptide (TAP) (Mooren et al., 2003; Raraty et al., 
2000; Sherwood et al., 2007).  
 
 
Figure 1.3: Demonstration of the co-localisation theory. In the normal cell on the left, 
the zymogen granules and lysosomes are manufactured within the Golgi apparatus, but 
processed and transported to the apex separately. In the abnormal cell on the right, 
there is an apical block, which allows zymogen granules to fuse with lysosomes. 
Cathepsin B, a lysosomal protease is then able to activate trypsinogen to trypsin in the 
acinar cells. Pancreatitis develops when the local safeguard pancreatic secretory 
trypsin inhibitor (PSTI) is overwhelmed by trypsin, and pancreatic enzymes are then 
activated within the acinar cell.  
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Trypsin and other activated pancreatic enzymes are likely to be directly 
damaging to the acinar cell when production overwhelms the PSTI present in the acinar 
cells. The potential direct actions of these enzymes are detailed in Table 1.1.  
Table 1.1 
ENZYME  PATHOPHYSIOLOGICAL ACTION 
Trypsin  Activation of other proteases 
Coagulation and fibrinolysis (disseminated intravascular coagulation) 
Phospholipase 
A2 
Hydrolysis of cell membrane phospholipids 
Pulmonary surfactant degradation (cell necrosis and liberation of toxic 
substances such as myocardial depressant factor, respiratory distress, 
neurological signs) 
Elastase  Degradation of elastin in blood vessel walls (haemorrhage, oedema, 
respiratory distress) 
Chymotrypsin  Activation of xanthine oxidase and subsequent generation of oxygen-derived 
free radicals (membrane damage) 
Kallikrein  Kinin generation from kininogens 
Kinins  Vasodilation, pancreatic oedema (hypotension, shock) 
Complement  Cell membrane damage, aggregation of leucocytes (local inflammation) 
Lipase  Fat hydrolysis (local fat necrosis, hypocalcaemia) 
Role of pancreatic enzymes in the systemic pathophysiology of pancreatitis. Adapted 
from Williams DA (1996)  
 
Early experimental models favour the notion that the activated enzymes spilling 
over into the interstitium is the triggering factor for progression from mild to severe 
pancreatitis (Halangk et al., 2000).  
1.2.2.2 The recruitment of neutrophils and production of reactive oxygen species  
Following the direct damage to the pancreas, inflammation ensues. 
Inflammation is defined as vasodilation of local blood vessels, increased permeability 
of local capillaries allowing leakage to the interstitial spaces, clotting of fluid in the 
interstitial spaces, migration of granulocytes to affected tissue and swelling of cells 
(Guyton and Hall, 2006). Neutrophils contain agents such as superoxide (O2
-), 
hydrogen peroxide (H202) and hydroxyl ions (-OH
-) that are collectively termed 28 
 
reactive oxygen species (ROS). ROS are directly toxic to cells and further increase 
cellular and vascular permeability, as well as enhancing the expression of inflammatory 
mediators.  
Pancreatitis has been proven to be less severe in mice with neutrophil depletion 
(Bhatia et al., 1998a). However, other studies have shown that blockage of ROS 
doesn’t ameliorate pancreatitis, and so other factors must also contribute to 
development of severe disease (Wang et al., 1996; Wisner et al., 1988). One possible 
mechanism is via nitric oxide (NO) as discussed in the next section.  
Chemokines are a group of small molecular weight cytokines that have 
chemotactic properties, and therefore play a large role in recruiting leucocytes to areas 
of injury. Generally they are subdivided into the CXC and CC subfamilies based on 
their amino acid sequence (Bhatia et al., 2000). The CXC chemokines that possess a 
conserved amino acid sequence (ELR) at their N terminus are potent neutrophil 
attractors, and the best example of this group is interleukin-8 (IL-8). Neutrophil 
migration to the pancreas is thought to be mainly initiated byIL-8 early in the course of 
inflammation (Frossard and Pastor, 2002; Gross et al., 1992). 
The adhesion of leucocytes to the endothelial wall is via expression of 
intercellular molecule adhesion-1 (ICAM-1) and other selectins mediated by IL-8 and 
others (Bhatia et al., 2000; Makhija and Kingsnorth, 2002). ICAM-1 is an inducible 
molecule normally only expressed at low levels on endothelial surfaces, but has been 
shown to be increased in experimental pancreatitis (Frossard et al., 1999). ICAM-1 
knockout mice are protected to some extent against the development of acute 
pancreatitis and associated organ damage, emphasising the role of adhesion molecules 
in this disease (Frossard et al., 1999).  
One study recently analysed the role elastase and trypsin play in neutrophil 
migration in acute pancreatitis (Keck et al., 2005). They developed an in vitro 29 
 
assessment of neutrophils and cultured endothelial cells, then exposed them to 
increasing doses of trypsin and elastase, as well as in a correlating in vivo model of 
severe pancreatitis in rats. Using confocal microscopy it was found that both trypsin 
and elastase up-regulate expression of adhesion molecules on white blood cells and 
endothelial cells. What is most striking is that this was done in the absence of pro-
inflammatory cytokines or free radicals and so was a direct action. As this effect only 
occurred in the presence of serum, a co-factor such as complement may be necessary. 
Activated neutrophils then follow a chemokine gradient into the pancreatic 
tissue (Bhatia et al., 2000). The activated neutrophils and other leucocytes such as 
macrophages, may contribute to the development of inflammation in distant organs as 
they are produced by the bone marrow and are present in the circulation (Gloor et al., 
1998a). Leucocyte accumulation occurs initially in the perivascular areas of the 
pancreas, and then following oedema and the resultant change in permeability, the 
leucocytes egress to the pancreatic body (Pezzilli, 2009).  
Neutrophils have also been implicated in the shift from apoptosis to necrosis in 
pancreatic cells. Necrotic cells release cytosolic contents into the extra-cellular space 
and elicit a profound inflammatory response (Frossard and Pastor, 2002). Apoptotic 
cells, on the other hand, are rapidly phagocytosed by macrophages and don’t elicit an 
inflammatory response (Anderson and Wang, 1998; Majno and Joris, 1995). Milder 
forms of experimental pancreatitis have more apoptosis than necrosis (Bhatia, 2004; 
Kaiser et al., 1995). It may be that recruitment of neutrophils into the acinar cells 
promotes a shift from acinar cell apoptosis to necrosis (Windsor and Hammodat, 2000). 
This is probably intricately linked to pancreatic microcirculation (discussed in this 
1.2.2.4) and proportional to the degree of oxidative stress (Frossard and Pastor, 2002). 
There are also vasoactive mediators that have been implicated in the development of 
necrosis, such as endothelin-1 and PLA-2 (Al Mofleh, 2008).  30 
 
1.2.2.3 Nitric oxide (NO) and further oxidative stress 
 
  NO is a small inorganic molecular compound that has been shown to regulate 
pancreatic exocrine secretion, promote capillary integrity, inhibit leucocyte adhesion 
and modulate pancreatic microvascular blood flow (Ang et al., 2009; DiMagno, 2007; 
Dobosz et al., 2005). The biological functions of NO are diverse, as it can be regulatory 
or cytotoxic and the function is determined by the NO synthase (NOS) isoform 
involved in synthesis of NO, the location of NO production and the amount produced 
(Mashimo and Goyal, 1999). NOS isoforms are named after their initial location in the 
vascular endothelium (eNOS), neurons (nNOS) or macrophages (iNOS). Genetic 
mouse models with each isoform deleted have been developed to assess the role of each 
of these in a variety of inflammatory conditions. In the pancreas, eNOS and nNOS are 
constitutively expressed and are calcium-dependent enzymes that stimulate low levels 
of NO production. On the other hand, iNOS is calcium insensitive and produces high 
amounts of NO that circulates throughout the body (DiMagno, 2007).  
  Studies in experimental acute pancreatitis have had differing conclusions about 
the role of NO. Some have shown NO to confer a benefit (Molero et al., 1995; Werner 
et al., 1997), whilst others showed a minimal or a negative effect (Dabrowski and 
Gabryelewicz, 1994; Lomis et al., 1995). These differences may be explained by the 
different biological effects of the different NOS isoforms. Decreased eNOS function 
causes a shift from low-level production of NO to high-level ROS production and 
oxidative stress, a phenomenon that has been demonstrated in vascular diseases in 
people (DiMagno, 2007). One study using mice showed that early up-regulation of 
eNOS was associated with amelioration of pancreatitis severity, which was proposed to 
be due to maintenance of pancreatic microvascular blood flow as eNOS is localised to 
the vascular endothelium in the pancreas (DiMagno et al., 2004). Studies have also 
shown that eNOS is down-regulated in the latter stages of pancreatitis, whilst iNOS 31 
 
was greatly increased in the acinar cells and lungs, in proportion to the disease severity 
(Al-Mufti et al., 1998; Ang et al., 2009; Cheng et al., 2010; Ueno et al., 2005).  
 When NO concentration increases within cells due to increased iNOS 
expression, mitochondrial respiratory function is impaired and NO becomes 
peroxynitrite. Peroxynitrite is an oxidant that can cause lipid peroxidation, protein 
nitration, DNA strand damage and cell necrosis (Szabo, 2003). As well, NO can 
directly cause production of ROS, thereby perpetuating oxidative stress, and also 
stimulate prostaglandin production and activity. 
It has been shown that tumour necrosis factor-α (TNF-α) reduces expression of 
eNOS in bovine endothelial aortic cells and both Nuclear Factor kappa-B (NF-κB) and 
IL-8 increase expression of iNOS in the lung and pancreas during experimental rodent 
pancreatitis (Anderson et al., 2004; Leindler et al., 2004; Long et al., 2005; Ueno et al., 
2005). NO derived from nNOS is poorly studied in pancreatitis, but could potentially 
play a role in amplifying the neurogenic inflammation mediated by substance P, as 
discussed in section 1.2.2.7 (Bhatia et al., 1998b).  
It is still unclear the exact role NO plays in naturally occurring human 
pancreatitis, and there may be different roles associated with the aetiology and severity 
(Ang et al., 2009). One recent study showed a significant positive correlation between 
plasma NO and severity in a group of people with acute pancreatitis (Que et al., 2010). 
Oxidative stress was greatest in the group that developed systemic complications. 
Therapeutic manipulation of the NO system has had unproven benefit to date in human 
medicine (DiMagno, 2007). Further studies elucidating the role of NO and the various 
NOS isoforms are needed in canine pancreatitis.    
1.2.2.4 Pancreatic microcirculation 
 
Disturbed pancreatic microcirculation plays a very important role in pancreatic 
inflammation and permeability (Bassi et al., 1994; Borodin et al., 2006; Gardner et al., 32 
 
2008; Knoefel et al., 1994). In animal models, vasoconstriction within the pancreas 
appears to be an early event in acute pancreatitis (Kusterer et al., 1993; Schröder et al., 
1985). Additionally, administration of phenylepinephrine (a potent vasoconstrictor) 
converts mild, oedematous pancreatitis to a severe, necrotising form (Klar et al., 1991). 
In people, early onset spasm of large pancreatic vessels has been shown to correlate 
with poorly perfused areas of the pancreas, and subsequent high mortality rates (Takeda 
et al., 2005). One experimental study in rats also identified that lower pancreatic 
perfusion was associated with more severe pancreatitis (Foitzik et al., 1995).  
The vascular disturbance in pancreatitis is likely to be multi-factorial in origin 
and may occur as a result of increased vascular permeability resulting from 
inflammatory cytokines (to be discussed), the direct effects of pancreatic proteases, 
and/or microthrombi formation resulting from hypercoaguability (Gardner et al., 2008; 
Keck et al., 2005). In addition to these mechanisms, the pancreas is intrinsically 
susceptible to ischaemia, as demonstrated by subclinical pancreatitis being identified in 
people with hypovolaemia (Cuthbertson and Christophi, 2006). Following ischaemia or 
reperfusion there is increased adherence of leucocytes to endothelium and formation of 
ROS (Zhou and Chen, 2002). It is likely that a similar process occurs in dogs as well. 
Impaired lymphatic drainage could also contribute to poor circulation, as red blood 
cells can enter the lymph and enhance leucocyte adhesion (Foitzik et al., 1995). These 
factors are depicted in Figure 1.4. 
An additional cause of the disturbances in the circulation of the pancreas is the 
intricate exocrine-endocrine balance (Windsor and Hammodat, 2000). Due to the 
complicated and collateral blood supply, acinar cells are exposed to high concentrations 
of hormones produced in the islet cells. The capillary network in the pancreas is very 
permeable, facilitating this communication. It may well be that amylin, an 
inflammatory product originating from islet cells, could favour acinar necrosis by 33 
 
causing a selective reduction in pancreatic blood flow (Svensson et al., 1994). 
Metalloproteinase-9 (MMP) may also play a role in altering the permeability of the 
blood vessels and perpetuating the neutrophilic response (Al Mofleh, 2008).  
 
Figure 1.4 Demonstration of the changes in pancreatic microcirculation during 
pancreatitis. O2= oxygen; CO2 = carbon dioxide; PMN= neutrophils; ICAM= 
Intercellular adhesion molecule 
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1.2.2.5 Kallin-kallikrein system  
An early and direct action of pancreatic proteases is to cause the kallikrein-kinin 
system to become activated, which is depicted in Figure 1.5. The pancreas has a high 
tissue concentration of kallikrein, generally stored as prekallikrein (Griesbacher, 2000). 
Pancreatic tissue kallikrein releases kallidin, whilst plasma kallikrein releases 
bradykinin. Kinins precipitate oedema via vasodilation of arteries and increased 
capillary permeability. They are also potent activators of nociceptive neurones , attract 
cytotoxic factors into tissue and enhance production of prostaglandins (Griesbacher, 
2000).  There are two major kinin receptor types, with B2 constitutively expressed in 
tissue that becomes the major receptor during acute inflammation. The nociceptive and 
vascular effects of the kinin system are predominantly mediated by B2 receptors. 
Production of the kallikreins in acute pancreatitis has been confirmed in experimental 
models (Griesbacher, 2000; Shimizu et al., 1993). Kinins have a short biological half-
life, and are degraded by kininase II which is structurally identical to angiotensin-
converting enzyme (Thal et al., 1963). Along similar lines, B2 receptor antagonists 
appear experimentally to have beneficial effects on pancreatic blood flow, necrosis and 
survival in necrotising models even when given after induction of disease (Bloechle et 
al., 1998; Hoffmann et al., 1996; Satake et al., 1996). 35 
 
 
 
Figure 1.5 Representation of the kallikrein-kinin system, the actions of enzymes are 
solid arrows, whilst the metabolic pathways are broken arrows. Adapted from 
Griesbacher; 2000. There is the potential for blockage of the B1 and B2 receptors to 
have some beneficial effect in pancreatitis. LMW= low molecular weight; HMW = high 
molecular weight 
1.2.2.6 The complement system  
Whilst it is unknown to what extent or in what fashion activation of the 
complement system occurs in canine acute pancreatitis, it has been shown to be 
activated early in people with acute pancreatitis, and to a greater extent in those with 
severe disease (Gloor et al., 2003). It is most likely that the alternative complement 
pathway is initiated in pancreatitis, as there is an absence of antibodies or microbes as 
the primary trigger.  C5a is one of the most potent mediators of the complement 
system, and substantially enhances vascular permeability. Surprisingly, in a study using 
a mouse model where C5a receptors were genetically ‘removed’ it was actually found 
that the resultant pancreatitis was worse (Bhatia et al., 2001). It is not entirely 
elucidated as to why C5a appeared to be anti-inflammatory, but it may well be that it 
limits the recruitment of pro-inflammatory mediators (Bhatia et al., 2000; Saluja and 36 
 
Steer, 1999). In contrast to this, one group of researchers found a strong association 
between expression of C3a and necrotising versus oedematous pancreatitis (Hartwig et 
al., 2006). Additionally, blockade of the complement receptor 1 led to amelioration of 
the local pancreatic inflammation and down-regulation of the leucocyte-endothelial 
interaction. It is possible the conflicting conclusions of these studies are due to the 
different experimental model used. Alternatively it may be that the complement system 
is a complex one, with opposing and synergistic actions of various components within 
it.  
1.2.2.7 Substance P and the Renin Angitotensin System  
Substance P is a peptide produced by nerve endings that acts by binding to 
Neurokinin-1 (NK-1) receptors. As well as mediating pain, it is thought to increase 
vascular permeability, therefore potentially playing a role in progression of pancreatitis. 
A mouse study has shown up-regulation of NK-1 receptors and the amount of 
Substance P in acute pancreatitis (Bhatia et al., 1998b). It appears to be particularly 
related to lung injury, and genetic deletion of NK-1 receptors in mice is protective 
against the systemic effects of pancreatitis. It is also proposed that NO and Substance P 
interact and synergistically amplify pain and inflammation (Ang et al., 2009). No 
studies to date have assessed the role of Substance P in canine pancreatitis. 
One area that has been poorly investigated in both experimental and naturally 
occurring disease is the role the renin-angiotensin system (RAS) may play in the 
initiation and perpetuation of pancreatic inflammation (Pezzilli, 2009). Angiotensin-II 
receptors have been identified in the pancreas (Leung et al., 1999). Expression of genes 
encoding these receptors and metabolites of the RAS has been shown to be up-
regulated in acute pancreatitis (Leung et al., 2000). As RAS metabolites may trigger 
ROS production, this is an area that warrants further evaluation.  37 
 
1.2.2.8 Cytokine ‘storm’ 
Prior to, during, and after inflammatory cells have appeared within the pancreas 
there occurs activation of multiple cytokines and chemokines. This is a complexly 
mediated phenomenon, and has been referred to as a ‘cytokine storm’, with a multitude 
of cytokines all contributing to the clinical consequences (Makhija and Kingsnorth, 
2002; Mayer et al., 2000; Norman, 1998). Cytokines are small proteins produced in 
response to stimuli, and act to up or down regulate various aspects of the inflammatory 
process. There are an increasingly discovered number of cytokines that are produced by 
T cells to either drive or facilitate a Th1 or Th2 immune response. Th1 responses 
mediate cellular immunity and activate neutrophils, macrophages and natural killer 
cells. Th2 responses mediate humoral immunity via B cell activation or the recruitment 
of eosinophils. Each cytokine has the capacity to act synergistically with others, and 
there is a large overlap in their functions, as represented in Figure 1.6.  
The initiating step of this process in pancreatitis, as in many other inflammatory 
diseases, appears to be the activation of NF-κB (Gukovsky et al., 1998; Steinle et al., 
1999). NF-κB is a transcription factor that modulates the expression of most cytokines. 
High NF-κB expression in peripheral blood mononuclear cells from people with acute 
pancreatitis has been demonstrated, with a correlation to the development of systemic 
complications (Satoh et al., 2003). It also stimulates production of adhesion molecules 
as well as iNOS (Long et al., 2005).  
In one rodent model, cytokine activity within the pancreas was determined by 
tissue mRNA and real-time polymerase chain reaction (RT-PCR) (Norman et al., 
1997b). Early in the onset of pancreatic inflammation TNF-α and IL-1β were detected. 
IL-6 was located in the pancreas after some time, whilst distant expression of all these 
cytokines was evident in the lung, liver and spleen after a delayed period; but never in 38 
 
the kidney, heart or skeletal muscle. The amplitude of the cytokine expression 
correlated with the severity of pancreatic inflammation. 
Pancreatic acinar cells have been shown to be capable of producing TNF-α 
(Gukovskaya et al., 1997; Norman et al., 1995). TNF-α is synergistic with many other 
inflammatory cytokines, and also promotes cell adhesion (via ICAM) and programmed 
cell death (Makhija and Kingsnorth, 2002). IL-1 is a pro-inflammatory cytokine that is 
synergistic with TNF. The production of IL-1 requires IL-1β and two IL-1 receptors 
that have similarity to toll-like receptors. This production is mediated by a group of 
enzymes called caspases, which also cause the production of other inflammatory 
cytokines such as IL-8. The caspase family (previously known as interleukin-1 
converting enzyme) appears to favour necrosis over apoptosis compared to TNF-
mediated inflammation in acinar cells, and worsens severity (Norman et al., 1997a; Rau 
et al., 2001a; Rau et al., 2001b).  
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Figure 1.6 (previous page) Demonstration of the activation of the cytokine storm in 
acute pancreatitis. Systemic Inflammatory Response Syndrome (SIRS) results from the 
cytotoxic effects when the pro-inflammatory mediators (red)overwhelm the anti-
inflammatory mediators (blue) and is manifested as  vasodilatation and increased 
capillary permeability. TNF; tumour necrosis factor; IL, interleukin; IL-ra, IL-1 
receptor antagonist; NO, nitric oxide; ROS, reactive oxygen species or superoxide, AA, 
arachidonic acid; MCP-1, monocyte chemoattractant protein-1; RANTES, regulated on 
activation, normal T cell expressed and secreted. SIRS (Systemic inflammatory 
response syndrome) is a syndrome characterised by presence of capillary permeability, 
hypotension and subsequent organ changes.  
 
IL-1β is a potent facilitator of neutrophil migration and strongly associated with 
the development of systemic inflammatory response syndrome (SIRS) (Dinarello, 
1996). Additionally, it activates the transcription of ICAM-1 and NF-κB, further 
perpetuating the inflammatory cascade. The early activation of this cytokine has been 
demonstrated in experimental models of acute pancreatitis (Fink and Norman, 1997; 
Norman et al., 1997b; Tanaka et al., 1995). Its action is counteracted by an IL-1 
receptor antagonist (IL-1ra). In people with acute pancreatitis, an imbalance in IL-
1β:IL-1ra was highly predictive of pulmonary failure (Mayer et al., 2000). Further to 
that, IL-1 knockout mice did not develop pancreatitis, emphasising the role this 
cytokine has in the early initiation and progression of acute pancreatitis (Norman et al., 
1996).  
IL-6 is produced by a variety of mononuclear cells, endothelial cells and 
fibroblasts. It is produced in response to stimulation by TNF and IL-1β (Makhija and 
Kingsnorth, 2002). It is increased early in the course of experimental pancreatitis 
(Norman et al., 1997b). As it is more reliably measured than either TNF or IL-1β, it has 
been negatively correlated with prognosis in naturally occurring human acute 
pancreatitis (Chen et al., 1999a; De Beaux et al., 1996; Leser et al., 1991; Mayer et al., 
2000; Pezzilli et al., 1995).   
IL-8 is a pro-inflammatory chemokine intimately involved in neutrophil actions, 
both as an inciter and product of the Th1 profile. Similar to IL-6, concentration of IL-8 40 
 
has been correlated with the severity of naturally occurring pancreatitis in people (De 
Beaux et al., 1996; Pezzilli et al., 1995; Rau et al., 1997). Platelet activating factor 
(PAF) is a cytokine produced predominantly by neutrophils that has been extensively 
studied in experimental models. It appears to be particularly associated with lung injury 
(Formela et al., 1994). Blockade of this cytokine has led to reduction of lung-associated 
complications in naturally occurring disease in some studies, although there is not 
uniform agreement with this (Heinrich et al., 2006; Johnson et al., 2001; McKay and 
Imrie, 2004).  
In experimental studies, IL-10 has been assessed due to its anti-inflammatory 
effects, which favours a shift to a Th2 cytokine profile and down-regulates NF-κB 
transcription. There were some promising results with IL-10 ameliorating the severity 
of pancreatitis in experimental models (Kusske et al., 1996; Van Laethem et al., 1998). 
Additionally, IL-10 knockout mice were shown to get a more severe form of 
pancreatitis (Gloor et al., 1998b). Pre-treatment of rats with IL-10 also reduced iNOS 
levels, and increased TGF-β1, which correlated to an increase in the rate of apoptosis 
(Zhang et al., 2007b). This along with a demonstration that serum IL-10 was increased 
in people with severe pancreatitis suggested a potential treatment avenue (Chen et al., 
1999b). Unfortunately, IL-10 therapy has had limited success in treatment of human 
acute pancreatitis (Pezzilli, 2009).  
As the knowledge in this area continues to expand there are a multitude of other 
cytokines that are also being evaluated in pancreatitis; such as IL- 2, -4, -11, -18 
(Mayer et al., 2000; Rau et al., 2001a). Regulated on activation, normal T cell 
expressed and secreted (RANTES) is now known as CC chemokine ligand 5 (CCL5), 
and is produced by circulating T cells under the stimulation of TNF-α and IL-1. It is 
responsible for protection against viruses, and is a potent chemoattractant for recruiting 41 
 
leucocytes (Makhija and Kingsnorth, 2002). Similarly, monocyte chemoattractant 
protein-1 (MCP-1) is a potent leucocyte recruiter as well.  
Whether any of these inflammatory mediators become clinically important in 
canine pancreatitis, either from a treatment or aetiological point of view, remains to be 
seen. Certainly, it is highly likely that they contribute to systemic effects of disease to 
some extent. Frossard summarized very well the various genetic knockout studies that 
have been performed to elucidate the inflammatory process that occurs in acute 
pancreatitis (Frossard and Pastor, 2002). This has been reproduced with permission in 
Figure 1.7. This is a clear demonstration of the complexity and interaction of the 
inflammatory pathways, which emphasises that targeting just one cytokine would be 
unlikely to result in a substantial clinical benefit.  
 
 
Figure 1.7 reprinted with kind permission from Frossard and Pastor 2002. Dotted lines 
represent a positive or beneficial effect, whilst plain lines indicate a deleterious effect.  
In summary, the genetic knockout models have shown that genetic deletion of cathepsin 
B reduces intra-pancreatic production of trypsin; Deletion of the NK1R gene reduces 
lung associated injury; Deletion of TNF-α protects mice with pancreatitis via down-
regulation of ICAM-1; ICAM-1 deletion also protects against pancreatitis and distant 
organ disease; Over expression of metallothionein-1 (MT-1), which scavenges ROS is 
associated with less severe pancreatitis; Deletion of IL-1 protects against lung injury; 
Over-expression of IL-10 is protective to some extent.   42 
 
1.2.2.9 Perpetuation of disease 
Pancreatic and peritoneal inflammation may cause vomiting due to stimulation of 
peripheral chemoreceptors in the mesentery and circulating emetic agents may also 
reach the chemoreceptor trigger zone (CTZ) adjacent to the vomiting centre in the 
medulla in pancreatitis. Vomiting results in significant third space losses, and 
splanchnic circulation subsequently decreases as part of circulatory shock. The body 
can adjust for this by increasing the oxygen extraction from systemic circulation up to 
90% (Takala, 1996). It is thought that prolonged oxygen extraction > 70% can lead to 
regional ischaemia (Rowell et al., 1984). Ischaemia of the intestine increases 
permeability and mucosal acidosis, which as it progresses increases the rate of 
apoptosis of enterocytes and decreases nutrient transport of intestinal epithelial cells 
(Fink, 1991). Additionally, the increased bowel permeability that ensues leads to 
cytokine release, and skeletal muscle lysis (Wilmore et al., 1988). 
There are currently two proposed models as to how the intestine may contribute to 
the inflammatory state, although in reality it is likely to be a combination (Flint and 
Windsor, 2003).  
1.  The Gut Starter model: Neutrophils are primed during reperfusion of ischaemic 
intestine, and then are provoked by exposure to endotoxin in systemic 
circulation (Moore et al., 1994). This is mediated via PLA-2  in the mesenteric 
blood system (Gonzalez et al., 2001). The primed neutrophils are then potent 
mediators of distant organ dysfunction. 
2.  The Gut Motor model: Disruption of the intestinal barrier leads to translocation 
of bacteria and inflammatory cells to the portal venous and lymphatic systems, 
which activates downstream immune cells in the absence of infective foci 
(Meakins and Marshall, 1986). 43 
 
One porcine experimental pancreatitis study showed decreased intestinal blood flow 
caused mucosal acidosis (Juvonen et al., 1999). In people with severe acute 
pancreatitis, low mucosal pH has been shown to be closely related to development of 
multiple organ dysfunction syndrome (MODS) and death (Bonham et al., 1997). A 
calculated intramucosal pH ≤ 7.25 predicted death with an overall accuracy of 82% 
(sensitivity 100%, specificity 77%). This is a higher association than many of the 
clinical scoring systems or measurement of serum inflammatory markers described in 
later sections (Al Mofleh, 2008). It is also proposed that xanthine oxidase is produced 
on reperfusion of ischaemic intestine, leading to production of free radicals which 
perpetuate the inflammatory process (Fink, 1991).  
The intestinal barrier is a functional rather than strictly anatomical unit that is 
maintained by intestinal microflora, appropriate gut motility, digestive enzymes, mucus 
layer, epithelial layer, endothelial layer, mucosal-associated lymphatic tissue and the 
gut-liver axis. It is thought the epithelial layer is the most important part of the 
intestinal barrier, as it is a single cell layer that is very prone to disturbances in 
microcirculation (Flint and Windsor, 2003). In people and cats it has been shown the 
oxygen counter-current exchange system and the anatomical position of the villi 
circulation predispose to hypoperfusion during times of decreased splanchnic 
circulation (Fink, 1991; Kampp et al., 1968). This is because in intestinal villi the artery 
and vein run parallel, but in opposite directions, with a dense capillary network close to 
the top of the villus. This results in a decreasing tissue PO2 gradient from the base up to 
the tip of the villi (Takala, 1996).  The change in PO2 may also be due to the higher 
metabolic activity of cells located in the tip. Regardless of the mechanism, this low PO2 
tension makes the villi tips susceptible to tissue hypoxia if vasoconstriction occurs. In 
dogs, a similar vascular anatomy in the villus is present, with a single arteriole 
unbranched to the tip of the villus (Strombeck, 1996). It is possible that dogs may be 44 
 
exquisitely sensitive to villus hypoxia as the drainage from the capillary network to the 
veins occurs closer to the tip of the villus than in other species (Strombeck, 1996).  
The epithelial layer forms tight junctions that prevent passage of molecules > 
11.5Ǻ in diameter, which includes lipopolysaccharides and other inflammatory 
mediators (Ravin and Fine, 1962). It is hypothesised that bacteria may not be able to 
pass through the gut in healthy rodent models, due to the size of these junctions 
(Wolochow et al., 1966), but other properties such as polarity of the microbes and 
surveillance by the gut-associated lymphoid tissue, are probably as important. 
1.2.3 Classification of pancreatitis  
There is a lot of confusion about the nomenclature surrounding pancreatitis and 
its various definitions in the veterinary literature. This is probably because pathological 
classifications are dependent on histological descriptions. As the different types of 
pancreatitis overlap in their clinical presentation and biopsy specimens are rarely 
obtained ante-mortem in acute pancreatitis, a clinical bias in terminology currently 
exists in the veterinary literature. 
The current edition of a major reference veterinary pathology textbook 
discusses acute pancreatic necrosis (APN) in a different sub-section from pancreatitis 
(Charles, 2007). They make the definition of APN based on necrosis, not inflammation, 
being the predominant histological feature. They also state that the aetiology and 
pathogenesis is different for APN and acute pancreatitis, although this has not been 
proven. What is most likely is that the response is to the same stimuli, but the 
progression and final outcome is different between the two.  
The initial histological events for APN are described as perilobular necrosis and 
reactive inflammation at the periphery of affected lobes, with a variable degree of 
involvement of adjacent adipose and other tissue. The duct system and centrilobular 
parenchyma appear to be spared in the early stages (Charles, 2007).  45 
 
A specific histological form, acute haemorrhagic pancreatic necrosis is also 
described (Charles, 2007). This term is rarely used anymore, and only in specific 
instances such as secondary to a scorpion bite or an L-asparginase reaction. The 
necrosis in this form is centred on the ducts.  
Acute interstitial pancreatitis is defined as a swollen organ due to diffuse 
interlobular oedema, and occasionally haemorrhage or necrosis, and is most commonly 
seen in Toxoplasma-associated pancreatitis in cats (Mergener and Baillie, 1998). 
Chronic interstitial pancreatitis arises by extension of an inflammatory process that 
commences in the ducts, and is usually of minor clinical consequence.  
The biggest and most confusing contradiction is that in pathology-based 
descriptions, APN is stated to smoulder and persist, and then cause EPI or diabetes 
mellitus as a result (Charles, 2007). This is in contrast to the definition in many human 
and veterinary medical textbooks where acute pancreatitis is considered to be a 
completely reversible condition (Mergener and Baillie, 1998; Williams, 1996). 
Additionally, in recently published veterinary medical literature acute pancreatitis is 
defined as having no underlying fibrosis (Kalli et al., 2009; Newman et al., 2006; 
Watson et al., 2007; Williams, 1996). Chronic pancreatitis, which is diagnosed when 
there is fibrosis, is instead cited as being the major cause of diabetes mellitus or 
exocrine pancreatic insufficiency (Simpson and Lamb, 1995; Watson, 2004; Watson, 
2003; Watson et al., 2010; Williams, 1996; Xenoulis et al., 2008). Chronic pancreatitis 
is more likely to be recurrent as the fibrosis renders the pancreas less distensible, and so 
some duct obstruction develops, predisposing to ductular based inflammation (Watson, 
2004).  This then becomes recurrent acute pancreatitis, termed ‘acute-on-chronic’ by 
some authors (Kalli et al., 2009; Watson et al., 2007). 
Clinically, this histological differentiation is seldom determined as pancreatic 
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relates to the severity and longevity of clinical signs. Where this becomes important is 
that not all acute cases have severe disease, and not all chronic cases have mild disease.   
Mild acute pancreatitis causes no multi-system failure and has an uncomplicated 
recovery, whilst severe acute pancreatitis causes multi-system failure or development 
of complications. It is recommended that the term necrotising is used as a sub-category 
of acute pancreatitis only when it is histological proven, acknowledging that this is 
most likely to be present in severe disease (Watson, 2004).  
Again this definition is similar to that in people, where acute pancreatitis is an 
inflammatory process centred on the pancreas, with possible multi-organ involvement 
(Al Mofleh, 2008). The process is considered reversible, with no fibrosis present 
(Bradley, 1993). Acute pancreatitis is sometimes sub-classified into necrotising or non-
necrotising, with the consensus being that there is a worse outcome with the former (Al 
Mofleh, 2008; Blum et al., 2001). Necrosis is generally diagnosed by computed 
tomographic (CT) evaluation in people. Severe acute pancreatitis in people is defined 
as being associated with organ failure, local complications (such as local fluid 
collections, infected necrosis, pseudocysts) or both (Windsor and Hammodat, 2000). 
The presence of infected necrosis and the extent of the necrosis are the two most 
important determinants of outcome in people. Such a determinant has not been made in 
dogs, partly due to the difficulty in assessing the amount of necrosis.  
1.2.4 Aetiology and risk factors in dogs 
The list of potential aetiologies that can cause pancreatitis in dogs is long and 
includes nutritional excesses, hyperlipoproteinaemia, drugs, toxins, hypercalcaemia, 
duct obstruction, duodenal/biliary reflux, pancreatic trauma, ischaemia/reperfusion and 
miscellaneous (Charles, 2007; Williams, 1996). Specific diseases such as babesiosis 
and leishmaniasis are also reported to cause pancreatitis in dogs, although for the latter 47 
 
it is unclear whether it is the disease or the treatment that is responsible (Aste et al., 
2005; Carrasco et al., 1997; Mohr et al., 2000). 
Drugs that have been reported in the veterinary literature to cause pancreatitis 
include azathioprine, chlorthiazine, hydrochlorthiazide, zinc, potassium bromide, 
vinblastine, sulphonamides, cisplatin, organophosphates, L-asparginase and 5-
aminosalicylate amongst others (Charles, 2007; Dalefield et al., 1999; Hammond et al., 
2004; Kook et al., 2009; Mikszewski et al., 2003; Segev et al., 2008; Stewart, 1994; 
Trepanier et al., 2003; Williams, 1994; Williams, 1996).  
The potential of glucocorticoids to cause pancreatitis in cats and dogs is 
controversial, with some authors believing there is a connection between glucocorticoid 
administration and pancreatitis (Schaer 1979). Pancreatitis has been reported in a small 
percentage (3.1%) of dogs with intervertebral disc disease treated with intravenous 
corticosteroids, primarily dexamethasone (Moore and Withrow 1982). Only 2 of these 
dogs had pancreatitis confirmed at post-mortem, but there may have been other 
precipitating factors for pancreatitis, such as hypotension associated with severe spinal 
cord disease, that caused this inflammation, rather than the corticosteroids per se. 
Corticosteroid treatment in healthy dogs or those with neurological signs failed to 
induce clinical pancreatitis but did result in an increase in serum pancreatic enzyme 
concentrations in at least three studies (Fittschon and Bellamy, 1984; Lucena et al., 
1999; Parent, 1982).  
There is often evidence cited that low-protein, high-fat diets induce pancreatitis 
and high-fat diets in dogs cause a more severe pancreatitis (Haig, 1970; Yago et al., 
1997). These studies did not assess whether there was pancreatic necrosis or 
inflammation, rather the volume of pancreatic secretion and the pancreatic enzymes 
within those secretions. Thus the clinical validity of this extrapolation is questionable. 48 
 
All of the test diets (the high protein, high fat, and high starch diet) increased the 
volume of pancreatic juice produced, but the high-fat diet didn’t change the protein 
composition.  
Overweight dogs are at greater risk of pancreatitis, and this may be associated 
with abnormal dietary intake or indicate a general predisposition to inflammation (Lem 
et al., 2008). A chronic inflammatory state is associated with adipose tissue, and 
adipokines in people, and likely also occurs in dogs (Federico et al., 2010; Radin et al., 
2009). This may be an important factor in canine pancreatitis especially in 
consideration of the peri-pancreatic fat involvement, but this has yet to be evaluated.  
In one retrospective survey, dogs with recent ingestion of unusual food items 
and garbage ingestion all showed an increased risk of developing pancreatitis, rather 
than dogs that appeared to have a higher intake of treats and snacks (Lem et al., 2008). 
This study suggested, but could not prove, that inappropriate food rather than the 
fat/protein content of food per se may be most important in the development of 
pancreatitis. To date, the connection between high fat diets and pancreatitis in dogs 
remains anecdotal (Shukla, 2010). However, it is possible that increased CCK 
production could result from increased fat content in the diet. Additionally, it has been 
observed that feeding a low-protein, high fat diet to dogs for prevention of struvite 
urolithiasis (Hill’s SD
®) causes and increased incidence of pancreatitis (D Williams, 
personal communication).  
Acute pancreatitis may also directly result from hypoxia, and ductal 
hypertension, via an effect on pancreatic microcirculation as previously discussed 
(Charles, 2007; Cuthbertson and Christophi, 2006; Mithofer et al., 1995). This is 
reflected in the high incidence of pancreatitis reported after abdominal surgery, 
especially adrenalectomy (Lem et al., 2008; Schwartz et al., 2008). Despite the 49 
 
experimental association between premature trypsin activation and hypercalcaemia, 
common conditions such as lymphoma that cause hypercalcaemia are not reported to 
cause pancreatitis in dogs. This may be that the increase in calcium is more gradual 
than seen in people, where hypercalcaemia-associated pancreatitis is most often seen in 
cardiopulmonary bypass (Dervenis et al., 1999). It may also be that the disease is sub-
clinical and escapes diagnosis in those dogs.  
One review of canine pancreatitis found that Yorkshire terriers were at 
increased risk, whilst Labrador retrievers and Miniature poodles had a decreased risk of 
developing pancreatitis (Hess et al., 1999). Another review found that Miniature 
schnauzers, Miniature poodles and terriers were more often affected (Cook et al., 
1993), and other studies have also identified terriers to have a higher incidence (Lem et 
al., 2008; Ruaux and Atwell, 1998a).  Whether this reflects a true predisposition, or 
breed preferences in those localities cannot be determined from the available data. 
Hereditary pancreatitis has been proven in people (Blackstone, 1998; Chen and Ferec, 
2000; Whitcomb et al., 1996), and is suspected in some breeds especially Miniature 
Schnauzers, but a genetic abnormality has yet to be established in dogs (Bishop et al., 
2004; Bishop et al., 2010).  
Concurrent disease, particularly diabetes mellitus, hypothyroidism and 
hyperadrenocorticism are commonly reported in canine pancreatitis (Cook et al., 1993; 
Hess et al., 1998; Lem et al., 2008). Some possible connections between diabetes 
mellitus and pancreatitis include sub-clinical pancreatitis causing progressive islet cell 
destruction or autoantibodies directed against insulin secreting cells promoting a 
generalised pancreatic inflammation. All three of these endocrinopathies are associated 
with changes in serum lipid concentrations, and the association between 
hyperlipidaemia and pancreatitis cannot be discounted (Xenoulis and Steiner, 2010). 50 
 
Uraemia has been associated with pancreatitis but the severity of the pancreatitis is 
generally mild and often an incidental finding (Williams 1995).  
1.2.5 Prevalence and mortality rates in dogs 
Prevalence of pancreatitis is very difficult to determine. One older reference 
quoted 3.2%, but this is likely to be grossly inaccurate as both under diagnosis of 
chronic pancreatitis and over diagnosis of acute pancreatitis likely occurs (Strombeck, 
1990). Prevalence of chronic pancreatic inflammation in one post-mortem study was 
34%, but there was no determination of how clinically important these changes were 
(Watson et al., 2007). Other studies identified between 75 and 92% of dogs in a referral 
institution to have pancreatic inflammation on post-mortem examination (Newman et 
al., 2005; Newman et al., 2006). This is likely to be an over-estimation, as most of the 
reported inflammation is likely to have been incidental, and also reflects a referral bias.  
The reported mortality rate in dogs ranges from 27% to 58% (Charles, 2007; 
Cook et al., 1993; Ruaux and Atwell, 1998a; Schaer, 1979). This reported rate is also 
questionable as the reports were from referral centres and therefore predisposing to 
more severe cases, or there was a lack of definitive gold standard diagnosis. Euthanasia 
for non-medical reasons may also influence the true mortality of this condition. Even 
taking those factors into account, it is a higher mortality rate than the 5-15% reported in 
human studies (Al Mofleh, 2008).  
1.2.6 Clinical signs 
 
Dogs with acute pancreatitis generally present with a sudden onset of anorexia, 
depression and vomiting (Hess et al., 1998; Watson, 2004; Williams and Steiner, 2005). 
Fresh blood may be in the vomitus when vomiting is prolonged as for any other severe 
gastrointestinal disease, and occasionally diarrhoea will be present. Veterinary 
textbooks often quote that ingestion of a fatty meal precedes clinical signs (Williams 51 
 
and Steiner, 2005). However, a recent retrospective analysis found that recent exposure 
to unusual food items rather than fat content of the food is more likely to be the inciting 
cause (Lem et al., 2008). Most dogs will have abdominal pain (Hess et al., 1998). 
The findings on clinical examination vary considerably with the severity and 
stage of the disease, and the associated degree of dehydration and shock. Severely 
affected dogs will have signs of dehydration and shock such as tachycardia, 
tachypnoea, prolonged capillary refill time, hypothermia and dry mucous membranes 
(Williams and Steiner, 2005). Mildly affected dogs may have less dramatic signs. 
Complications such as icterus due to extra-hepatic bile duct obstruction develop 2-3 
days after the onset of vomiting (Watson, 2004).  
In a retrospective review by Hess et al (1999) of 70 dogs with fatal acute 
pancreatitis, the history and physical examination findings were reported. These have 
been tabulated (Table 1.2). 
Table 1.2 
HISTORICAL FINDING  NUMBER OF CASES  PERCENTAGE 
Anorexia  64  91 
Vomiting  63  90 
Weakness  55  79 
Diarrhoea  23  33 
Polyuria/polydipsia  35  50 
Neurological 
abnormalities 
14  20 
Melena  11  16 
Weight loss  8  11 
Haematemesis  7  10 
Haematochezia  3  4 
 
Summary of clinical findings of 60 dogs with fatal acute pancreatitis. Adapted from 
Hess et al (1999)
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1.2.7 Complications 
1.2.7.1 Systemic 
Systemic inflammatory response syndrome (SIRS) is a generalised systemic 
reaction, with resultant organ dysfunction that is characterised by peripheral 
vasodilation and increased capillary permeability (Barton, 2005). The development of 
systemic complications in acute pancreatitis is due to an imbalance between the 
development of SIRS and the compensatory anti-inflammatory response syndrome 
(CARS) (Windsor and Hammodat, 2000). This is likely to be mediated by the cytokine 
storm, NO and other inflammatory mediators as previously discussed. The clinical 
criteria for SIRS in dogs is tachycardia (heart rate > 120 beats per minute), tachypnoea 
(respiratory rate > 40 breaths per minute), pyrexia (>39˚C) or leucocyte abnormalities 
(> 18,000 or < 5000 WBC/µL) (Barton, 2005). Multiple organ dysfunction (MODS) is 
an extension of SIRS, and is defined as altered organ function such that homeostasis 
cannot be maintained without intervention. It is unknown how many dogs with 
pancreatitis have SIRS, but approximately 60% of people with acute pancreatitis have 
been reported to have SIRS, and it is considered a sign of severity (Singh et al., 2009).   
Acute renal failure may develop secondary to the hypovolaemia and ischaemia 
resulting from vomiting in acute pancreatitis as well as potential development of 
intravascular coagulopathy and direct inflammation (Zhang et al., 2008a). It has been 
postulated that NF-κB activation may also cause aggregation of activated neutrophils in 
the glomeruli (Satoh et al., 2003). Endotoxin released during intestinal ischaemia may 
promote renal vasoconstriction (and thereby contributing to renal failure) due to high 
affinity for binding on the renal artery (Windsor et al., 1993). Acute respiratory injury 
is most closely linked to platelet activating factor, although PLA-2 , TNF-α and IL-1β 
may also play a role (Lopez et al., 1995). The histological changes in lung from rodents 
with experimentally induced acute pancreatitis include substantial neutrophil 53 
 
infiltration, damage of endothelial cells, interstitial oedema and intra-alveolar 
haemorrhage (Gomez Cambronero et al., 2002). Additionally, there may be change in 
pulmonary surfactant or apoptosis of type II pneumocytes (Gomez Cambronero et al., 
2002). Other systemic complications include disseminated intravascular coagulation 
and cardiac arrhythmias, all mediated by the many systemic inflammatory cascades 
initiated by acute pancreatitis (Ruaux, 2000; Williams and Steiner, 2005). 
Diabetes ketoacidosis (DKA) is a commonly reported complication in canine 
pancreatitis. It is not possible to determine if DKA occurs before, or in conjunction 
with the pancreatic inflammation. It is possible that the acidosis present in DKA may 
cause trypsin activation and then acinar cell necrosis, rather than the exocrine 
inflammation destroying the acinar cells (Bhoomagoud et al., 2009).  
Late onset complications include chronic relapsing pancreatitis and the 
subsequent development of exocrine pancreatic insufficiency or diabetes mellitus 
(Hylands, 2006; Watson, 2003). Recently in people, sub-clinical exocrine insufficiency 
has been demonstrated following a bout of acute pancreatitis (Boreham and Ammori, 
2003; Pezzilli et al., 2009). This may not be adequately appreciated in dogs, as sub-
clinical exocrine insufficiency is difficult to diagnose (Wiberg and Westermarck, 
2002). The reported systemic complications of pancreatitis in dogs are detailed in Table 
1.3, as extracted from (Williams, 1994).  
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Table 1.3 
Organ system  Complication 
General  Hypovolaemic shock 
Cardiovascular  Cardiac arrhythmias 
Myocardial depression 
Gastrointestinal  Haematemesis 
Haemorrhagic diarrhoea 
Ileus 
Renal  Pre-renal azotaemia with oliguria 
Associated renal parenchymal necrosis 
Thrombi 
Metabolic  Diabetes ketoacidosis 
Hypocalcaemia 
Hyperlipidaemia 
Haematological  Disseminated Intravascular Coagulation 
(DIC) 
Central nervous system  Cerebral vascular accident (secondary to 
DIC) 
Pulmonary  Pulmonary oedema 
Systemic complications in canine acute pancreatitis 
1.2.7.2 Local complications  
Acute fluid collections are defined in the human medical literature as fluid 
accumulations within the pancreatic parenchyma that develops in the first 6 weeks 
following a bout of acute pancreatitis (Wu and Conwell, 2010b). A pseudocyst on the 
other hand, develops at least 6 weeks after an episode, does not contain an epithelial 
lining and its contents are composed of amylase-rich pancreatic secretion, generally 
occurring in milder cases of acute pancreatitis (Wu and Conwell, 2010b).  Another late 
development local complication is a walled off area containing necrotic tissue. In 
people, this may become a nidus for infection, but in dogs this late onset change is 
rarely diagnosed.  
Despite the term pancreatic abscess commonly being used in the veterinary 
literature, on review of all papers discussing pancreatic abscess or pseudocyst, 
development of fluid in the canine pancreas is invariably acute in onset and sterile in 
nature (Bellenger et al., 1989; Edwards et al., 1990; Johnson and Mann, 2006; 55 
 
Marchevsky et al., 2000; Salisbury et al., 1988; Smith and Biller, 1998; VanEnkevort et 
al., 1999). This suggests that instead they should have been termed acute fluid 
collections. Additionally, the presumption that these are infected is not borne out in the 
veterinary literature. Out of a total of 29 with culture results, only one dog had a 
positive mixed culture, and it is likely this was due to secondary pancreatic infection 
resulting from a septic peritonitis (Bellenger et al., 1989; Edwards et al., 1990; Johnson 
and Mann, 2006; Marchevsky et al., 2000; Salisbury et al., 1988; Smith and Biller, 
1998; VanEnkevort et al., 1999)..  
In pathological descriptions, a phlegmon is a solid mass of indurated pancreas 
and adjacent tissue that results from inflammation, oedema and necrosis. It typically 
develops within a few days of acute pancreatitis, and resolves spontaneously within 2-3 
weeks (Charles, 2007). This term is seldom used clinically.  
Another local complication that occurs in acute pancreatitis is the development 
of extra-hepatic bile duct obstruction (Williams and Steiner, 2005). This may occur due 
to physical obstruction of the bile duct, or be functional secondary to localised 
peritonitis. This condition typically manifests as jaundice 3-7 days after the onset of 
acute pancreatitis. Dogs may be systemically well despite the jaundice, or at times this 
is associated with a deterioration in clinical status. In most dogs, the jaundice and bile 
duct obstruction resolves with time (Herman et al., 2005). This may be due to reduction 
in the size of the pancreas. However, as the pancreas does take weeks to return to 
normal size, it is more likely to be due to resumption of oral intake, and subsequent gall 
bladder contraction.  
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1.3 Pancreatitis: The Diagnosis 
 
1.3.1 Differential diagnosis 
The clinical signs of acute pancreatitis in dogs are not pathognomonic. The 
differential diagnoses for acute pancreatitis that need to be eliminated as a priority are 
the life threatening conditions such as intestinal obstruction, closed pyometron or septic 
peritonitis, which all require surgical intervention and have very similar presentations. 
Other differentials include non-specific gastroenteritis, dietary indiscretion, diabetic 
ketoacidosis, liver disease, uraemia and other metabolic causes of vomiting.  
1.3.2 Routine clinical pathology 
Most laboratory abnormalities present in dogs with pancreatitis result from 
hypovolaemia or inflammation and are therefore not specific for pancreatitis (Whitney, 
1993; Williams, 1994). Many of the differential diagnoses for pancreatitis, such as 
uraemia or gastrointestinal inflammation, will also result in similar laboratory changes 
(Simpson and Lamb, 1995; Williams, 1994). In brief, these changes include 
leucocytosis, azotaemia and increased liver enzymes. Decreased calcium has also been 
documented in dogs with acute pancreatitis, and has been suggested to be associated 
with a poorer prognosis (Holowaychuk et al., 2009; Jacobs et al., 1985; Schaer, 1979).  
1.3.3 Specific biochemical assessment 
1.3.3.1 Lipase and Amylase 
  Serum lipase and amylase concentrations have been shown to increase in experimental 
and naturally occurring canine pancreatitis (Akuzawa et al., 1994; Jacobs et al., 1985; 
Whitney, 1993). However, neither enzyme is specific to the pancreas as they also 
originate from gastrointestinal mucosa and are excreted by the kidneys (Williams, 
1996). Serum lipase activity has been shown to be markedly increased in dogs with 57 
 
acute enteritis, gastroenteritis, liver disease and in renal failure (Mansfield and Jones, 
2000; Rallis et al., 1996; Walter et al., 1992). Lipase concentration can also be elevated 
up to five-fold by the administration of dexamethasone in dogs with no pancreatic 
inflammation (Williams, 1996).  Conversely, dogs with exocrine pancreatic 
insufficiency have been shown to have measurable serum lipase concentration 
(Simpson et al., 1991; Steiner et al., 2006).  Serum lipase and amylase concentrations 
can also be normal in dogs that do have pancreatitis. In one retrospective review by 
Hess et al (1998) less than 50% of dogs with acute fatal pancreatitis had increased 
lipase concentrations, whilst only 30.8% had increased amylase concentrations (Hess et 
al., 1998). Other estimates place the value more conservatively at 15-20% of dogs with 
acute pancreatitis having normal serum lipase and amylase concentrations (Mansfield 
and Jones, 2000; Stewart, 1994). This value is probably much greater in dogs with 
chronic pancreatitis (Watson et al., 2007). This dilemma obviously places the clinician 
in a difficult position. Not only is there a huge overlap of clinical and laboratory 
findings seen in dogs with pancreatitis and with other diseases, but also there is no 
guarantee that a dog with pancreatitis will have increased lipase and amylase.  
1.3.3.2 Trypsinogen Activation Peptide 
Trypsinogen activation peptide (TAP) is the cleavage peptide produced when 
trypsinogen is cleaved to trypsin (Figure 1.2). Theoretically, in pancreatitis TAP will be 
released into the abdominal cavity and then the circulation in high concentrations, and 
subsequently be cleared through the kidneys (Hurley et al., 1988). Several studies in 
people showed a high correlation between the severity of pancreatitis and urinary TAP 
concentration, and a high degree of specificity and sensitivity for diagnosis (Gudgeon 
et al., 1990; Neoptolemos et al., 2000). A reference interval for measurement of TAP in 
healthy dogs was established and its utility as a diagnostic test for canine pancreatitis 
was assessed (Mansfield and Jones, 2000). Unfortunately it was not highly sensitive for 58 
 
diagnosis, although it was specific (Table 1.4). There may be some benefit in 
establishing clinical severity however, as discussed in a later section (Mansfield et al., 
2003).  
1.3.3.3 Trypsin-like Immunoreactivity  
  Serum trypsin-like immunoreactivity (TLI) is an accurate and specific indicator of 
pancreatic mass and is thought to be entirely pancreatic in origin (Batt, 1993). It has 
been shown in experimental models of pancreatitis that there is an early increase in the 
serum TLI concentration, followed by a rapid decrease (Simpson et al., 1989). 
However, in clinical cases the TLI concentration is often decreased by the time of 
sampling and can be affected by other diseases such as renal disease so is seldom useful 
(Mansfield and Jones, 2000; Ruaux and Atwell, 1999). These reasons, along with an 
often lengthy delay in receiving results, make its usefulness for the diagnosis of 
pancreatitis questionable.  
Table 1.4 
   Plasma TAP  Urinary TAP  UTCR  TLI  Lipase  Amylase 
AUC  0.666  0.615  0.640  0.645  0.525  0.556 
Diagnostic Cut-off  4.53 nM  162.6 nM  24.5  100 µg/L  770 U/L  5400 U/L 
Sensitivity %  40.5  29.4  30.8  37.5  63.6  22.7 
Specificity %  76.5  96.6  94.7  89.3  54.8  78.1  
Summary of receiver-operating characteristics (ROC) analysis of a selection of 
laboratory methods for diagnosing pancreatitis. Data were analysed from 22 dogs with 
histologically confirmed pancreatitis and 34 dogs with other disease (Mansfield and 
Jones 2000). The diagnostic cut-off for lipase used was three times the upper reference 
interval. UTCR = Urinary TAP to creatinine ratio; TLI = Trypsin like 
immunoreactivity; TAP = Trypsinogen activation peptide 
 
1.3.4 Canine Pancreatic Lipase 
Canine pancreatic lipase is one of the most recently established laboratory tests 
in veterinary medicine, and its use is now widespread. The premise of this test is that it 
measures lipase that originates solely in the pancreas, and so it will only be increased in 
pancreatic inflammation (Steiner and Williams, 2002). Immunolocalization studies 59 
 
showed pancreatic lipase was present only within pancreatic tissue of dogs, and serum 
concentrations in dogs with absent exocrine pancreatic function were decreased 
(Steiner et al., 2002; Steiner et al., 2006). The assay itself (first a radioimmunoassay, 
and then a enzyme immunoassay) has been well validated (Steiner et al., 2003; Steiner 
and Williams, 2003). The canine pancreatic-lipase immunoreactivity (cPLI) assay was 
then further developed into a commercially available specific canine pancreatic lipase 
(spec-CPL) sandwich ELISA, using a recombinant peptide as the antigen and 
monoclonal antibody for measurement. This new commercially available assay shows a 
good correlation to the original assay, as well as high reproducibility (Huth et al., 
2010). The newer assay has caused a change in the reference intervals for the diagnosis 
of pancreatitis, with results < 200 µg/L expected in healthy dogs, and results > 400 
µg/L considered consistent with a diagnosis of pancreatitis (Steiner, 2003; Williams 
and Steiner, 2005). A new in-clinic rapid semiquantitative assay has also been 
developed, and shows good alignment and reproducibility with the laboratory-based 
fully quantitative assay (Beall et al., 2011).  
The original abstract published about this test quoted a sensitivity of 88%, much 
higher than for total lipase in the same group of dogs (Steiner et al., 2001). It is 
important to put that into context however, as this only assessed 11 dogs, all with 
relatively severe pancreatitis. In a later study to evaluate the sensitivity of pancreatic 
lipase, 22 dogs were assessed (Steiner et al., 2008a). These dogs had a post-mortem 
performed within 6 hours of death, and all demonstrated gross evidence of pancreatic 
disease. The pancreas was fixed in its entirety and a histological activity index was 
recorded based on a previously published paper (Newman et al., 2006). According to 
this classification, out of the 22 dogs there were 4 with moderate disease and the rest 
had mild disease. It is not possible to determine how clinically severe each case was, 
and the final cause of death or potential other primary diseases were not discussed. 60 
 
However, using the Atlanta criteria (discussed in section 1.3.8), it would appear that 8 
had severe pancreatitis. Both cPLI and spec-CPL had an overall sensitivity of 63.6% in 
diagnosing pancreatitis, compared to 40.9% and 31.8% for amylase and total lipase 
respectively. If only the 8 severely affected dogs were assessed, the sensitivity for the 
two assays (cPLI and spec-CPL) increased to 100%, as compared to 62.5% and 50% 
for amylase and lipase respectively. If using a 3 times- upper reference interval for 
lipase as indicated in a previous study (Mansfield and Jones, 2000), the sensitivity for 
total lipase decreased (14%). Again, it must be emphasised that there is no proven 
direct correlation between the histological index and clinical disease.   
A study from a different research group has just become available for review 
that assessed 70 dogs consecutively presented for post-mortem at a tertiary referral 
centre (Trivedi et al., 2011). Sixty-three of those were found to have pancreatic 
inflammation on histology (56 mild, 7 moderate), whilst 7 had no histological evidence 
of pancreatic inflammation. The estimated sensitivity of canine pancreatic lipase was 
21% for mild disease, and 71% for moderate disease. This was a lower sensitivity than 
total lipase (54 and 71% respectively) in the same cohort. Although only 7 dogs were 
classified as having normal pancreatic histology, they published a specificity of 86% 
for cPL as compared to 43% for total lipase. Again, this study has limitations due to the 
small number of dogs classified as true negatives, and the lack of correlation between 
clinically significant disease and the histological grading.  
A recent paper was published to assess the specificity of pancreatic lipase in 
dogs (Neilson-Carley et al., 2011). In this study they assessed a total of 64 dogs, 20 
from the previously mentioned study by Steiner et al with gross evidence of pancreatitis 
on post-mortem, and 44 other dogs that were euthanased and submitted for post-
mortem analysis. Out of those 44 dogs, 27 were from a shelter and 26 of them were 
clinically healthy, whilst one emaciated dog was found to have diabetes mellitus. 61 
 
Seventeen dogs from a referral centre with a variety of diseases (trauma 5, dystocia 2, 
osteosarcoma 1, osteoarthritis 1, diabetes ketoacidosis 1, adrenal tumour 1, metastatic 
sarcoma 1, pancreatic carcinoma 1 and pancreatitis 2) were also included. The pancreas 
from each dog was sectioned and inflammation scored as previously described 
(Newman et al., 2006). The authors classified 40 dogs as having no pancreatic disease 
due to an absence of clinical signs and no inflammation on histology. Thirty-eight of 
those 40 dogs had a SpecCPL value below 200 µg/L, and 39 had values below 400 
µg/L. This resulted in a specificity using the lower cut-off value of 95% (95% CI 83.1-
99.4), and using the higher cut-off value a specificity of 97.5% (95% CI 86.8-99.9). 
The major drawback in this study is that the majority of animals without pancreatitis 
were clinically healthy, and so this specificity does not reflect a sick population of dogs 
in which pancreatitis would be considered as a differential. Additionally, there were no 
dogs with acute renal failure in this group, and decreased clearance of total lipase 
through the kidneys has been demonstrated in dogs (Mansfield and Jones, 2000; Polzin 
et al., 1983). It has not been demonstrated that the clearance of pancreas-specific lipase 
differs in any substantive manner from that of total lipase, except in one study that 
assessed dogs with experimentally induced chronic renal failure (Steiner et al., 2010). It 
is difficult to determine if this could be extrapolated to a clinical situation, with acute 
onset of decreased glomerular filtration rate.  
To summarise, the three studies currently published that assess sensitivity of 
cPL (and cPLI) with pancreatic histology as the gold standard were combined for 
analysis (Steiner et al., 2001; Steiner et al., 2008a; Trivedi et al., 2011). Using the 
diagnostic cut-off of > 400 µg/L, a sensitivity of 41% (39/96) overall was determined, 
albeit with an increasing sensitivity for more severe inflammation. This result is lower 
than that quoted for three times the upper reference interval of lipase (64%) (Mansfield 
and Jones, 2000). Conversely, cPL does appear to be highly specific when considering 62 
 
pancreatic inflammation, although in the face of acute renal failure this is unknown. 
Additionally, a histological diagnosis of pancreatic inflammation may not be clinically 
relevant, if there is another life-threatening reason for the animal’s clinical signs. This 
is demonstrated in an as yet unpublished study that has been supplied in the Appendix. 
This study showed a poor correlation between a positive cPL test and a primary 
presentation of acute pancreatitis in an emergency care setting.  
1.3.5 Serum Pancreatic Elastase 
Pancreatic elastase (PE-1) came to the attention of researchers and clinicians 
alike in the late 1960s, when elastase was shown to be involved in the pathogenesis of 
haemorrhagic pancreatitis in experimental models. This was later confirmed to occur at 
the same time or immediately after trypsin activation (Hartwig et al., 2007). Studies 
have shown that when macrophages are exposed to pancreatic elastase they up-regulate 
the expression of TNF-α, and so this supports the role of elastase in the systemic 
response to pancreatic inflammation (Zhang et al., 2003). Additionally, elastase has 
proteolytic effects, hydrolyses scleroprotein elastin, is fibrinolytic and increases the 
oxidative activity of neutrophils. It has been closely linked to the development of adult 
respiratory distress syndrome in severe pancreatitis (Wereszczynska-Siemiatkowska et 
al., 2003).  
The most widely used application of pancreatic elastase in human medicine is 
measurement of the enzyme in faeces as a determinant of exocrine pancreatic function 
(Pezzilli et al., 2009; Tran et al., 2008). Faecal cPE-1 appears to be of limited use in 
dogs for the diagnosis of exocrine pancreatic insufficiency (Wiberg et al., 2000).  
In an early study in people, one group determined a sensitivity of 100% and 
specificity of 96% for measurement of serum PE-1 in diagnosing acute pancreatitis 
(Malfertheiner et al., 1987). They used a polyclonal RIA that measures the 1-α-anti-
trypsin complex (not α-macroglobulin), and all people were assessed within 72 hours of 63 
 
onset of clinical signs. Overall the specificity of the test was 77%, and there was a large 
amount of overlap especially between people with non-pancreatic gastrointestinal 
disease and chronic pancreatitis. The authors concluded this was most likely due to 
other stimuli of pancreatic secretion; however a lack of gold standard for diagnosis of 
pancreatitis may have led to misclassification of the control group. The same group of 
researchers found no prognostic role in this test (Buchler et al., 1986). These results 
were similar to a larger study, which found that people with acute pancreatitis had 
significantly increased concentrations (Lesi et al., 1988). However, it remained 
measurable in some people that had had a complete pancreatectomy and was increased 
in acute ileo-colic disease.  
It is important to put any early human papers published on PE-1 in context, as 
they are all based on an RIA. The RIA detects polyclonal elastase (as bound to 1-α-
anti-trypsin complex) and has a half-life of 2.2 days. The ELISA that has been more 
recently developed detects free or unbound elastase, and has a half-life of 0.4 days 
(Millson et al., 1998). This means that the advantages of a prolonged increase in serum 
elastase cited by authors cannot hold for the ELISA (Buchler et al., 1986). 
Additionally, there is a reasonable variation in the reference interval in healthy people, 
with some authors recommending an upper reference interval >2 ng/mL, whilst the 
manufacturers recommend a cut-off >3.5 ng/mL. The canine PE-1 assay is an ELISA 
(Schebo Biotech
®). 
Later human studies assessing PE-1 measured by ELISA found that elastase 
was not more sensitive at diagnosing acute pancreatitis than lipase (Millson et al., 1998; 
Scheefers-Borchel et al., 1992; Wereszczynska-Siemiatkowska et al., 2003; Wilson et 
al., 2005).  
There has been a report in dogs that supports serum PE-1 as a diagnostic marker 
for pancreatitis, with a range of 32.1- 659.3 ng/mL (median 55.8) in 16 healthy dogs, 64 
 
24-1720 ng/mL(median 160) in 14 dogs with pancreatitis and 5-182 ng/mL (median 
43.3) in 6 dogs with renal disease (Spillman et al., 2002). When only dogs with severe 
pancreatitis (n=9) were analysed, there was a significant difference from healthy and 
renal dogs. A further study from the same authors assessed the measurement of serum 
cPE-1, along with amylase, lipase and TLI in seven healthy Beagles after endoscopic 
retrograde cholangiopancreatography (ERCP), a procedure which in people is 
commonly associated with the development of pancreatic inflammation (Spillman et 
al., 2004). There was no difference between the baseline and any subsequent 
measurement of cPE-1 in any dog, although there was in the other 3 enzymes. 
Additionally the range at baseline for the seven healthy dogs was quite wide (0.1-411.6 
ng/mL) with a median of 5.5 ng/mL. This study calculated an appropriate intra-assay 
CV (range 2.1-11.6%) and inter-assay CV (range 3.4-10.8%) for the assay. These are to 
date the only data available about the serum measurement of cPE-1 in dogs.  
There is a strong suggestion that serum elastase is not affected by renal 
clearance, as compared to many other pancreatic enzymes. In one study of 24 healthy 
people and 47 people with various degrees of renal insufficiency (but no known 
pancreatic disease) the measurements of elastase, lipase, amylase, pancreas-specific 
amylase, PLA-2  and trypsin were compared (Seno et al., 1995). Elastase was the least 
affected of all the enzymes, only increasing to a significant amount when the creatinine 
clearance reduced below 10 mL/minute. All other enzymes were increased when 
creatinine clearance was below 40 mL/min, although lipase tended to be less so. The 
proposed reason for this is that elastase circulates in the serum bound to inhibitor 
proteins such as α-macroglobulin, and is too large to pass through the glomeruli, 
relying on extra-renal metabolic pathways for clearance. There was also a suggestion 
that there could be an age-related decline in non-renal clearance.  65 
 
1.3.6 Diagnostic Imaging 
1.3.6.1 Radiology 
The radiological findings in dogs with acute pancreatitis are not particularly 
sensitive (Schaer, 1979). Changes that may be present include decreased contrast and 
lack of detail in the cranial abdomen due to the surrounding peritonitis. As can be 
appreciated, this is often difficult to detect and is also not specific for pancreatitis, as it 
may occur in a number of conditions such as septic peritonitis. Other changes include a 
widened pyloric-duodenal angle, with a lateral shift of the descending duodenum 
towards the abdominal wall (Williams, 1994). These changes have been reported in 
only 22% of dogs with severe pancreatitis (Hess et al., 1998), whilst in another earlier 
study 76% of radiographs were considered abnormal (Schaer, 1979).  
Despite these limitations, abdominal radiography is still a very important part of 
the diagnostic work-up for a dog with acute onset of vomiting or abdominal pain. This 
is mainly due to the ability to evaluate for differential diagnoses, such as intestinal 
obstruction or other changes such as free gas within the abdomen or a distended uterus.  
1.3.6.2 Ultrasound 
 
  Abdominal ultrasound is increasingly performed in veterinary practice, and aids 
substantially in the diagnosis of acute pancreatitis in dogs. Changes in pancreatic 
echogenicity and development of focal lesions can be detected (Lamb and Simpson, 
1995; Murtaugh et al., 1985; Nyland et al., 1983). Acute necrotizing pancreatitis is 
frequently associated with an enlarged, hypoechoic pancreas and peri-pancreatic 
necrosis (manifested as hyperechogenicity surrounding the pancreas), as demonstrated 
in Figure 1.8, and is relatively easy to identify, although gas and ingesta in the 
gastrointestinal tract may hamper visibility (Hecht and Henry, 2007).  
It is extremely difficult to elucidate a sensitivity or specificity for this diagnostic 
modality. The diagnostic utility of ultrasound is highly operator dependent, and also 66 
 
requires equipment that is of high standard. In the reviews from the 1990s, operator 
skill and equipment were not described in detail and there was a quoted sensitivity of 
about 68% (Hess et al., 1998; Mansfield and Jones   2000). It is likely that this 
sensitivity is now inaccurate. Expertise and training in this area has improved greatly in 
the past two decades, so it would be logical to assume the sensitivity is greater now 
than previously. It is also likely that this modality is much better at detecting acute 
necrotising pancreatitis due to the peri-pancreatic necrosis that results in an obvious 
hyperechoic area surrounding the pancreas. In one recent study, ultrasound was 
reported to have a sensitivity of 66% (Steiner et al., 2008a). However, this was only an 
assessment of nine dogs. On further analysis, the 3 dogs that had a negative ultrasound 
would not have been considered to have severe disease using many of the established 
criteria (as discussed in section 1.3.8). Of the 6 dogs that did have a positive ultrasound 
diagnosis, 4 of them were severely and 2 were moderately affected. In many ways this 
study demonstrated that in severe pancreatitis abdominal ultrasound is probably just as, 
if not more, sensitive in the diagnosis of canine pancreatitis as any available serum 
marker. This was also suggested with a 100% sensitivity and specificity (albeit in only 
8 dogs) from another study (Trivedi et al., 2011). Specificity of this modality is 
virtually impossible to determine, as histology would need to be performed in order to 
establish this.  It certainly remains an important component of a diagnostic work-up to 
evaluate for other abdominal disease.  67 
 
 
Figure 1.8 Ultrasound image of a dog with acute pancreatitis. There is marked 
hyperechogenicity in the area surrounding the pancreas (arrows) correlating with peri-
pancreatic fat necrosis as identified on post mortem examination. (Image courtesy N. 
Lester) 
 
Ultrasound can identify hypoechoic areas within the parenchyma, but cannot be 
used to differentiate between pancreatic neoplasia, inflammation, necrosis, true 
pseudocysts, infected necrosis or acute fluid collections (Hecht and Henry, 2007).  
1.3.6.3 Magnetic resonance imaging (MRI) and computed tomography (CT) 
 
CT scanning is the imaging modality of choice in people for detecting necrosis 
and infected necrosis of the pancreas (Dervenis et al., 1999). However, it is not 
recommended for use as a first line imaging test due to the radiation exposure and 
expense (Al Mofleh, 2008). Similarly, in veterinary patients it is not frequently used 
due to expense and availability. One report of two dogs used contrast-enhanced CT in 
combination with ultrasound (Jaeger et al., 2003). Both of the dogs had a diagnosis 
made on combination of clinical and laboratory findings, and also had consistent 
findings on abdominal ultrasound, suggesting no great clinical advantage in veterinary 
medicine in using CT. It was suggested it could be useful for detecting infected 68 
 
necrosis, but as previously discussed this is not an important consideration in dogs, and 
diagnostic confirmation still requires sampling that is best guided by ultrasound. 
MRI is also used, although not frequently, in people as it is considered a 
sensitive indicator of necrosis and provides greater detail of the pancreatic ducts than 
CT (Gosset et al., 2004). This again is a seldom used modality in veterinary patients 
due to the prolonged anaesthetic time required (which may be detrimental in a 
hypoperfused pancreas) and the expense. Additionally, the incidence of duct strictures 
or stones causing pancreatitis in dogs is much less than in man so its use is not justified.  
1.3.6.4 Endoscopic ultrasonography 
 
The use of an ultrasound probe inserted endoscopically theoretically reduces the 
interference from gas, ingesta and abdominal fat in obtaining clear ultrasound images 
of the pancreas (Barthel, 2005). This modality has not been described in dogs with 
acute pancreatitis, and again may have limited application in veterinary medicine due to 
the equipment and expertise required, along with a need for general anaesthesia.  
1.3.7 Histopathology 
 
Histological grading schemes have been developed for diagnosing pancreatitis 
in dogs, and to assist in assessing the sensitivity and specificity of diagnostic tests. The 
failing of these schemes is a lack of correlation with clinical severity, and therefore an 
understanding of the clinical significance of those grading systems. It has been 
established that pancreatic histological changes can be unevenly distributed throughout 
the pancreas, necessitating frequent sectioning along the organ in order to be able to 
rule out pancreatic inflammation (Newman et al., 2004). Chronic pancreatitis 
(lymphocytic inflammation) appears to be the most common inflammatory change, and 
less than 10% of dogs examined at post-mortem had no pancreatic abnormalities in one 
referral-centre based study (Newman et al., 2006). A slightly altered scoring system 69 
 
was also adapted by another group, and focused on the classification of the chronic 
changes particularly (Watson et al., 2007). Both of these schemes describe grading of 
the severity of both inflammation and fibrosis.  
  The finding of hyperplastic nodules in the pancreatic parenchyma is 
thought to be incidental, and increase with age (Newman et al., 2005). These nodules 
can be both grossly and microscopically evident, and are very common. Approximately 
96% of dogs with fatal pancreatitis were shown to have necrosis on post-mortem 
examination (Hess et al., 1998). This would suggest that dogs with more severe 
presentations will have some degree of necrosis within the pancreas or surrounding 
peri-pancreatic fat, although infected necrosis is extremely unlikely. Peri-pancreatic fat 
necrosis is demonstrated in Figure 1.9. 
Although technically the gold standard, in cases of acute pancreatitis, it is 
extremely unlikely in practice that biopsy samples will be obtained in these animals due 
to the level of invasiveness required, along with potential detriment of a general 
anaesthesia. A less invasive modality such as laparoscopic biopsies may be of some 
use, as it has been shown to have a higher diagnostic yield than ultrasound (Webb and 
Trott, 2008). However, this is not a technique in widespread use and still requires 
general anaesthesia. 
 
 
Figure 1.9 Haematoxylin and eosin 
stain (x100) section of an area of 
peripancreatic fat illustrating 
prominent neutrophil cell 
infiltration and necrosis of fat. 
Image courtesy M O’Hara.  
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1.3.8 Assessing severity 
In order to be able to assess the usefulness of a diagnostic test, provide 
prognostic information or to evaluate individual treatment in research studies, it is ideal 
to have a method of stratifying severity of disease. This is unlikely to be one single 
laboratory test, or indeed be dependent on histological evaluation.   
In people, early detection of severe pancreatitis is considered particularly 
important as this enables rapid transfer to intensive care units and improves the 
outcome (Al Mofleh, 2008). There is a plethora of studies assessing various clinical 
staging systems, in too large a number to be explored in this thesis, so they have been 
briefly summarised.  
The most common system referenced in the medical literature is the Atlanta 
criteria produced in 1992, where severe pancreatitis was defined as the presence of 
local complications, organ failure, or death (Bradley, 1993). This certainly seems a self-
evident and arbitrary classification scheme. There are several other clinical methods 
available for predicting the severity of pancreatitis in people. There are multifactorial 
scoring systems such as the Ranson, Glasgow and APACHE II (Acute Physiology and 
Chronic Health Evaluation) scores that take a large number of variables into account 
(Blum et al., 2001; Leese and Shaw, 1988; Muddana et al., 2009; Ranson et al., 1974); 
a system assessing obesity, age and aetiology (Dervenis et al., 1999; Karimgani et al., 
1992);  and other methods assessing blood markers in combination with the presence of 
pancreatic necrosis or age or respiratory status (Halonen et al., 2003; Ueda et al., 2007).  
There has also been an explosion in measuring various blood markers, such as 
IL-6, -8, -18,  PLA-2, CRP, PMN-elastase, matrix metalloproteinases (MMP)-9, serum 
amyloid A (SAA), trypsinogen-2, TAP and procalcitonin (Aufenanger et al., 2002; 
Gross et al., 1990; Leser et al., 1991; Mayer et al., 2002; Modrau et al., 2005; 71 
 
Neoptolemos et al., 2000; Pezzilli et al., 1995; Pooran et al., 2003; Rau et al., 1997; Uhl 
et al., 1991; Wereszczynska-Siemiatkowska et al., 2004).  
The multifactorial systems appear effective for predicting severity and the 
presence of necrosis, but require assessment of dynamic changes and highly specialised 
assessments. This makes them most useful in tertiary-level intensive care units 
(Frossard et al., 2001). The APACHE system is considered the best of these systems, 
but although the negative predictive value (NPV) is very high the positive predictive 
value (PPV) or ability to predict a fatal outcome is low (Blum et al., 2001). It appears 
that currently the best method to predict disease severity in people is an APACHE II 
score ≥ 8 and fulfilment of more than two Ranson Criteria. This results in a PPV of 75-
89% for predicting severe disease within the first 48 hours of admission (Ioannidis et 
al., 2008). The added assessment of obesity is only of relevance in populations where 
obesity is common (Muddana et al., 2009; Yeung et al., 2006). A survival prediction 
index has been described in dogs admitted to critical care facilities, but faces similar 
problems in its ability to be applied in non-referral centres and does not consider body 
condition score (King et al., 2001).  
Serum markers of inflammation as mentioned above are effective at early 
detection of severity but seem to be particularly associated with the risk of acute lung 
injury rather than mortality per se (Chen et al., 1999a; Gross et al., 1992; Leser et al., 
1991; Pooran et al., 2003).  Of these, IL-6 seems to have the most clinical relevance 
(Frossard et al., 2001; Leser et al., 1991). TNF-α has been investigated in dogs with 
presumed pancreatitis (Ruaux et al., 1999). There was no difference in dogs with a 
severe classification of pancreatitis compared to those with mild disease. This study 
suggests that this is not a viable method to predict prognosis in dogs. 
C-reactive protein (CRP) is an acute phase protein that changes rapidly in the 
circulation when there is inflammation, or tissue damage, and is the blood marker most 72 
 
commonly used in human medicine. SAA, which is also an acute phase protein though 
shows promise of increasing to a greater degree in severe pancreatitis at an early stage, 
and may replace CRP in the future (Mayer et al., 2002). CRP has been measured in 
dogs, and has been shown to be increased in a number of inflammatory conditions, 
including pancreatitis (Holm et al., 2004; Nakamura et al., 2008). Although the values 
are increased within 24 hours of an insult, there is often variation between dogs, so a 
change in CRP from day to day may be more relevant in dogs for predicting outcome 
(Otabe et al., 1998).  
TLI and α-macroglobulin were reported to be poorly correlated with survival in 
dogs, with presumptive pancreatitis (Ruaux and Atwell, 1999). Serum lipase appears to 
be loosely associated with clinical severity in dogs, along with creatinine and phosphate 
concentration, but the most closely correlated measurement was urinary TAP-creatinine 
ratio in one study (Mansfield et al., 2003). This mirrors findings in people, but 
unfortunately due to technical difficulties with the assay it is unlikely to become 
available in the mainstream veterinary practice (Neoptolemos et al., 2000).  
In contrast to using scoring systems or single markers, the persistence of organ 
failure or the presence of obesity, pleural effusion, necrosis (infected or sterile), SIRS 
and MODS appear to be the major determinants of mortality in people (Al Mofleh, 
2008; Brown et al., 2007; Buter et al., 2002; Isenmann et al., 1999; Singh et al., 2009). 
The presence of SIRS has been shown to be associated with a high mortality rate in a 
study of dogs admitted to an intensive care unit, but this has not been specifically 
assessed in dogs with pancreatitis (Okano et al., 2002). The use of obesity as a poor 
prognostic indicator is not something that has been evaluated prospectively in dogs, but 
it is an interesting concept as obesity may contribute to inflammation via production of 
adipokines (Papachristou et al., 2006). Obese dogs are more commonly reported in 73 
 
series of pancreatitis, but it is unclear whether this reflects the canine population of the 
centres, or is a real bias (Cook et al., 1993; Hess et al., 1999).  
The biggest and most recent study in people assessed over 18,000 patients with 
acute pancreatitis in over 200 centres (Wu et al., 2008). This study used classification 
and regression tree (CART) analysis to predict in-hospital mortality. They determined 
five factors that contributed to prognosis including azotaemia, impaired mental status, 
the presence of SIRS, age > 60 years and the presence of pleural effusion. The 
mortality rate was significantly greater with a higher number of abnormalities present. 
This is a similar concept to a severity score developed in dogs, where assigned points 
were correlated to mortality rate (Ruaux and Atwell, 1998b). This scheme is discussed 
in detail in Chapter 4, but in that study the diagnosis was not definitive, the treatment 
was not standardised and death due to euthanasia on non-medical grounds was not 
taken into account.  
1.4 Pancreatitis: Treatment 
There is a paucity of controlled studies evaluating the optimal treatment of acute 
pancreatitis in the dog. In fact using multiple search engines (PubMed, Ovid, Web of 
Science, CAB abstracts) to search for prospective clinical trials, only one published 
article written in the course of this project was identified (Mansfield et al., 2011a). As 
such, the current treatment recommendations rely on extrapolated experimental studies, 
or general advice relating to treatment of critically ill dogs with other diseases. 
1.4.1 Intravenous (IV) fluid therapy 
Dogs that develop acute pancreatitis are typically dehydrated, and often 
hypovolaemic. In severe cases there may be substantial third space losses. As such, 
basic first aid principles would predicate the use of resuscitative intravenous fluid. The 74 
 
major goals of fluid therapy are to maintain cardiac output, improve pancreatic and 
splanchnic perfusion and correct acid-base abnormalities.   
The blood flow to and capillary structure of the pancreas is complex, as 
discussed in the first section of this review. This is in order to allow integration 
between the endocrine and exocrine functions of the pancreas, and requires a relatively 
high blood flow to maintain function (Gardner et al., 2008). One of the major factors 
that progresses mild pancreatitis to severe pancreatitis is disturbed pancreatic 
microcirculation (Bassi et al., 1994; Borodin et al., 2006; Knoefel et al., 1994). This 
disturbance is usually multi-factorial in origin and can occur as a result of increased 
vascular permeability resulting from inflammatory cytokines, and microthrombi 
formation resulting from hypercoagulability (Gardner et al., 2008). The increased 
capillary permeability leads to oedematous changes in the acinar cells, and further 
migration of inflammatory cells. In necrotising pancreatitis there is a progressive 
reduction in capillaries after acinar cell injury, which cannot be reversed by fluid 
resuscitation (Bassi et al., 1994). In rodent models, vasoconstriction within the pancreas 
appears to be an early event (Kusterer et al., 1993; Schröder et al., 1985). In fact, in 
people, early onset spasm of large pancreatic vessels has been shown to correlate with 
poorly perfused areas of the pancreas, and subsequently high mortality rates (Takeda et 
al., 2005). 
As stated earlier in this chapter, there is substantial splanchnic hypoperfusion 
and regional mucosal acidosis that develops with acute pancreatitis. Reperfusion injury 
is hypothesised to occur when the splanchnic flow is restored. The initial ischaemia 
causes accumulation of hypoxanthine and depletion of ATP. Xanthine oxidase (XO) is 
produced upon reperfusion, which converts hypoxanthine to xanthine, and subsequently 
leads to production of free radicals (O2
-). XO is present in large quantities in gut 
epithelial cells (Fink, 1991). Free radicals are chemoattractants for neutrophils and 75 
 
inflammatory cytokines, which in turn amplify the inflammatory response.  Therefore 
theoretically, the return of splanchnic circulation with fluid resuscitation may 
potentially be detrimental. However, delaying or reducing fluid resuscitation to avoid 
this theoretical problem is neither supported by the literature, nor indeed by common 
sense. One study in people has shown that early fluid resuscitation (as opposed to at 24 
and 72 hours after onset of pain) leads to a better clinical outcome (Warndorf et al., 
2011). This benefit was most apparent in people with milder forms of pancreatitis, and 
therefore may be a suitable comparative study for the majority of dogs hospitalised for 
pancreatitis.  
In the veterinary literature there is no current recommended preference for 
either the use of Lactated Ringer’s (LRS) or saline solution as the initial crystalloid of 
choice. LRS is an isotonic fluid, containing the following electrolyte concentrations: 
sodium 130 mmol/L, chloride 109 mmol/L, lactate 28 mmol/L, potassium 4 mmol/L 
and calcium 1.5 mmol/L. It has a pH of 6.5, but is considered an alkalinising solution. 
Normal (0.9%) saline, on the other hand, contains 154 mmol/L of both sodium and 
chloride, and has a pH of 5.5. This fluid is considered a safe and first line fluid choice 
for resuscitation, but studies in people have shown that hyperchloraemic metabolic 
acidosis develops when it is used (Prough and Bidani, 1999).  
In a landmark experimental study evaluating fluid resuscitation in rats with 
septic shock (induced by intravenous endotoxin administration), Kellum demonstrated 
that there was a higher mortality rate in rats treated with IV normal saline or LRS, as 
compared to hetastarch (Kellum, 2002). The premise for this study was that although 
hyperchloraemic metabolic acidosis invariably resulted from saline resuscitation, it was 
not proven that this was in fact detrimental. Survival in this study was significantly 
associated with higher arterial pH and hyperchloraemia, but not with lower lactate 
concentration. It is possible that acidosis directly contributes to the systemic 76 
 
inflammatory state by stimulation of cytokine production, especially NF-κB, the 
precursor of many inflammatory cytokines.  
Experiments using rodent models have also identified that high acinar pH 
protected against secretagogue induction of pancreatitis (Bhoomagoud et al., 2009; 
Noble et al., 2008). Possible reasons for this include the tendency for lysomosal 
proteins and zymogen granules to co-localise in the face of an acidic environment; and 
the presence of proton pumps on acinar cells, which help regulation of zymogen 
secretion and activation (Bhoomagoud et al., 2009; Waterford et al., 2005).  
One experimental study in dogs (using a bile-trypsin induced method) showed 
that low rate infusion of LRS (1.75 ml/kg/hour) resulted in diminished pancreatic blood 
flow compared to a high rate LRS infusion (6.5 mL/kg/hour) over a 4-hour period 
(Knol et al., 1987). Whether this experimental finding correlates to a clinical benefit in 
naturally occurring disease in dogs is unknown. Initial work in people suggests that 
there may be an advantage in aggressive fluid resuscitation with LRS (Wu et al., 2011). 
Patients receiving LRS showed significant reductions in serum CRP concentration and 
reduction in the severity of SIRS at 24 hours compared to those receiving normal 
saline, regardless of the rate protocol used.  
Another experimental study that induced acute pancreatitis in dogs via a bile 
infusion measured the pulmonary arterial pressures in dogs resuscitated with 4 mL/kg 
of hypertonic saline-dextran solution and LRS to effect compared to dogs resuscitated 
to effect with LRS alone (Horton et al., 1989). They identified that the dogs 
resuscitated with LRS alone required approximately 5L more fluid during resuscitation 
to maintain systemic pressures, and this resulted in pulmonary hypertension and 
pulmonary oedema. There are multiple rodent experimental models that also show 
dextrans has a beneficial effect in acute pancreatitis (Donaldson and Schenck, 1979; 
Knol et al., 1983; Schmidt et al., 1993; Hotz et al., 1996). The benefit appears to be 77 
 
independent of the molecular weight, concentration (6% or 10%), or combination with 
hypertonic saline.  
There is no current evidence that any particular type of fluid resuscitation 
protocol or fluid type is advantageous in severe canine pancreatitis. However, 
extrapolation of the experimental and human studies would suggest that LRS is 
preferable to normal saline. It may also be wise to formulate a similar rate protocol to 
that used in the most recent human paper (Wu et al., 2011), and to use LRS as the 
initial resuscitative crystalloid fluid in dogs with severe pancreatitis. In this protocol, 
fluid was administered as a bolus, with 8-hourly checkpoints to determine if this had 
been successful in correcting fluid imbalances. A potential fluid algorithm for dogs is 
detailed in Figure 1.10. Further evaluation of colloid therapy (hetastarch or dextrans) 
would also be of great clinical benefit. 
  
Figure 1.10 Extrapolated fluid therapy algorithm (using crystalloid therapy) from Wu 
et al (2011).  
1.4.2 Plasma 
The use of plasma in dogs with acute pancreatitis is widely reported in review 
papers and textbooks (Heinrich et al., 2006; Logan et al., 2001; Snow et al., 2010; 
Williams and Steiner, 2005; Wu and Conwell, 2010a). Administration of plasma was 78 
 
shown to be superior to both crystalloid and colloid administration in a rat experimental 
model of pancreatitis (Leese et al., 1988). Purported benefits include replacement of 
circulating α-macroglobulins, replacement of coagulation factors and treatment of SIRS 
with anti-inflammatory factors (Weatherton and Streeter, 2009). Depletion of α-
macroglobulin has been documented in an experimental model of canine pancreatitis, 
and correlated with severity of pancreatic inflammation (Murtaugh and Jacobs, 1985). 
Systemic effects of the pancreatic inflammation were not assessed in that study, nor 
whether there would have been amelioration with administration of plasma. Another 
experimental study in dogs with pancreatitis induced by a trypsin infusion showed that 
death occurred when α-macroglobulins were consumed (Balldin et al., 1978). One 
study of sick dogs with increased lipase and probable pancreatitis showed that serum 
concentration of α-macroglobulins did not correlate with the severity of disease or 
clinical outcome (Ruaux and Atwell, 1999). It is unlikely that any benefit seen with 
plasma will be due to colloid like properties, as fresh frozen plasma (FFP) has only 
about 20-30% of the oncotic properties of colloids. However, haemostatic proteins in 
FFP are well preserved regardless of whether freeze-thawed or not (Iazbik et al., 2001; 
Yaxley et al., 2010). 
There are no controlled studies that prove the benefit (or lack thereof) of plasma 
transfusion in dogs with naturally occurring pancreatitis. The use of plasma for treating 
acute pancreatitis in dogs has been declining over the past 5 years (Snow et al., 2010). 
One retrospective veterinary study analysed data from a 10-year period, and identified 
77 dogs with pancreatitis that were admitted for treatment during that time (Weatherton 
and Streeter, 2009). Of these cases, 20 (approximately 26%) were given plasma at a 
mean infused volume of 16 mL/kg, with the volume given not differing between 
survivors and non-survivors. There was a significantly higher mortality (P= 0.008) in 
dogs that received plasma (7/20) compared to those that did not (6/57). There appeared 79 
 
to be no difference in the choice to administer plasma based on the presence of SIRS or 
a documented coagulopathy, however there was insufficient data to allow for 
meaningful analysis of this. This study is inherently flawed due to its retrospective 
nature, and the lack of stratification of disease severity or standardisation of other 
treatments. The biggest bias is likely to be that the clinically more severely affected 
dogs may be administered plasma due to the perceived benefit. Thus, those dogs that 
received FFP by inference would be more severely affected and inherently were more 
likely to die as a result of their disease. However, the lack of benefit seen in this study 
does reflect much of the human literature on this same subject (Leese et al., 1987).  
In one randomised prospective study of 200 people assessing low-dose FFP 
administration over 2 consecutive days, there was no survival benefit observed. A 
reduction in α-macroglobulin over three consecutive days was present, which suggested 
the volume of FFP may also play a role. The same group of researchers then assessed 
the benefit of high dose FFP therapy in a group of 72 patients predicted to have severe 
pancreatitis (Leese et al., 1991). These were randomly assigned to receive either FFP (8 
units daily for 3 days) or colloids. Again, there was no difference in survival between 
the two groups. This is despite a documented increase in serum anti-proteases in the 
treatment versus control group. This again highlights the difficulties in extrapolating 
experimental benefits to clinical settings.  
Although there is little evidence either supporting or refuting the use of FFP, it 
remains an expensive treatment for veterinary patients. None of the studies in people or 
dogs, although limited, have shown a clinical benefit and in fact suggest it may not be 
useful. In the light of these findings, administration of FFP should probably be reserved 
for those dogs with documented coagulation abnormalities, or where overt 
disseminated intravascular coagulation (DIC) is present.  80 
 
1.4.3 Anti-emetics 
Anti-emetics are a commonly used group of drugs in the management of 
gastrointestinal disease in dogs. The overall aim of anti-emetic therapy is to reduce 
volume loss when there is refractory vomiting, and therefore also reduce subsequent 
electrolyte and fluid imbalances. Vomiting in dogs with pancreatitis is likely to be both 
centrally mediated due to the presence of circulating emetic agents, and peripherally 
mediated due to ileus, peritonitis, and pancreatic distension (Elwood et al., 2010). 
There are no studies published on the efficacy of individual anti-emetic drugs in 
canine pancreatitis. Due to the large number of possible drugs that could be discussed, 
this review will concentrate on the most commonly used anti-emetics in veterinary 
practice: the dopamine-antagonistic (and weakly 5-HT3 antagonistic) agent 
metoclopramide; the NK1- receptor antagonist maropitant; and ondansetron, a 5-HT3 
selective antagonist that is being increasingly used in veterinary practice (Elwood et al., 
2010). 
Metoclopramide has been used in veterinary medicine for a long period of time, 
and in the acute setting can be given as intermittent boluses (intravenously or 
intramuscularly), or as a constant rate intravenous infusion (Elwood et al., 2010). In 
one veterinary study assessing the efficacy of this drug in dogs with parvovirus, the 
number of emetic episodes was not reduced when metoclopramide was given as an 
intermittent bolus (Mantione and Otto, 2005). Additionally, there was no correlation 
between a positive outcome and the number of emetic events.  
There is some anecdotal advice that suggests because metoclopramide is a 
dopaminergic antagonist, it should not be used in acute pancreatitis (Williams, 1994). 
Experimental animal models have shown that dopamine infusion improves the outcome 
in acute pancreatitis, and ameliorates the inflammatory severity of the disease (Karanjia 
et al., 1990; Karanjia et al., 1991). This does not appear to be related to blood flow to 81 
 
the pancreas, and is instead postulated to be due to reduction of pancreatic 
microvascular permeability (Karanjia et al., 1991).  Low-dose infusion of dopamine 
may be more effective at preventing distant lung injury than reducing pancreatic 
inflammation per se (Kaya et al., 2005). There is therefore a theoretical disadvantage in 
giving metoclopramide to dogs with acute pancreatitis, although this is unproven.  
Maropitant, which blocks the Neurokinin 1 (NK1)-receptor and therefore the 
actions of Substance P is an effective anti-emetic agent that blocks centrally and 
peripherally mediated emesis (Benchaoui et al., 2007; Conder et al., 2008; De la 
Puente‐Redondo, 2007a; De la Puente‐Redondo, 2007b; Rau et al., 2010; Sedlacek et 
al., 2008). In one experimental study in dogs, it was shown to be more effective than 
metoclopramide, but not ondansetron, in controlling emetic episodes due to peripheral 
emetic stimulation (Sedlacek et al., 2008). It was more effective than ondansetron, but 
not metoclopramide, in controlling emetic episodes due to centrally-mediated emesis 
(Sedlacek et al., 2008). In another study, this time prospectively assessing dogs with 
vomiting due to naturally occurring disease in Europe, maropitant was superior to 
metoclopramide, both within the first 24 hours, and then for every day up to 5 days, 
when the trial was stopped (De la Puente‐Redondo, 2007). Therefore as emesis in 
pancreatitis is mediated both centrally and peripherally there is a theoretical advantage 
in using maropitant compared to either metoclopramide or ondansetron.  
As well as being effective in controlling emesis, there is another theoretical 
benefit to NK1-receptor antagonism, via blocked production of Substance P. Substance 
P is a mediator that is produced by nerve endings throughout the body. It has been 
shown to be up-regulated in mouse models of acute pancreatitis (Frossard and Pastor, 
2002). Substance P mediates capillary permeability and is produced when NK1 
receptors are stimulated. Substance P has also been shown to be up-regulated in acinar 
cells during murine experimental pancreatitis (Frossard and Pastor, 2002).  When the 82 
 
NK1 receptor was blocked in a genetic mouse model, there was no difference in the 
amount of pancreatic inflammation produced, but distantly-mediated lung injury was 
reduced (Pastor and Frossard, 2001). It is this possible effect that may be of benefit in 
dogs with severe pancreatitis, as they are at risk to develop acute lung injury in addition 
to the potential to reduce pain.  
Apart from one study experimentally inducing emesis, there have been no direct 
comparisons of ondansetron to maropitant in dogs. Anecdotally, many veterinary 
surgeons will give ondansetron either in conjunction with or instead of maropitant to 
control nausea. In people assessed post-operatively, there is evidence that NK-1 
receptor antagonists are equal or superior to ondansetron in controlling nausea, and 
result in fewer emetic episodes (Diemunsch et al., 2009). Although there is again a 
danger of direct extrapolation, the NK1-receptor function is considered the same in 
dogs as in people (Leffler et al., 2009).  
Consequently, current levels of knowledge suggest maropitant should be used 
as the first line treatment for controlling vomiting and nausea in dogs with acute 
pancreatitis. Although there is no evidence of any adjunctive benefits, it is possible that 
combination with ondansetron may improve nausea control.  
1.4.4 Antibiotics 
Antibiotic therapy is commonly used in the management of canine pancreatitis, 
despite the necrosis invariably being sterile, and a lack of data suggesting that 
antibiotics improve survival or outcome.  
There has been a degree of controversy over the past few years regarding the 
use of prophylactic antibiotics in people with acute pancreatitis. The main purpose of 
antimicrobial use in people is to treat or prevent the infection of necrotic pancreatic 
tissue or ascending cholecystitis (Sainio et al., 1995). Many people with pancreatitis 
either have gall stones or alcohol-induced disease, so have different susceptibilities to 83 
 
infections than dogs. Additionally, there is a high rate of hospital-introduced infections 
in people with acute pancreatitis (Sainio et al., 1995). This may also be the case in the 
veterinary population, but this has not been determined.  
There have been a number of studies assessing antibiotics in people 
(Delcenserie et al., 1996; Isenmann et al., 2004; Luiten et al., 1995; Nordback et al., 
2001; Sainio et al., 1995; Schwarz et al., 1997), as well as numerous meta-analyses 
(Golub et al., 1998; Sharma and Howden, 2001; Villatoro et al., 2006; Yao et al., 
2010). These all have quite conflicting results, with the initial recommendation being 
that there should be prophylactic use of a drug with good tissue penetration, namely 
imipenem (Heinrich et al., 2006; Hirota et al., 2010; Villatoro et al., 2006). The basis 
for this recommendation was that although the numbers of infections are not reduced 
when people are treated with β-lactams compared to fluoroquinolones, the mortality 
rate is (Villatoro et al., 2006). This parallels the observations that carbapenems, some 
cephalosporins, trimethoprim-sulphonamide and enrofloxacin all have good pancreatic 
tissue penetration in people and dogs (Bradley, 1989 ; De Waele, 2010). However, in 
the clinical studies additional management protocols were used, so the beneficial 
effects could not be credited to antibiotic therapy alone (Luiten et al., 1995; Sainio et 
al., 1995). 
To add confusion to the issue, there have also been studies that imipenem 
reduces infection rate, but has no effect on mortality (Pederzoli et al., 1993). This study 
was open labelled, and so some bias is present. Additionally, an increasing incidence of 
resistant organisms and fungal infections has been noted in people with pancreatitis 
pre-treated with antibiotics, and reflects an emerging trend (Behrman, 2011).  
Overall, with more recent multi-centre double-blinded prospective studies 
(Dellinger et al., 2007; Garcia-Barrasa et al., 2009; Isenmann et al., 2004) and multiple 
meta-analyses the overall suggestion is that there is no benefit in prescribing 84 
 
prophylactic antibiotics in people, regardless whether necrosis is present or not 
(Charbonney and Nathens, 2008; De Waele, 2010; Nathens et al., 2004; Nicholson, 
2011). Instead, antibiotics should only be given when a documented infection is 
present, and should be given early in the course of the disease (De Waele, 2011; 
Pezzilli, 2009). 
The documented organisms isolated from the pancreas in most people originate 
from extra-pancreatic sites, and may result from seeding during surgical resection, the 
overuse of prophylactic antibiotics and concurrent central intravenous lines to provide 
total parenteral nutrition (Behrman, 2011). The lower use of surgical interventions in 
dogs, along with the differences in aetiologies may well account for the lower numbers 
of documented pancreatic infection in dogs. In a canine induced-pancreatitis model, 
plasmid labelling showed that organisms detected in the mesenteric lymph nodes and 
pancreas were the same that colonised the intestine, indicating bacterial translocation 
(Liu et al., 2000).  
Unpublished observations have identified the presence of bacteria in the 
pancreas of cats with no overt signs of pancreatitis using culture independent methods 
(K Simpson, personal communication). The true clinical significance of that in cats is 
yet to be determined. Cats have a common bile and pancreatic duct, in comparison to 
dogs. It is likely that this predisposes cats to bacteria being present in the pancreas, but 
it is unlikely such an incident occurs in dogs.  
As true pancreatic infection is extremely rare in dogs with acute pancreatitis, the 
use of antimicrobials must be questioned. The biggest indication for their use would be 
signs consistent with a high risk of bacterial translocation along with a documented 
pro-inflammatory state (SIRS). Signs consistent with a high risk of bacterial 
translocation include bloody diarrhoea, prolonged fasting and haematemesis. The 85 
 
penetration of antibiotics into the pancreatic tissue would therefore be of lesser 
importance in antibiotic selection than a spectrum effective against gut pathogens.  
The standard use of prophylactic antibiotics in dogs without signs of concern 
may lead to increased community resistance to antibiotics. The use of fluoroquinolones 
or vancomycin is strongly discouraged without documented evidence for their use.  
1.4.5 Analgesia 
It is commonly accepted in the veterinary (Watson, 2004; Williams, 1994; 
Williams and Steiner, 2005) and human literature (Pezzilli, 2009; Wu and Conwell, 
2010a) that analgesia is a vital component of managing acute pancreatitis. It should be 
presumed that dogs with pancreatitis severe enough to require hospitalisation also 
require analgesia (Williams and Steiner, 2005). Recently, the use of patient controlled 
analgesia in human gastroenterology has improved outcomes and reduced 
hospitalisation times (Hirota et al., 2010; Wu and Conwell, 2010a). Additionally, in 
rodent experimental models, the use of thoracic epidural analgesia has been shown to 
improve pancreatic blood supply and decrease mortality (Freise et al., 2006).  
Opioids are the first line therapy in the management of pain. Buprenorphine 
does not cause contraction of the sphincter of Oddi, and therefore theoretically could be 
preferable as first line therapy (Jakobs et al., 2000). That being said, there is no 
indication that the stimulation of the sphincter of Oddi that this class of drug causes is 
detrimental in pancreatitis.  
If opioid analgesia is considered insufficient, then other multi-modal delivery of 
analgesia can be used. It is important if the pain in an individual animal appears to be 
increasing that a complication such as acute fluid collection is ruled out and treated as 
necessary (discussed in section 1.4.7). An alternative analgesic agent is ketamine, given 
as a continuous rate infusion. This modality is attractive due to the lack of detrimental 
effect on gastrointestinal motility (Bares et al., 1995). Other alternative modalities 86 
 
include epidural analgesia (morphine with or without gabapentin), inter-pleural blocks 
and lignocaine continuous rate infusion (Dravid and Paul, 2007; Smiley et al., 2004). 
None of these have been evaluated in canine acute pancreatitis, and modification of the 
analgesia plan should be performed on an individual basis.  
The use of pancreatic enzyme supplements to provide analgesia when feeding 
animals with pancreatitis has been recommended, but there have been no studies to 
validate this (Williams, 1994). Only one randomised placebo-controlled trial in people 
has been undertaken, and this showed no analgesic benefit when given early in the 
course of the disease (Patankar et al., 1995). Additionally, only 52% of people assessed 
in a meta-analysis actually preferred oral enzymes (Gachago and Draganov, 2008). 
This is despite some earlier studies showing a significant advantage in people with 
idiopathic, mild disease (Isaksson and Ihse, 1983; Slaff et al., 1984). One possible 
reason for this discordance of results is the small number of people in each trial, the 
difference in enzymes (enteric vs. non-enteric coated preparations), a high placebo rate 
and also the possibility of inactivation within the stomach or duodenum. It is also 
highly likely that different sub-sets of patients will have different responses to this 
treatment. Currently, there is insufficient evidence to recommend their use in dogs, 
unless there is pain directly associated with feeding.  
1.4.6 Gastric acid suppression 
 
Reduction of gastric acidity medically or via physical suctioning of gastric 
contents is recommended in many veterinary summaries (Kalli et al., 2009; Stewart, 
1994; Watson, 2004; Williams, 1994). The rationale these summaries have provided for 
this include that reduction of gastric acid production will lead to decreased pancreatic 
exocrine stimulation and that acute pancreatitis predisposes to the development of 
gastric mucosal ulceration due to hypovolaemia and local peritonitis.  87 
 
There have been no studies that report on the efficacy of gastric acid 
suppression in dogs with acute pancreatitis. However, a lack of proven benefit does not 
negate the treatment if no adverse effects occur. Thus it remains ambiguous as to the 
recommendation for their use. The physical presence of a feeding tube across the 
gastro-oesophageal sphincter may well predispose to the development of severe 
oesophagitis due to gastro-oesophageal reflux, and so should not be routinely used.  
In people with mild to moderate disease, there have been randomised clinical 
trials assessing nasogastric suctioning.  None of these have shown any benefit of this 
treatment in reducing pain or hospitalisation duration (Field et al., 1979; Fuller et al., 
1981; Levant et al., 1974; Loiudice et al., 1984; Naeije et al., 1978; Navarro et al., 
1984; Sarr et al., 1986). In fact, some of these have actually shown prolongation of pain 
and nausea (Fuller et al., 1981; Loiudice et al., 1984; Navarro et al., 1984; Sarr et al., 
1986). A meta-analysis of cimetidine confirmed that its use had no clinical benefit, and 
actually tended to increase the incidence of complications (Morimoto et al., 2002).  
There are no meta-analyses or well controlled studies on the use of proton-pump 
inhibitors in acute pancreatitis in people, and very few in any disease in dogs. 
Theoretically proton pump inhibitors may have directly beneficial effects by blocking 
the vacuolar ATPase pump on pancreatic acinar cells. This is based on the observation 
that lower pH within the acinar cell accelerates zymogen activation, and amplifies the 
subsequent inflammatory damage (Bhoomagoud et al., 2009; Waterford et al., 2005). 
One experimental study in rats showed pantoprazole reduced inflammatory changes 
and leakage of acinar cells (Hackert et al., 2010). This must be an indirect effect, as in 
vitro there appears to be no direct effect of proton pump inhibitors on pancreatic 
exocrine secretion (Cai et al., 2007).  
Currently, there is no evidence that reducing gastric acidity improves outcome 
in dogs with acute pancreatitis. However, if there is evidence of gastric ulceration 88 
 
(substantial haematemesis, melena) or oesophagitis, then gastric acid suppression is 
indicated. In human medicine it is recommended that the gastric pH is increased to 
more than 4 for approximately 16-22 hours per day in critically ill patients or patients 
with severe gastro-oesophageal reflux (Bersenas et al., 2005). Omeprazole, a proton 
pump inhibitor, has been shown to be the most effective at increasing gastric pH for the 
longest period of time in dogs compared to famotidine, pantoprazole, and ranitidine 
(Bersenas et al., 2005; Tolbert et al., 2011). Dogs and cats are often dosed with oral 
omeprazole at 0.7-1mg/kg daily, but recent work would suggest that doses should be 
increased up to 2.5 mg/kg day, in divided doses (Tolbert et al., 2011). 
1.4.7 Treatment of complications  
 
Complications that develop in acute pancreatitis are broadly divided into the 
local pancreatic complications and systemic complications. Prediction of dogs likely to 
be affected with systemic complications will help guide the level of monitoring. Based 
on extrapolation from human experience (Singh et al., 2009), dogs with SIRS, lack of 
enteral nutrition, hypotension and hypovolaemia would be at high risk of developing 
complications. A proportion of dogs that present with acute pancreatitis have diabetic 
ketoacidosis (DKA), and this also requires specific treatment (Watson, 2004; Williams 
and Steiner, 2005). Although there is an assumption that the pancreatic inflammation 
causes damage to the islet cells and therefore causes DKA, it is possible that the 
ketoacidosis actually precipitates pancreatitis due to the lowering of acinar pH 
(Bhoomagoud et al., 2009; Noble et al., 2008; Waterford et al., 2005) 
Oxygen therapy is recommended in many human society guidelines to maintain 
arterial oxygen saturation > 95% (Hirota et al., 2010; Johnson, 2005; Nathens et al., 
2004; Wu and Conwell, 2010a). This is partly due to the high rate of lung injury 
associated with acute pancreatitis in people (Wang et al., 2006), a decreased respiratory 89 
 
drive due to narcotic use and pain (Muddana et al., 2009); and the risk of pulmonary 
oedema with fluid overload. No studies of this modality have been undertaken in dogs.  
Surgery to treat pancreatic acute fluid collections in dogs has invariably resulted 
in a high mortality rate (> 50%), regardless of the technique used (Bellenger et al., 
1989; Edwards et al., 1990; Johnson and Mann, 2006; Salisbury et al., 1988).  There 
have been reported spontaneous resolutions of acute fluid collections in the veterinary 
literature, and good responses to percutaneous drainage, suggesting these are preferable 
methods for managing this particular complication (Smith and Biller, 1998; 
VanEnkevort et al., 1999).  
Current human recommendations are not to debride sterile fluid collections, and 
if infection is documented then there should be treatment with antimicrobials for as 
long as possible prior to surgical debridement. (Heinrich et al., 2006; Johnson, 2005; 
Muddana et al., 2009; Nathens et al., 2004). As well, there is increasing evidence that 
ductal disruption is more commonly associated with progression of local pancreatic 
complications, such as pancreatic fistulae, whereas normal ductal anatomy usually 
results in spontaneous resolution (Wu and Conwell, 2010b). Therefore if ductal 
disruption is not present, even in the face of documented infection, percutaneous or 
endoscopic guided drainage may be sufficient for treatment. However, surgical 
necrosectomy is still the preferred method in advanced cases of infected pancreatic 
necrosis (Heinrich et al., 2006; Hirota et al., 2010; Johnson, 2005). 
Various surgical techniques have been described to treat extra-hepatic bile duct 
obstruction in dogs, including choleduodenectomy (Matthiesen and Rosin, 1986) and 
cholecystectomy (Mehler et al., 2004). These are invariably associated with a high 
mortality rate. Percutaneous drainage of the gall bladder has been described, and is a 
relatively safe and minimally invasive procedure (Herman et al., 2005). The benefits of 90 
 
this approach appear to outweigh the risks, but there are no strict criteria indentified for 
when drainage of the gall bladder is required.  
1.4.8 New therapeutic directions 
 
There have been many studies in the past three decades to assess new medical 
treatments for acute pancreatitis based on experimental success. These have been drugs 
that target specific cytokines, counteract proteases or reduce pancreatic secretion along 
with  novel treatments such as continuous haemodiafiltration and peritoneal dialysis 
(Pezzilli, 2009; Williams, 1994). None of the novel interventional treatments have been 
widely accepted or been shown to be particularly effective (Buchler et al., 1993; 
Dervenis et al., 1999; Johnson et al., 2001; Pezzilli, 2009), and as such don’t warrant 
extensive discussion in this review.  
The most common drugs studied include the anti-proteases aprotinin and 
gabexate mesilate; and the anti-secretory drug octreotide. Initially, there was some 
promise for protease inhibitors in both reducing mortality or complications in rodent 
experimental models and naturally occurring disease in people (Andriulli et al., 1998; 
Buchler et al., 1993; Chen et al., 2000; Mikami et al., 2005). However, stringent 
analysis of multiple randomised and well controlled clinical trials has shown no benefit 
for these agents to reduce mortality or morbidity (Heinrich et al., 2006; Imrie et al., 
1978; Uhl et al., 1999).  Additionally, it is recommended that these drugs be given 
within 24 hours of onset of pain, and be continued for at least 7 days (Pezzilli, 2009). 
The lack of effect of gabexate mesilate in human clinical trials has been replicated in 
canine experimental models (Luh et al., 1999), with the greatest effect seen in 
prevention of lung injury prior to onset of acinar cell injury, but not following it. These 
findings, along with the lack of availability and prohibitive costs make this drug 
impractical in the treatment of acute pancreatitis in dogs.  91 
 
Somatostatin and it long-acting analogue, octreotide, have been studied in 
people. They are potent inhibitors of pancreatic secretion, and also stimulate the 
reticuloendothelial system, and are considered cytoprotective to the pancreas (Pezzilli, 
2009). However, this theoretical benefit is counterbalanced by the powerful splanchnic 
vasoconstrictive properties of these agents, something that contributes to and 
perpetuates pancreatic necrosis (Klar et al., 1991). They appear to be agents best used 
as prophylaxis for prevention of ERCP-associated pancreatitis, and not in treatment of 
already established pancreatitis (Bang et al., 2008). There was no amelioration of 
histological inflammation in a study of dogs with induced pancreatitis treated with a 
somatostatin analogue (Ko et al., 1992). Again, clinical trials and meta-analysis have 
failed to identify a benefit with using these agents in people, and there is little to 
support their investigation in dogs (Heinrich et al., 2006; Uhl et al., 1999).  
In dogs, there have been no well-controlled studies of secretory inhibitors. 
There has been one case report of the use of chlorpromazine in a dog suffering 
pancreatitis as a result of organophosphate toxicity (Dalefield et al., 1999). This was an 
uncontrolled single observation, and as such lacks any level of evidence for efficacy. 
Despite interest in these agents beginning well over a decade ago, there is not sufficient 
basis to evaluate this further. Similarly, the use of glucagon cannot be recommended 
(Hirano and Hirano, 1999).  
The effects of specific anti-cytokine therapies appear to be highly variable, as 
they are generally useful at ameliorating only one aspect of the inflammatory cascade. 
Along those lines, a TNF-α inhibitor showed no protective effect in dogs undergoing 
ERCP (Buscaglia et al., 2008). Neutrophil-elastase inhibition had no benefit in an 
experimental dog model, although survival was not assessed (Imamura et al., 1998). 
Platelet-activating factor antagonists such as lexipafant reduced lung-associated injury 
in rodent models when given prophylactically, but this did not translate to a clinical 92 
 
benefit in well-powered human trials of spontaneous disease (Formela et al., 1994; 
Heinrich et al., 2006; Johnson et al., 2001; McKay and Imrie, 2004). However, on close 
review of those studies, when people that were treated with lexipafant within 48 hours 
of onset of symptoms, there was a significant reduction in the development of 
pseudocysts, early onset sepsis and death compared to placebo (Pezzilli, 2009). 
As there are multiple cytokine cascades stimulated with acute pancreatitis, it is 
not surprising that antagonism of just one cytokine is unlikely to provide substantial 
benefit when used later in the onset of disease. The decreased likelihood of dogs being 
presented for veterinary attention shortly after onset of signs, a lack of widespread 
availability of anti-cytokine drugs in veterinary medicine and prohibitive costs, makes 
this group of drugs an unappealing avenue to pursue in veterinary medicine.   
1.4.9 Anti-inflammatory therapy  
1.4.9.1 Non-steroidal anti-inflammatory drugs (NSAIDs) 
Although NSAIDs have potent analgesic and anti-inflammatory effects (Bang et 
al., 2008), they cannot be recommended for use in critically ill dogs with acute 
pancreatitis. This is due to the dehydration that is generally present, and the potential 
effects on renal perfusion and gastric mucosal health that may result from their use 
(Bang et al., 2008). There have been some small studies in people that show small 
differences in outcome when using indomethacin or diclofenac, but only in prevention 
of ERCP-associated pancreatitis (Bang et al., 2008).    
1.4.9.2 Glucocorticoids 
It is ironic that glucocorticoids, previously feared as a potential cause of 
pancreatitis are beginning to be used and evaluated again for treatment of acute 
pancreatitis. Historical reluctance to use this drug in dogs, and to a lesser extent in 
people, probably resulted from the presumption that corticosteroids could lead to 
pancreatitis. The putative link between pancreatitis and glucocorticoids in dogs may be 93 
 
attributed to early studies showing dexamethasone increased pancreatic enzyme 
concentrations, but had no effect on pancreatic tissue (Imahori et al., 1984; Parent, 
1982; Strombeck et al., 1981). Whilst theoretically any drug can cause pancreatitis in 
any individual dog, corticosteroids are no longer considered to be high risk in people 
(Bang et al., 2008). Alongside this, glucocorticoids are the one group of drugs that are 
known to counteract virtually all pathways of inflammation. 
Corticosteroids may have multiple benefits in acute pancreatitis because they 
inhibit release of pro-inflammatory mediators, decrease sequestration of neutrophils in 
the pulmonary vasculature, reduce adhesion of primed neutrophils to the endothelial 
surface of pulmonary vasculature, reduce release of elastase and free radicals from 
adherent neutrophils and reduce pulmonary vascular permeability (Sun et al., 2007; 
Williams, 1994). A specific role of corticosteroids in enhancing apoptosis, and 
increasing production of pancreatitis-associated protein (PAP), which confers a 
protective effect against inflammation has also been proposed (Heller et al., 1999; 
Iovanna et al., 1991; Ortiz et al., 1998; Zenilman et al., 1996). In addition to these 
effects, the concept of relative adrenal insufficiency as discussed below, also has 
potential applications to acute pancreatitis.  
1.4.9.2.1 Relative adrenal insufficiency 
It order to put into context the concept of relative adrenal insufficiency it is 
important to first know the interaction of the hypothalamic-pituitary-adrenal (HPA) 
axis in illness (Marik et al., 2008). Anti-diuretic hormone (ADH), also known as 
vasopressin, is a weak adrenocortical-stimulating hormone (ACTH) secretagogue and 
vasoactive peptide that acts synergistically with corticotrophic-releasing hormone 
(CRH) to increase secretion of ACTH (Marik et al., 2008). More than 90% of 
circulating cortisol is bound to corticosteroid-binding globulin (CRG), and during acute 
illness this reduces to as much as 50%, leading to a higher amount of circulating free 94 
 
cortisol (Marik et al., 2008). Cortisol exerts systemic effects by binding to intracellular 
glucocorticoid receptors (GR). The cortisol-GR complex moves to the nucleus, where it 
binds to DNA sequences called glucocorticoid-responsive elements in the promoter 
regions of target genes, thus causing up or down regulation of genes involved in 
inflammation (Marik et al., 2008).  
Cortisol may directly affect activity of NF-κB. Cortisol also increases blood 
glucose by activating hepatic gluconeogenesis and inhibiting peripheral glucose uptake 
by peripheral tissue; activates lipolysis to release free fatty acids into the circulation; 
and increases catecholamine and glucagon production (Marik et al., 2008). 
Haemodynamic effects are mediated by an increase in sensitivity to vasopressors 
(ADH-1 and ADH-2 receptors) in vascular smooth muscle, resulting in increased blood 
pressure (Marik et al., 2008).   
During acute illness the HPA axis is stimulated as shown in Figure 1.11, but in 
about 10-20% of critically ill people and 60% of people with septic shock, this pathway 
becomes impaired (Marik et al., 2008). Mechanisms that lead to this dysfunction are 
complex and poorly understood.  Possible causes include decreased production of CRH 
or ACTH; dysfunction of peripheral glucocorticoid receptors; or dysfunction of the 
adrenal gland due to haemorrhage or thrombosis, all in the face of high circulating 
cortisol concentration (Marik et al., 2008).  95 
 
 
Figure 1.11 Activation of the HPA axis in response to stress. TGF-β, transforming 
growth factor β; POMC, pro-opiomelanocortin; LIF, leukaemia inhibitory factor; 
CRH, corticotrophin-releasing hormone; ADH, anti-diuretic hormone; ACTH, 
adrenocorticotrophic hormone.  
 
The latest recommendation from the American College of Critical Care 
Medicine is to use the term critical illness-related corticosteroid insufficiency (CIRCI) 
to describe the adrenal dysfunction that occurs during critical illness in people (Marik 
et al., 2008). Effectively, CIRCI occurs when there is an adrenal insufficiency along 
with tissue resistance to the effects of corticosteroids, due to a prolonged and severe pro 
inflammatory state.  In particular, it causes hypotension and a poor response to fluid or 
vasopressor therapy. It is in the sub-group of people with poor response to resuscitative 
measures (fluid and vasopressor therapy) and those with acute lung injury, where 
cortisone replacement appears to be the most effective (Marik et al., 2008).  
Low-dose hydrocortisone is the current recommended treatment for those 
people with septic shock and CIRCI, whilst methylprednisolone is recommended for 
those with acute lung injury. Continuous rate infusion therapy may result in better 
glycaemic control, and is advocated in septic shock, and abrupt cessation is not 96 
 
recommended (Marik et al., 2008). Dexamethasone administration is not recommended 
due to prolonged suppression of the HPA axis. These recommendations have not been 
extended to people with acute pancreatitis to date.  
These recommendations are based on a number of papers where low doses of 
hydrocortisone appeared to improve survival and haemodynamic status in people with 
septic shock poorly responsive to vasopressor treatment (Bollaert et al., 1998). Another 
trial in people with documented CIRCI showed that 50 mg hydrocortisone (combined 
with fludrocortisone) resulted in greater survival and no increase in adverse effects 
(Annane et al., 2002). However, a recent double-blind, placebo controlled, randomized 
trial of 499 people showed that there was no difference in survival between those 
treated with placebo or those treated with hydrocortisone, irrespective of their adrenal 
function testing (Sprung et al., 2008). Those people that had reversal of their shock had 
a quicker response when given hydrocortisone than those given placebo. However, 
there was a greater rate of superinfections and new septic episodes with hydrocortisone 
treatment.  They were administered a higher dose of hydrocortisone (100 mg) than in 
the other studies.  
1.4.9.2.2 Cortisol metabolism in people with acute pancreatitis 
The potential role of CIRCI in spontaneous pancreatitis in people has begun to 
be explored (Muller et al., 2006). One study assessing 109 people with acute 
pancreatitis showed initially high free and total cortisol, low ACTH and CBG. Over 
time however, the ACTH concentration increased, whilst the cortisol concentrations 
decreased. In people with necrotising pancreatitis the ACTH increase occurred at day 5, 
whilst in oedematous pancreatitis it occurred at day 3 and there was no overall 
difference between the two groups at day 6.  
Another study of severely ill people with acute pancreatitis identified a 
relatively low circulating cortisol response to ACTH in non-survivors (Peng et al., 97 
 
2009). As well as correlating to survival, CIRCI was also related to rates of pancreatic 
necrosis, bacteraemia and degree of organ dysfunction, especially cardiovascular 
dysfunction. However, another study found no difference in mortality or rate of 
necrosis between people with or without CIRCI (De Waele et al., 2007). The testing in 
the latter study was not as early as the study by Peng et al (2009). This timing 
discrepancy and therefore potential for treatments to influence results, the low numbers 
in the studies, the different doses of synthetic ACTH used, and the different causes of 
pancreatitis may account for the differences between the studies. Regardless, there is a 
moderate level of evidence that CIRCI may exist in people with severe acute 
pancreatitis.  
1.4.9.2.3 Corticosteroid therapy in animal models of pancreatitis 
There have been multiple animal experimental models assessing the effects of 
glucocorticoids in pancreatitis. In short, they have shown a reduction in the treated 
groups in pro-inflammatory cytokines, arachidonic acid metabolites, serum amylase 
concentration, necrosis, histological indices, PLA-2 concentration, incidence of 
leucopenia and mortality (Gloor et al., 2001; Kilic et al., 2010; Kimura et al., 1998; 
Muller et al., 2008; Osman et al., 1999; Yubero et al., 2009a; Yubero et al., 2009b; 
Zhang et al., 2008b; Zhang et al., 2010). These effects appeared to be greater in 
necrotizing forms of the disease than in milder, oedematous forms. Additionally, 
reduced expression of P-selectin protein which is a marker for white cell adhesion to 
endothelial cells has been shown in dexamethasone treated animals (Zhang et al., 
2010). Similarly, ICAM-1 has reduced expression in rodents pre-treated with 
hydrocortisone before induction of pancreatitis (Sun et al., 2007).  
In another study, in vitro and in vivo rodent models showed that dexamethasone 
up regulates the expression of pancreatitis-associated protein (PAP) (Kandil et al., 
2006). PAP is thought to have multiple protective effects, including anti-bacterial, anti-98 
 
inflammatory and amplifying pancreatic response to injury (Heller et al., 1999; Iovanna 
et al., 1991; Ortiz et al., 1998; Zenilman et al., 1996). It has been demonstrated that 
PAP decreases expression of NF-κB in an in vitro line of epithelial cells (Folch Puy et 
al., 2006), and that altered gene expression of PAP exacerbates the severity of 
pancreatitis (Zhang et al., 2004). 
Not all studies have shown such a benefit in mortality, even though there was 
decreased ascites production and increased apoptotic index (Zhang et al., 2007a; Zhang 
et al., 2007c). It may well be that the short duration of the study (12 hours) prevented a 
difference in survival being able to be determined. Interestingly, there was no 
relationship between the apoptotic index and any particular inflammatory mediator, 
suggesting there may be a direct as well as indirect effect on apoptosis by 
corticosteroids.  
1.4.9.2.4 Extrapolation to clinical cases (people and dogs) 
As has been proven with the other forms of potential treatment, a theoretical 
basis and experimental evidence does not always correlate to a clinical benefit. 
Currently there are a number of prospective trials being undertaken to evaluate the 
potential benefit of glucocorticoids in people with severe acute pancreatitis. A recent 
meta-analysis showed no benefit in giving corticosteroids as prophylaxis for ERCP 
induced pancreatitis (Zheng et al., 2008). This is perhaps not surprising considering that 
necrosis is not a common feature of this disease, and therefore the potential benefits are 
not applicable to this form.  
Before any further work is done assessing this treatment modality in dogs, it 
must be very carefully planned and used strictly only once the diagnosis of pancreatitis 
has been made. This is because the use of hydrocortisone in people has been associated 
with masking of oesophageal or intestinal perforation (Böhrer et al., 1996). The 99 
 
relevance to veterinary medicine is great, in that intestinal foreign body obstruction or 
septic peritonitis are major differential diagnoses for acute pancreatitis.  
There is no documented evidence that CIRCI occurs in dogs with acute 
pancreatitis, although it has been documented in dogs with hypotension and sepsis 
(Burkitt et al., 2007). This requires further evaluation, along with a standardised 
protocol for administering the adrenal function tests in affected dogs prior to evaluating 
efficacy of cortisone treatment. There is evidence that standard treatments given in an 
ICU setting could influence the ACTH stimulation results in dogs, and this influence 
should be accounted for in future studies (Sweeney et al., 2010).  
There may be a potential for the use of low-dose hydrocortisone infusion 
prophylactically during procedures where there is a high risk of pancreatitis developing, 
such as adrenal surgery (Mehler et al., 2004; Schwartz et al., 2008). Experimentally, 
administration of glucocorticoids early after interventional procedures (within 1 hour) 
showed the highest benefit (Marik et al., 2008). In addition to prophylactic usage, there 
may be a potential role for using low-dose hydrocortisone in dogs with severe acute 
pancreatitis that have poor systolic pressures with minimal response to fluid 
resuscitation. However, optimisation of the other aspects of management of canine 
pancreatitis should be completed before stringent analysis of corticosteroid therapy is 
undertaken.  
1.4.10 Follow-up management 
There is no defined management protocol following a bout of acute pancreatitis 
in dogs. Extrapolating from human gastroenterology, and applying common sense, it 
would be logical to treat any underlying conditions that may predispose to recurrent 
bouts of pancreatitis. Recurrent bouts of acute pancreatitis may lead to fibrosis, chronic 
pancreatitis and in some cases ultimately exocrine pancreatic insufficiency and diabetes 
mellitus (Tran et al., 2008; Watson, 2003; Watson et al., 2007; Wu and Conwell, 100 
 
2010b). The exact factors or mechanisms by which this occurs are not fully elucidated 
in dogs.  
Although in most instances the initiating cause of pancreatitis is not known, in a 
certain percentage of dogs there may be an underlying lipid disorder and therefore it 
may be prudent to check serum triglyceride and cholesterol 1-2 weeks after recovery 
from a bout of acute pancreatitis. (Hess et al., 1999; Williams and Steiner, 2005; 
Xenoulis et al., 2011). If drug administration is implicated in the aetiology, such as 
azathioprine or potassium bromide, then withdrawal of that drug should be undertaken.  
There is no evidence that dogs with dietary indiscretion will be predisposed to 
recurrent bouts of acute pancreatitis (Lem et al., 2008). However, the current consensus 
is that in those dogs where dietary factors are considered likely triggers, that they are 
fed low-fat and low-protein diets for an undetermined duration (Williams and Steiner, 
2005).  
A proportion of people following acute pancreatitis will have exocrine 
insufficiency that is manifested as steatorrhoea and diarrhoea (Wu and Conwell, 
2010b). One study has shown that the degree of exocrine insufficiency following a bout 
of acute pancreatitis in people is directly correlated with the amount of necrosis, as is 
the presence of pancreatic pseudocysts (Boreham and Ammori, 2003; Niederau et al., 
1990). Sub-clinical exocrine pancreatic insufficiency has been diagnosed in dogs, and 
is not always manifested by overt steatorrhoea (Wiberg and Westermarck, 2002). Based 
on this, in severely affected dogs, treatment with exocrine pancreatic enzymes for 3-4 
weeks following a bout of acute pancreatitis may be beneficial in selected instances.  
1.4.11 Nutrition 
1.4.11.1 Hypotheses and historical background 
Some of the nutritional challenges seen with acute pancreatitis in people are equally 
applicable to dogs. These challenges are namely that acute pancreatitis is a catabolic 101 
 
disease with significant nitrogen losses strongly associated with mortality (Ioannidis et 
al., 2008); ileus often complicates feeding; the sub-group of patients with necrosis have 
greater nutritional requirements, but are more difficult to effectively treat than those 
without necrosis and acute pancreatitis is diabetogenic (Thomson, 2006). 
In human and animal (pig, rodent, canine) experimental models it has been 
shown that fasting leads to intestinal mucosal atrophy (Hernandez et al., 1999; King 
and Kudsk, 1997), an increased rate of enterocyte apoptosis in the intestine (Fukuyama 
et al., 2001), changes in mucin composition of goblet and deep crypt cells (Sharma and 
Schumacher, 1995), and decreased glutamine and arginine transport (Sarac et al., 
1994). Overall, these changes result in a breakdown of the intestinal barrier and 
increased intestinal permeability, potentially leading to bacterial translocation (Deitch 
et al., 1987; Flint and Windsor, 2003; King and Kudsk, 1997).   
However, the initial model put forward by researchers of bacterial translocation 
(Wolochow et al., 1966) has been superseded as perhaps being too simplistic. The 
gastrointestinal tract itself is now thought to be a major contributor to the systemic 
inflammatory state during acute pancreatitis, particularly if it is not supplied topical 
nutrients.  These theories of the gut starter or gut motor model in perpetuation of acute 
pancreatitis were discussed in section 1.2.2.9, and are depicted in Figure 1.12.  
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Initially in human (and veterinary) gastroenterology the idea was to ‘rest’ the 
pancreas and therefore provide no exocrine stimulation during bouts of acute 
pancreatitis.  These recommendations were based on the assumption that ongoing 
pancreatic secretion could be harmful by perpetuating the inflammation (Stewart, 1994; 
Williams, 1994). Two experimental studies in dogs paved the way for complete 
intestinal rest to be recommended in dogs with acute pancreatitis (Konturek et al., 
1972; Vidon et al., 1978). These showed that despite pancreatic secretion being less 
when nutrients were delivered to the jejunum than to the duodenum in both people and 
dogs, it still occurred to some extent. As such, the authors proposed that in order to 
prevent pancreatic secretion, complete intestinal rest would be the only way to achieve 
this. 
There is also a differing rate and content of pancreatic secretion in response to 
different food types. This is exemplified in one experimental canine model that showed 
dispersed oleate is a more effective stimulus of pancreatic secretion than the non-
dispersed (oil phase), and when the intestinal pH is ≥ 7 only fatty acids longer than 8 
carbons stimulate pancreatic secretion (Meyer and Jones, 1974). Additionally, when 
Figure 1.12 The interaction between the intestine and pancreas, perpetuating 
inflammatory responses and leading to the development of systemic inflammatory 
syndrome (SIRS) or multiple organ dysfunction (MODS).   
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triglycerides are placed directly into the duodenal lumen there is no pancreatic 
stimulation, rather this occurs only when the products of lipolysis are present. The 
clinical relevance of this study is difficult to establish, but it emphasises that it may be 
the molecular structure of a diet that may be as important as the overall nutrient profile. 
1.4.11.2 The shift from parenteral to enteral nutrition in acute pancreatitis 
Although total parenteral nutrition (TPN) was used to treat acute pancreatitis for 
a considerable length of time, in the 1990s the role of the intestine in initiating or 
perpetuating systemic inflammation began to receive attention and enteral nutrition was 
preferentially used in people. However, feeding was delivered into the jejunum rather 
than into the duodenum. The presumption for this was that jejunal administration of 
nutrients stimulated exocrine pancreatic production of digestive enzymes to a lesser 
degree, as shown in healthy people (Kaushik et al., 2005; Ledeboer et al., 1998). It had 
previously been shown in dogs that intra-jejunal administration of neutral pH elemental 
nutrition did not lead to pancreatic secretion, and glucose into the jejunum actually had 
a negative feedback effect (Ragins et al., 1973).  
There were also a number of studies that supported jejunal feeding compared to 
TPN by suggesting trypsin secretion is minimal to none in jejunal feeding, although 
trypsin may still be produced by the pancreas (Bodoky et al., 1991; O'Keefe et al., 
2006; O’Keefe et al., 2005). As well, in 4 rodent experimental models inducing 
pancreatitis of variable severity (oedematous, necrotic, haemorrhagic) it was 
demonstrated that exocrine pancreatic function was actually decreased during 
experimental pancreatitis (Niederau et al., 1990).  
  Running in parallel to these studies, vigorous assessment of TPN was also 
beginning. A study by Alverdy et al (1988) looked at bacterial translocation in rats 
(Alverdy et al., 1988). Two thirds of the rats receiving TPN had culture-positive 
mesenteric lymph nodes, compared to 1/3 of the orally fed group and none of the 104 
 
controls. This could have clinical ramifications for dogs with pancreatitis, as decreased 
gut permeability may worsen this bacterial translocation. TPN was also associated in 
other experimental studies with increased mortality, and showed no proven benefit in 
people with pancreatitis (King and Kudsk, 1997; Sax et al., 1987).  
Studies of TPN compared to no nutritional intervention for acute pancreatitis 
support the notion that TPN before volume resuscitation worsens prognosis, but may 
actually improve it afterwards (He et al., 2004; McClave et al., 2006; Sahin et al., 
2007). This effect was even more apparent when TPN was supplemented with 
glutamine, although the studies were under-powered (He et al., 2004; Ockenga et al., 
2002). This is based on the fact that glutamine is the preferred respiratory fuel for 
rapidly growing cells like enterocytes and lymphocytes, so potentially has a role to play 
both in gut health and lymphocyte function (Furst et al., 1997). The pancreas is also 
considered to have the highest turnover of glutamine in the body (Furst et al., 1997).  
Meta-analysis shows that TPN has a higher relative risk compared to enteral nutrition 
(EN) for hyperglycaemia and insulin requirements in people with acute pancreatitis, 
worsening prognosis (Petrov and Zagainov, 2007). The significance of this 
phenomenon is based on work in critically ill people that has shown tight glycaemic 
control reduces the risk of mortality and infectious complications (Van den Berghe et 
al., 2001).  
Pancreatitis is one of the conditions where TPN is recommended as the first line 
nutritional support in dogs (Chan and Freeman, 2006; Stewart, 1994; Williams, 1994). 
TPN solution is a combination of dextrose, an amino acid solution and lipid solution. 
There is no evidence that lipid content will be detrimental to dogs with pancreatitis, and 
the current recommendation is only to reduce the lipid content when 
hypertriglyceridaemia is present (Chan and Freeman, 2006; McClave et al., 2006). 105 
 
Interestingly, in dogs both protein and fat are potent stimulants of pancreatic secretion, 
even when given intravenously (Konturek et al., 1979).  
Despite the recommendations, TPN in dogs is poorly evaluated. It has been 
experimentally demonstrated in dogs that TPN reduces stomach, duodenal and gall 
bladder motility (Kaji et al., 2002). This could perpetuate ongoing vomiting due to 
ileus, and increase the risk of extra-hepatic bile duct obstruction due to diminished gall 
bladder contractility. There have been few reviews on the clinical efficacy, or not, of 
TPN in any specific condition in dogs. One study identified a mortality rate of nearly 
50% in over 200 dogs that received TPN, along with a high rate of metabolic (70%), 
mechanical (25%) and septic (5%) complications (Reuter et al., 1998). Despite a 
similar rate of complications, a more recent paper reported that complications of 
parenteral nutrition had no relationship with outcome (Queau et al., 2011). This study 
assessed both peripheral and centrally administered parenteral nutrition and a risk 
factor for death was a prolonged period of anorexia prior to the initiation of parenteral 
nutrition. Due to the retrospective nature of the study, it was not possible to specifically 
evaluate dogs with pancreatitis.  
1.4.11.3 Animal experimental models supporting enteral nutrition  
A number of studies to assess enteral nutrition in experimental models have 
been performed. In one rodent model study, dietary protein depletion and endotoxin 
administration caused a greater degree of bacterial translocation than with normal 
dietary protein intake (Deitch et al., 1987). Further studies have also confirmed 
increased gut permeability is present in people with acute pancreatitis, and the degree 
of increased permeability correlates to the severity of disease in rat models (Ryan et al., 
1993; Wang et al., 1996).  
One rodent study showed that enteral feeding maintained immune 
responsiveness and reduced villous atrophy compared to TPN (Kotani et al., 1999). 106 
 
Despite these positive findings, there was no difference in outcome (survival) or rate of 
pancreatic healing, although the model appeared to induce mild disease. In a series of 
studies by the same group of researchers inducing disease in dogs, enteral and 
parenteral nutrition was compared (Qin et al., 2002a; Qin et al., 2002b, 2003, 2007). 
Dogs receiving enteral nutrition did so via a jejunal feeding tube 24 hours after 
induction of disease. Dogs receiving TPN were given an iso-caloric and iso-nitrogenic 
diet via a jugular catheter. Dogs that were enterally fed had lower serum glucose 
concentrations, and decreased bacterial translocation and endotoxin concentration. 
There was no difference in severity of disease as assessed by blood markers and 
histological analysis at the end of the study at Day 7. It was not possible to compare 
survival or distant organ complications in this study.  
1.4.11.4 Clinical evidence for enteral nutrition in people with acute pancreatitis  
The theoretical (and experimental) benefit of enteral nutrition by maintaining 
host immune responsiveness and preservation of intestinal integrity does not ensure a 
tangible clinical benefit, and so further clinical studies were undertaken. Despite the 
difficulty in interpreting these studies due to low numbers of patients, some selection 
bias, and failure to standardise disease severity or other treatments, there is still a 
moderate amount of evidence that enteral feeding is preferable to TPN in people with 
severe acute pancreatitis. All of the studies mentioned in this section used naso-jejunal 
(NJ) delivery of nutrients to the intestine.  
Perhaps the biggest failing of the majority of studies is their failure to compare 
enteral nutrition to fasting (or full pancreatic rest), instead comparing to TPN. Meta-
analysis that supports the use of early enteral nutrition in severe pancreatitis does this in 
the face of knowledge that TPN is probably harmful (McClave et al., 2006; Meier et al., 
2006; Petrov et al., 2008b; Petrov et al., 2008c). In this way the studies are only 
comparing a treatment of unknown efficacy to one with harmful side effects (Marik and 107 
 
Zaloga, 2004). TPN, as previously discussed, has been shown to impair humoral and 
cell-mediated immunity, magnify the pro-inflammatory response, increase bacterial 
translocation and infection rate in critically ill patients (Marik and Pinsky, 2003).  
In an early study, enteral feeding was well tolerated, had fewer complications 
overall and a smaller rate of septic complications compared to TPN (Kalfarentzos et al., 
1997). There was no difference in hospital duration or outcome. Other studies 
comparing enteral feeding to TPN have been performed, and showed a global reduction 
of CRP concentration, APACHE score, development of SIRS, organ failure and length 
of stay in an ICU ward in the enteral group (Windsor et al., 1998).  As the feeding 
regimen was continued for 7 days, it is possible that within the TPN group many 
patients may have voluntarily eaten, and the persistence of a central line may have 
actually increased the inflammatory response in and of itself. It was not clear from the 
published data if there was a difference in response between the severely and mildly 
affected patients. Similar findings were present in other studies, with a faster reduction 
in serum CRP concentration in fed patients, however only small numbers were included 
(Louie et al., 2005; Doley et al., 2009). 
One of the better constructed studies compared enteral nutrition to TPN in 
patients with predicted severe pancreatitis (Petrov et al., 2006). This trial only included 
patients with onset of clinical signs within 72 hours prior to admission, and all had 
serum CRP concentrations > 150 mg/L and APACHE II scores > 10, with no 
differences between groups at the start of the project. There was no difference in the 
reduction of serum CRP or APCAHE-II scoring over the first 4-7 days of the study. 
However, overall there were significantly lower rates of pancreatic infectious 
complications (7 vs. 16), multi-organ failure in week 2 (7 vs. 17) and mortality (2 vs. 
12) in the enteral nutrition group compared to the TPN group. Interestingly there was 
no difference in early single-organ failure between the groups, suggesting that the 108 
 
benefit may be delayed and correspond to nutritional effects as well as immune 
functions.  
This was reflected in another non-randomised, prospective study that 
demonstrated single or multi-organ failure occurred in 79% of the TPN group (vs. 31% 
in the enterally fed group), infected pancreatic necrosis in 74% (vs. 20%) and death in 
35% (vs. 5%) (Modena et al., 2006). As this study was not randomised it is unclear to 
what degree selection bias played a role, by selecting more severely affected people to 
receive TPN. Indeed, a randomised clinical trial failed to show any difference in 
inflammatory markers, oxidative stress or endotoxin antibodies in people receiving 
enteral feeding versus TPN (Gupta et al., 2003). This particular study assessed mild 
disease only. 
The major problems when assessing the above-mentioned studies of acute 
pancreatitis is that they are typically under-powered, many are not randomised, the 
remainder of the treatment protocol is not consistent (therefore questioning the effect of 
the nutrition alone), and it is difficult to determine which patients are truly severe based 
on the description in the papers.  
1.4.11.5 Is enteral feeding better than resting the pancreas? 
There are very few human studies comparing enteral nutrition to complete 
intestinal rest, all of which contain critical design flaws. The conclusions of one study 
(Pupelis et al., 2001) was that enteral feeding via a naso-jejunal (NJ) tube decreased 
mortality and the rate of septic complications compared to IV fluid therapy only, with 
no difference in hospitalisation duration or the rate of non-septic complications. The 
flaws of the study are so marked however, that these conclusions cannot be strongly 
supported. All 60 patients recruited for the study had surgery for their disease, and 
secondary peritonitis cases as well as pancreatitis cases were included in each treatment 
group but not analysed individually. There was the potential for significant selection 109 
 
bias, and the patients in the NJ group received different dietary formulations at different 
rates. Additionally, the NJ tubes were inserted intra-operatively, and extrapolation of 
this to non-surgical patients is dangerous, as insertion of a NJ tube otherwise requires 
an additional anaesthetic procedure. The author of a meta-analysis (McClave et al., 
2006) contacted the principal author of this study and obtained data that excluded 
secondary pancreatitis, and included subjects from an earlier study of 29 people by the 
same group (Pupelis et al., 2000). Assessing this data together there were overall 71 
(out of the original 89) patients that could be assessed. Analysis showed a trend to 
decreased mortality but no other difference.  
There is only one study that was well constructed comparing enteral feeding to 
fasting published in the human literature, but this was limited by the small number of 
patients in the study (Powell et al., 2000). This study prospectively administered 21% 
of total caloric requirements via NJ tube to 13 people in the first four days of 
hospitalisation, compared to 14 people that were given bowel rest. The authors showed 
that intestinal permeability actually increased in the feeding group, which may be due 
to increased mucosal blood supply rather than functional changes in the gut. There was 
no difference in inflammatory markers between the two groups over 4 days, but it 
failed to assess differences in length of stay, outcome, infective and late complications 
between the two groups. This reiterates that there is a lack of prospective well 
constructed studies comparing standard treatment to enteral feeding in the medical 
literature. There are none in the veterinary literature.  
1.4.11.6 Is feeding proximal to the jejunum well tolerated? 
Although enteral nutrition in acute pancreatitis has gained popularity over the 
past decade, feeding was preferentially delivered into the jejunum rather than 
proximally into the stomach or duodenum. The cost of feeding via a nasogastric (NG) 110 
 
tube or by mouth is less than via an NJ tube, as well as being easier to insert. This is 
true in both human and veterinary medicine.  
One study tried to assess whether there was pain when people were fed orally 
compared to via an NJ tube (Pandey et al., 2004). This looked at consecutive 
admissions of people with acute pancreatitis, so the severity of disease was not 
uniform.  However, there was no significant difference in recurrence of pain between 
the two groups, although numbers were low.  
One of the first studies assessing NG feeding was published in 2005 (Eatock et 
al., 2005).  This was a randomised controlled trial of 49 people with severe pancreatitis 
comparing NG to NJ feeding. There was no difference in mortality hospitalisation 
duration, severity scores or CRP reduction between groups. There was also no 
difference in pain scores between groups, and NG feeding was very well tolerated.  
Another study in 2006 supported the idea that NG feeding was as well tolerated 
as NJ feeding, and there was no increase in pain upon feeding (Kumar et al., 2006). 
There was no difference in survival or duration of hospitalisation between the two 
groups, but there were potential flaws with the study. Conversely, a study that 
compared EN via an NG tube to TPN within 24 hours of admission suggested that early 
NG feeding may actually be detrimental as it might increase mucosal blood supply, and 
lead to increased permeability (Eckerwell et al., 2006). This conclusion is difficult to 
fully support as there were low numbers, and outcome was not fully evaluated. A meta-
analysis of NG tube feeding concluded that it did not result in different clinical 
outcomes from NJ feeding, and was well tolerated in 80% of people (Petrov et al., 
2008a).  
1.4.11.7 Consensus statements and meta-analysis of EN in acute pancreatitis 
The most current consensus statement recommends that although in mild 
pancreatitis there is no impact on disease with supplemental nutrition until after the first 111 
 
5 days, there is indication to provide assisted (tube) feeding in people with severe 
pancreatitis. They also concluded that additional TPN may be indicated if nutritional 
requirements are not met, and that naso-gastric feeding should be attempted first, with 
naso-jejunal feeding started only if it is not tolerated (Meier et al., 2006). Other 
consensus statements are along similar lines, albeit not always with robust support 
(Hirota et al., 2010; Johnson, 2005; Muddana et al., 2009). 
Multiple meta-analyses have also been performed. Meta-analysis is highly 
dependent on the number of studies included, as well as the design of those studies, so 
cannot always be given absolute credence. An example is one review which was 
primarily based on Powell’s study in 2000, and stated that EN decreased mortality 
when initiated within 48 but not 24 hours of admission (Petrov et al., 2008c). The 
original study cited did not actually compare or even detail survival characteristics, and 
was limited to 25 patients, making the conclusions of the meta-analysis questionable 
(Powell et al., 2000). It has been suggested that although there is no difference in 
mortality between EN and TPN, the lower cost and infectious complication rate 
associated with the former lends itself to be recommended at Level A in evidence-
based medicine (Heinrich et al., 2006).  
1.4.11.8 What to feed? 
Even if the notion that enteral nutrition is well tolerated and perhaps beneficial 
is supported, it is still unclear as to what diet to feed. The preponderance of poorly 
controlled reports in the medical literature make this a confusing area as well. One 
study assessed the administration of n-3 polyunsaturated fats at 3.3 grams per day in 
people with moderate to severe pancreatitis via a NJ tube (Lasztity et al., 2005). This 
was not a blinded or placebo-controlled study. There was no difference between groups 
in total antioxidant status or CRP concentrations, but there was a significantly 
decreased feeding duration and hospitalisation in the treated group. Enteral feeding 112 
 
supplemented with glutamine, arginine, tributyrin and n-3 fatty acids made no 
difference in CRP concentration in another study (Pearce et al., 2006). Clinical 
outcome wasn’t assessed however, and it is possible that arginine was detrimental as it 
has been shown to damage the pancreatic acini in a rat model (Lasztity et al., 2005).  
The use of probiotics is also controversial. One double-blinded, randomised 
prospective clinical trial initially suggested a benefit, as there was a significant 
reduction in infection of pancreatic tissue and the need for surgical intervention (Olah 
et al., 2002). However, overall length of stay, outcome, incidence of systemic 
inflammatory response syndrome and multi-organ failure were not different between 
the groups. The same group of researchers found no benefit when a larger cohort was 
assessed (Olah et al., 2007). A later and larger randomised, double-blind, placebo-
controlled study from another group also refuted the original findings (Besselink et al., 
2008). In fact, the mortality rate was significantly greater in the probiotic group 
compared to placebo. The biggest cause of death was MODS, although 3 people died of 
bowel ischaemia. Potential reasons proposed for this include perpetuation of bowel 
ischaemia by increasing requirement for blood mucosal supply, or increasing gut-
associated inflammation due to increased bacterial load (Besselink et al., 2008). At this 
point in time there is no support for the use of probiotics in critically ill people with 
pancreatitis, nor a valid set of evidence for their use in dogs.  
1.4.11.9 What about enteral nutrition in dogs with pancreatitis? 
There have been very few studies of nutritional intervention in dogs with 
pancreatitis. Most of these detail parenteral nutrition and the incidence of 
complications, without specifically assessing pancreatitis (Chan and Freeman, 2006; 
Chan et al., 2002; Queau et al., 2011; Reuter et al., 1998). Generally the rate of 
complications with parenteral nutrition is similar in all reports, although there was a 113 
 
tendency for a better outcome in dogs treated concurrently with enteral nutrition (Chan 
et al., 2002). 
In the only randomised, prospective study of enteral nutrition in dogs, there was 
a more rapid clinical improvement in dogs with parvovirus that were fed compared to 
those that were fasted (Mohr et al., 2003). There was no significant difference in 
survival, but the EN dogs gained more weight, and potentially showed improved gut 
barrier function.  
In veterinary medicine, when enteral nutrition has been recommended as 
potentially beneficial in dogs with acute pancreatitis, it is usually advocated that NJ 
tubes be used (Watson, 2004; Williams and Steiner, 2005). Insertion of feeding tubes 
into the jejunum requires a prolonged general anaesthetic in dogs already critically ill 
(Swann et al., 1997). As well, the catheter lumen is often very small, which prevents 
the administration of many veterinary diets. A technique to insert a feeding tube via a 
percutaneous endoscopic technique has been described (Jergens et al., 2007). This 
technique is technically challenging and requires specialised equipment. In addition 5 
of the 12 dogs reported in the initial study had complications with bolus feeding. A less 
invasive endoscopic assisted naso-jejunal insertion technique has also been described 
(Papa et al., 2009). This has not been evaluated in a sick population of dogs. Despite 
not requiring invasive surgery, the length of time required along with the expertise and 
equipment (endoscopy and ideally fluoroscopy), make these unlikely techniques to be 
used routinely in veterinary practice.  
1.5 Conclusions from the literature 
 
Despite a large number of publications and improved understanding of the 
cellular events that occur in pancreatitis, there has been a singular lack of effective 
translation to clinical medicine, let alone clinical veterinary medicine. There is a lack of 114 
 
robust evidence for the current diagnostic modalities in veterinary medicine. Much of 
this results from a rarely attainable gold standard for diagnosis, and a lack of studies 
assessing the clinical utility of the test modalities. In human gastroenterology, 
understanding of the pathophysiology of the disease has not significantly altered the 
mortality rate of acute pancreatitis. Many novel treatment options did not result in 
clinical benefit, perhaps due to the disease in people differing from experimental 
models, or the disease process being established for longer than in experimental 
models. There are similar challenges facing veterinary medicine, with expense and 
availability of certain treatments contributing to this challenge as well. Many 
difficulties with clinical trials were also highlighted in this literature review. Namely, 
when trying to assess one intervention, the study subjects have to have the same form 
and general level of severity of disease, receive the exact same treatment apart from the 
intervention, and be randomly assigned to treatment groups.   
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1.6 Hypotheses 
 
In the course of the background analysis, the following hypotheses were formulated: 
 
Pancreatic Elastase-1 will be a specific and sensitive indicator of pancreatic 
inflammation 
 
Pancreatic specific lipase concentration is correlated to the severity of pancreatic 
inflammation, but may be increased in other clinical conditions 
 
Analysis of data will identify clinical data that could help to stratify severity of disease 
in dogs with acute pancreatitis 
 
Plasma administration is not effective in the treatment of canine acute pancreatitis 
 
Dogs with severe acute pancreatitis will tolerate early enteral nutrition 
   116 
 
1.7 Aims and objectives 
 
The specific aims and objectives of this thesis are: 
 
-  To determine the sensitivity and specificity of canine pancreatic elastase-1 in a 
group of dogs presenting with similar clinical signs to acute pancreatitis 
-  To determine the clinical specificity and sensitivity of canine pancreatic lipase 
by correlating to level of pancreatic inflammation. 
-  Develop a clinical severity index in dogs with acute pancreatitis that correlates 
to outcome 
-  To determine (stratifying according to clinical severity) if the administration of 
plasma or minimal enteral nutrition has any potential benefits in the treatment 
of acute pancreatitis in dogs 
-  To determine if differing fat content of diet causes differing responses of the 
canine pancreas 
-   To determine if early interventional enteral nutrition delivered proximal to the 
pylorus is well tolerated by dogs with acute pancreatitis 
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Chapter 2: Specificity and sensitivity of serum canine pancreatic 
elastase-1 concentration in the diagnosis of pancreatitis  
The following is a modified version of the published paper: Caroline S Mansfield, 
Penny D Watson, Boyd R Jones (2011) Journal of Veterinary Diagnostic Investigation 
23(4):691-697 
2.1 Introduction 
Pancreatitis in dogs provides a diagnostic challenge for veterinarians. The 
difficulty in diagnosis is due to the lack of reliable laboratory testing for all types of 
pancreatitis. Acute pancreatitis is defined as inflammation and/or necrosis in the 
pancreatic or peri-pancreatic tissues, with an absence of permanent histological changes 
such as fibrosis and acinar atrophy (Xenoulis et al., 2008). Histological findings alone 
cannot determine the severity of acute pancreatitis, therefore clinical criteria are also 
used (Mansfield et al., 2008). Chronic pancreatitis is defined as a continuing 
inflammatory disease of the pancreas, with the presence of irreversible fibrosis and 
atrophy (Watson et al., 2007). When there is concurrent necrosis along with evidence of 
irreversible histological change, then this form of the disease can be termed recurrent 
acute or ‘acute-on-chronic’ pancreatitis (Watson et al., 2007). The term recurrent 
pancreatitis is preferred by the author and used throughout this chapter. It is possible 
that recurrent pancreatitis is indeed common in dogs, and this may compound the 
difficulties in diagnosis due to a lack of functional pancreatic mass able to produce 
circulating enzymes during times of inflammation.   
Serum amylase, lipase and trypsin-like immunoreactivity have been shown to 
have poor sensitivities and specificities even in severe pancreatitis in dogs (Hess et al., 
1998;  Mansfield  and  Jones,  2000).  Canine  pancreas-specific  lipase  (previously 
measured  as  canine  pancreatic  lipase  immunoreactivity)  was  initially  thought  to  be 
highly sensitive as published in an abstract (Steiner et al., 2001). A more recent study 
has shown a sensitivity of 63.6% for this test in the diagnosis of pancreatitis, although, 118 
 
when only severe cases of pancreatitis were included, this figure increased considerably 
(Steiner et al., 2008a). Canine pancreas-specific lipase on the other hand, has been 
shown to be specific (Trivedi et al., 2011). 
Pancreatic Elastase-1 (PE-1) is synthesised in pancreatic acinar cells, and during 
active pancreatic inflammation it is released into the blood stream at the same time or 
immediately  after  trypsin  (Hartwig  et  al.,  2007).  PE-1  contributes  to  the  ongoing 
inflammatory state during acute pancreatitis by enhancing neutrophil-mediated tissue 
injury,  and  has  been  shown  experimentally  to  induce  pancreatic  microcirculatory 
failure  in  the  presence  of  sera  co-factors  (Keck  et  al.,  2005).  There  have  been 
inconclusive  assessments  about  the  clinical  utility  of  serum  PE-1  in  people  for 
diagnosing acute pancreatitis (Buchler et al., 1986; Malfertheiner et al., 1987; Wilson et 
al., 2005). In chronic pancreatitis, the exocrine function of the pancreas may become 
diminished, and in people with chronic pancreatitis serum and faecal PE-1 is often 
reduced,  reflecting sub-clinical  exocrine pancreatic insufficiency
  (Lesi  et  al.,  1988).  
PE-1  has  been  measured  in  the  serum  of  dogs  undergoing  endoscopic  retrograde 
pancreatography (Spillmann et al., 2004), in healthy dogs, dogs with renal failure, and 
dogs with pancreatitis (Spillman et al., 2002). In the latter study, there was a significant 
difference in the median values of dogs with severe pancreatitis compared to healthy 
dogs  or  dogs  with  renal  failure.    Measurement  of  serum  cPE1  is  not  affected  by 
lipaemia according to the assay manufacturers, and is less affected by impaired renal 
function than most other pancreatic enzymes in people (Malfertheiner et al., 1987; Seno 
et al., 1995).  
This  part  of  the  project  was  designed  as  a  prospective  study  to  assess  the 
clinical utility of serum serum cPE1 in the diagnosis and differentiation of pancreatic 
disease in dogs.  119 
 
2.2 Materials and Methods 
Dogs  presenting  to  three  university  veterinary  referral  centres  (Murdoch 
University  Veterinary  Teaching  Hospital,  Murdoch,  Western  Australia;  University 
College, Dublin, Ireland; Queen’s Mother Hospital, University of Cambridge, United 
Kingdom)  with  clinical  signs  that  could  be  attributed  to  pancreatic  inflammation, 
including both vomiting and abdominal pain, were recruited into the study. All centres 
operate under NHMRC equivalent Animal Use codes, and the study was approved by 
the relevant institutional ethics committee.  
2.2.1 Animal Selection 
Dogs were designated to have primary pancreatic disease on the basis of abdominal 
ultrasound  and/or  histological  findings.  They  were  further  sub-divided  into  the 
following groupings: 
-  Severe acute pancreatitis: Dogs had marked pancreatic and peri-pancreatic fat 
necrosis  or  neutrophilic  inflammation  present  histologically  (obtained  at 
exploratory  laparotomy  or  post-mortem),  or  marked  peri-pancreatic 
hyperechogenicity  combined  with  abnormal  pancreatic  echogenicity  as 
determined by ultrasonography, (Hess et al., 1998; Lamb and Simpson, 1995; 
Steiner,  2003)  in  addition  to  either  a  severe  clinical  severity  index  ≥  2  as 
detailed  in  chapter  4  (Mansfield  et  al.,  2008),  or  the  need  for  intensive 
management.  
-  Mild acute pancreatitis: Dogs had pancreatic necrosis on histological evaluation 
(obtained at exploratory laparotomy or post-mortem), but did not satisfy the 
clinical or ultrasonographical criteria for having severe disease.  
-  Recurrent  acute  pancreatitis:  Dogs  had  histological  evidence  of  both  acute 
(necrosis)  and  chronic  (fibrosis  or  atrophy)  pancreatitis;  and  blood  and 120 
 
pancreatic samples were taken during a time of active clinical signs. Clinical 
severity was not determined for dogs in this group.  
-  Chronic pancreatitis: Histological evaluation of the pancreas obtained at post-
mortem or exploratory laparotomy showed evidence of chronicity (fibrosis and 
atrophy), with no active inflammation or necrosis.  
-  Pancreatic  neoplasia:  Primary  pancreatic  carcinoma  was  diagnosed  via 
histological evaluation of biopsies obtained at exploratory laparotomy or post-
mortem, with no concurrent inflammation 
All histological analysis was performed by board-certified veterinary pathologists, and 
all ultrasound examinations by board-certified veterinary radiologists in the respective 
centres in a prospective manner. Dogs that were classified as having non-pancreatic 
disease  had  a  confirmed  primary  diagnosis  with  no  to  minimal  pancreatic  changes 
observed  histologically,  in  multiple  sections  (minimum  4)  of  the  pancreas. 
Additionally,  dogs  did  not  have  exogenous  glucocorticoids  within  three  days  of 
admission.  One dog that underwent pancreatic surgery for excision of an insulinoma 
had serial blood samples taken prior to surgery and 24, 48 and 72 hours after surgery.  
2.2.2 Assays 
Blood was taken from all dogs recruited into the study within 12 hours of 
admission to the university referral centre. Separated serum was stored at -20°C, then 
shipped frozen to Giessen, Germany for analysis by operators blinded to the disease 
classification of the samples. A species-specific sandwich enzyme immunoassay based 
on two monoclonal antibodies highly specific for canine PE-1 (cPE-1) was performed. 
This assay has been shown to have an intra-assay co-efficient of variation (CV) ranging 
from 2.1 to 11.6% and an inter-assay CV ranging from 3.4 to 10.8% in dogs (Spillman 
et al., 2004). An earlier abstract of 16 healthy dogs had a minimum value of 32.1 
ng/mL, and a maximum value of 659.3 ng/mL, with a median concentration of 55.8 121 
 
ng/mL (Spillman et al., 2002). Unfortunately the mean values were not reported in that 
study.  
2.2.3 Statistical analysis 
Statistical software package GraphPad
® Prism 5 was used for calculations.  The 
sensitivity and specificity of serum cPE-1 was calculated using Receiver-Operating 
Characteristic (ROC) curves to determine the optimal cut-off value for diagnosis, and 
95% confidence intervals, positive, and negative likelihood ratios were also 
determined.  Statistical difference between groups was determined using Mann 
Whitney U-test at confidence interval of 95%, with significance being a P value < 0.05.  
2.3 Results 
2.3.1 Animal Information 
A total of 107 dogs were initially recruited into the study, but there was only 
sufficient information obtained for 61 dogs to be included.  Forty-nine had pancreatic 
disease (severe acute pancreatitis n=23, mild acute pancreatitis n=11, recurrent acute 
pancreatitis n=7, chronic pancreatitis n=3 and pancreatic carcinoma n=5). All dogs with 
acute pancreatitis had mean follow-up of 9 months (range 6-36 months). A further 12 
dogs with non-pancreatic inflammatory disease were evaluated: 4 dogs with 
inflammatory bowel disease, 2 dogs with small intestinal foreign bodies, 2 dogs with 
renal failure, and 1 each of immune-mediated thrombocytopenia, gastric carcinoma, 
multi-centric lymphoma, and insulinoma.  
 Eight of the samples were haemolysed on analysis (2 each from severe acute 
pancreatitis, mild acute pancreatitis, recurrent acute pancreatitis and non-pancreatic 
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2.3.2 Median and intervals 
 The median, mean and intervals for serum cPE-1 in all groups are presented in 
Table 2.1, and graphically in Figure 2.1. Overall, the median for all dogs with 
pancreatic disease was 19.3 ng/mL, and the mean 47.46 ng/mL. For dogs with acute 
(mild, severe, and recurrent acute) pancreatitis, the median was 20.85 ng/mL, and the 
mean 55.04 ng/mL. Dogs with non-pancreatic disease had a median of 5.81 ng/mL and 
a mean of 8.19 ng/mL. There was a significant difference in serum cPE-1 
concentrations between all pancreatic disease groups and the non-pancreatic disease 
group (P= 0.005) as well between the acute pancreatitis group (including mild, severe 
and acute-on-chronic) versus the non-pancreatic disease group (P= 0.002), but not 
between the acute pancreatitis groups versus the pancreatic neoplasia group (P=0.08). 
The difference between severe and mild acute pancreatitis was also significant (P= 
0.04), and there was a strongly significant difference between severe acute pancreatitis 
when compared to non-pancreatic disease (P=0.002).  
There was no change in significance when haemolysed samples were excluded 
from the analysis.  
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Table 2.1 
 
 
Minimum, maximum, median and mean concentrations of serum cPE1 in the nominated 
disease categories 
   
Measurement  Canine Pancreatic Elastase-1 (ng/mL) 
Diagnostic Group  Number of dogs  Median  Mean  Minimum  Maximum 
Severe acute 
pancreatitis 
23  26.29  84.04  0.86  444.50 
Mild acute 
pancreatitis 
11  9.25  15.34  3.05  45.04 
Acute-on-chronic 
pancreatitis 
7  20.85  22.19  4.34  45.62 
Chronic pancreatitis  3  5.11  6.44  2.01  12.20 
Pancreatic carcinoma  5  9.80  9.87  5.50  15.28 
Non-pancreatic 
disease 
12  5.80  8.19  1.33  26.08 124 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Serum Canine Pancreatic Elastase-1 concentrations for all disease groups. 
There is a significant difference between the means of all groups except when 
comparing all dogs with acute pancreatitis (mild, severe and acute-on-chronic) to dogs 
with pancreatic carcinoma 125 
 
Table 2.2  
  Severe Acute Pancreatitis  
vs. NPD  
95% CI  All Pancreatic inflammation vs. NPD  95% CI  Acute Pancreatitis vs. NPD  95% CI  
CPE-1 cut-off > 17.24 ng/mL 
 
Sensitivity 
78.26%  58.1-93.04  61.36%  46.62-74.28  65.85%  50.55-78.44 
Specificity  91.67%  64.61-98.51  91.67%  64.61-98.51  91.67%  64.61-98.51 
PLR  9.391  1.42-62.09  7.364  1.11-48.8  7.92  1.2- 52.3 
NLR  0.237  0.11-0.53  0.421  0.28-0.64  0.373  0.24-0.59 
CPE-1 cut-off > 5.5 ng/mL 
 
Sensitivity 
82.61%  62.86-93.02  81.82%  68.04-90.49  85.37%  71.56-93.12 
Specificity  50%  25.38-74.62  50%  25.38-74.2  50%  25.38-74.62 
PLR  1.652  0.91-3.0  1.636  0.91-2.93  1.707  0.96-3.05 
NLR  0.348  0.12-1.0  0.364  0.16-0.85  0.293  0.12-0.74 
The sensitivity, specificity, positive likelihood ratio (PLR) and negative likelihood ratio (NLR), with 95% confidence intervals (CI) 
were calculated for diagnosis of severe acute pancreatitis (as compared to non-pancreatic disease [NPD], diagnosis of all 
pancreatitis (severe acute, mild acute, recurrent acute and chronic), and diagnosis of dogs with all forms of acute pancreatitis 
(severe, mild and recurrent acute). The calculations were done using two cut-off values; 17.24 ng/mL, as calculated by ROC 
analysis and 5.5 ng/mL, the median determined in healthy dogs in another study (Spillmann et al., 2004).   
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2.3.3 Sensitivity and specificity cPE-1 
Using ROC analysis, an optimal diagnostic cut-off value of 17.24 ng/mL for serum 
cPE-1 was calculated, when comparing all groups (Figure 2.2).  The 95% confidence 
intervals (CI) for the sensitivity, specificity, positive likelihood ratio, and negative 
likelihood ratio were calculated with this cut-off value of 17.24 ng/mL, as well as with the 
previously reported median concentration of 5.5 ng/mL for healthy dogs (Spillman et al., 
2004). This is presented in Table 2.2.  There was a high specificity for the diagnosis of 
severe acute pancreatitis (91.7%) using a cut-off value of 17.24 ng/mL, resulting in a high 
positive likelihood ratio, but a lower sensitivity (78.3%) with wide confidence intervals.  
The sensitivity also decreased when assessing all types of pancreatic disease (61.4%), and 
all cases of acute pancreatitis (65.9%), but the specificity remained the same. When the 
value 5.5 ng/mL was used, the specificity greatly reduced, (50%) with an increased 
sensitivity for severe acute pancreatitis (82.61%), all types of acute pancreatitis (85.37%) 
and all pancreatic disease (81.62%). There was overall a low negative likelihood ratio, 
which was lower when assessing acute pancreatitis.  
The dog that underwent pancreatic surgery showed an increase in serum elastase 
concentration after the day of the surgery, but the measured elastase value had reduced to 
less than baseline by Day 3 (Figure 2.3).  
 
   127 
 
Figure 2.2 An area under the curve of 0.8261 was determined using ROC analysis 
comparing severe acute pancreatitis to non-pancreatic disease in measurement of serum 
PE-1, with a calculated optimal cut-off value of 17.24 ng/mL. 
 
 
Figure 2.3 Changes in serum PE-1 in a dog that underwent partial pancreatectomy 
 
2.4 Discussion 
Serum  cPE1  had  less  than  optimal  sensitivities  when  assessing  all  dogs  with 
pancreatic  disease  (61.4%)  in  this  study.  However,  when  only  dogs  with  severe  acute 
pancreatitis  were  considered,  the  sensitivity  increased  to  78.3%,  and  there  was  a  high 
positive likelihood ratio. Of significant interest was the finding of a specificity of 91.7%. 
ROC of Severe Acute Pancreatitis vs. Non Pancreatic Disease
0 20 40 60 80 100
0
20
40
60
80
100
Specificity%
S
e
n
s
i
t
i
v
i
t
y
 
%  128 
This  combined  with  a  high  positive  likelihood  ratio  and  low  negative  likelihood  ratio 
would suggest that a high cPE1 is likely to be due to pancreatitis.  This benefit was greatest 
when using a cut-off value of 17.24 ng/mL, and when assessing severe acute pancreatitis.  
Our study did not assess healthy dogs, as the aim was to determine the clinical 
utility by comparing groups of dogs that could be considered to have acute pancreatitis on 
presentation. As such, the cut-off value determined in this study by comparing dogs with 
similar clinical presentations is more clinically relevant than comparison to healthy dogs. 
Additionally, the authors did not compare this test modality to clinical suspicion (based on 
clinical  signs  at  presentation),  as  46  dogs  were  excluded  due  to  an  unknown  final 
diagnosis.  
Serum cPE-1 appears to be less sensitive than current modalities such as abdominal 
ultrasound for the overall diagnosis of pancreatic disease in dogs (61.4% versus 66%). This 
finding is contrary to initial studies in people where good correlation with disease was 
demonstrated, although overlap between groups was observed (Buchler et al., 1986; Lesi et 
al.,  1988;  Malfertheiner  et  al.,  1987).  Later  studies  did  not  show  such  a  convincing 
correlation (Millson et al., 1998; Wereszczynska-Siemiatkowska et al., 2003; Wilson et al., 
2005).  The  major  reason  for  this  discrepancy  is  that  the  earlier  studies  used  a 
radioimmunoassay  (RIA)  which  detects  polyclonal  elastase  (bound  to  1-α-anti-trypsin 
complex), with a half-life of 2.2 days. As a result the RIA detects greater amounts for a 
longer period. The ELISA, as used in this study, is a monoclonal assay that detects free or 
unbound elastase with a half-life of 0.4 days (Millson et al., 1998), thus decreasing the 
sensitivity of the test after a short period of time has elapsed since onset of clinical signs. 
Conversely,  this  makes  a  positive  result  more  likely  to  be  a  true  positive  if  there  is 
persistently an increased value.    129 
Most human studies suggest that serum cPE-1 is most clinically useful for 
diagnosis of severe acute pancreatitis. This is also supported by our findings, as well as 
previous reports in dogs. One abstract from 2002 describes a reference interval of elastase 
in 16 healthy dogs of 32.1- 659.3 ng/mL (median 55.8); 14 dogs with pancreatitis had a 
range of 24-1720 (median 160) and 6 dogs with renal disease had a range of 5-182 (median 
43.3) (Spillman et al., 2002). When the dogs with pancreatitis were classified into severe 
(n=9) or mild (n=6) forms based on histological and clinical features, there was a 
significant difference in serum cPE-1 between healthy dogs and dogs with renal failure 
compared to severe pancreatitis.  
It is uncertain why so many of the healthy dogs in that study had such high serum 
cPE-1 results compared to those measured in our study. However, a later publication from 
the same author also reported a wide-ranging baseline cPE-1 concentration in 7 healthy 
dogs (0.1-411.6 ng/mL) but with a median value of 5.5 ng/mL, similar to dogs with non-
pancreatic disease in our study (Spillman et al., 2004). This initially wide reference interval 
raises the question of whether sample handling or haemolysis may have contributed to the 
variability of measured values. The manufacturers of the assay report that haemolysis or 
storage above 8°C for more than 72 hours can artefactually increase serum cPE-1 
measurements. Haemolysis was recorded in only 8 of the 61 samples measured in our 
study. The results of these 8 samples were consistent with their diagnosis, and statistical 
analysis was unaffected by their inclusion or exclusion, so to mimic conditions expected in 
clinical practice the results were retained. In this light, more weight is lent to the premise 
that serum cPE-1 is highly specific.  
It is also possible that the high results observed in the study of healthy animals may 
be outliers, have sub-clinical pancreatic disease or that serum cPE-1 excretion may 
decrease with age, as non-renal excretory mechanisms may diminish (Seno et al., 1995).   130 
Laboratory error is another potential reason for the outliers. It is not possible from the 
available data of that study to further evaluate the most likely of these reasons.  
Each of the three dogs in this study that had severe renal failure and no pancreatic 
inflammation (urea 70.4 mmol/L, Reference < 12; creatinine 804 µmol/L, Reference < 
120, urine specific gravity <1.030) had serum cPE1 below the calculated value. There is a 
strong suggestion that serum elastase is not affected by renal clearance, as compared to 
many other pancreatic enzymes. In one study of 24 healthy people and 47 people with 
various degrees of renal insufficiency (but no known pancreatic disease) the measurements 
of elastase, lipase, amylase, pancreas-specific amylase, PLA-2 and trypsin were compared 
(Seno et al., 1995). Elastase was less affected than the other enzymes, only increasing to a 
significant amount in the serum when the creatinine clearance reduced below 10 
mL/minute. All other enzymes were increased when creatinine clearance fell below 40 
mL/min, although lipase tended to be less so.  
An interesting finding in our study was that serum cPE1 was generally lower in the 
chronic pancreatitis group than the other pancreatic disease groups, as well as being below 
the reference interval in many dogs with acute pancreatitis. This would suggest that these 
dogs may have reduced functional exocrine pancreatic mass.  
No information is available regarding the time interval between onset of clinical 
signs and the blood sample collection for the patients included in this study, although all 
samples were collected within 12 hours of admission to the veterinary referral centres. It 
was therefore unable to be determined if there was a relationship between the 
concentration of serum PE-1 and time after onset of clinical signs. However, in the dog 
that underwent pancreatic surgery there was a rapid decline in PE-1, confirming the short 
half-life for ELISA-measured PE-1. In general, dogs with severe pancreatitis will likely be 
presented much sooner after the onset of clinical signs than those with chronic disease. It   131 
may well be possible that cPE-1 is more useful when measured in the first 24-36 hours 
after the onset of clinical signs, but this strategy may not be a practical suggestion for 
clinical veterinary practice.  
No attempt was made to characterise the clinical severity of the recurrent acute 
pancreatitis group, as this was a histologically-based classification.  It is possible that the 
sensitivity of serum cPE-1 for the diagnosis of severe disease could be altered if animals in 
this group were re-classified.  The fact that all of the dogs in the non-pancreatic disease 
group had pancreatic histopathology performed increases the clinical significance of 
findings in this study.  Although not all dogs in the severe acute pancreatitis group had 
histopathology performed the combination of clinical and ultrasonographical changes were 
strongly supportive of a diagnosis of pancreatitis, although the presence of necrosis could 
not be confirmed. It is possible that some of these dogs had ‘acute-on-chronic’ disease, and 
if they were excluded from the analysis then the sensitivity of the assay may be even 
higher. However, in veterinary practice pancreatic biopsies are seldom performed in dogs 
that have severe clinical signs of disease and concurrent abnormalities on abdominal 
imaging.  
In the human literature it has been proposed that increased serum cPE-1 may be 
specific for pancreatic carcinoma (Ito et al., 1991), but this specificity is not supported in 
other studies (Buchler et al., 1986). Similarly, in our study, none of the dogs with 
pancreatic carcinoma had serum cPE-1 concentrations greater than the calculated cut-off 
value of 17.24 ng/mL, which may be related to the short serum half-life, reduced 
functional pancreatic mass or the lack of concurrent pancreatic inflammation.  Conversely, 
all dogs in the severe acute pancreatitis group had follow-up of sufficient duration (> 9 
months) to rule out the presence of concurrent pancreatic neoplasia.    132 
Abdominal imaging is often relied upon for confirmation of the diagnosis of acute 
pancreatitis.  This  modality has  a reported sensitivity of 66 to  68%  (Hess  et  al.,  1998; 
Mansfield and Jones, 2000; Steiner et al., 2008a). Although the sensitivity of ultrasound is 
reported as being low, these studies are not recent, and are assessing animals with chronic 
and mild disease as well as severe disease, decreasing the sensitivity of ultrasound as a 
result (Lamb and Simpson, 1995). Additionally, the specificity of ultrasound is actually 
quite high, meaning it is unlikely that any false positives were included in our patient 
group with severe disease. In a recently published paper, all dogs with severe pancreatitis 
had  a  positive  ultrasound  diagnosis  (Steiner  et  al.,  2008a).    The  presence  of 
hyperechogenicity  surrounding  the  pancreas  on  ultrasound  reflects  peri-pancreatic  fat 
necrosis in dogs, and necrosis is considered the most significant indicator of severe disease 
in people (Charbonney and Nathens, 2008; Jaeger et al., 2003).  
Serum cPE1 and cPLI appear to have similar sensitivities in the diagnosis of severe 
acute pancreatitis (Steiner et al., 2008a). The use of blood tests alone to diagnose 
pancreatitis should not be relied upon in clinical practice, and combination with abdominal 
ultrasound may well prove to have the highest sensitivity and specificity for diagnosis of 
severe acute pancreatitis in dogs. Additionally, abdominal imaging is very important to 
rule out non pancreatic causes of ‘acute abdomen’ that would require immediate surgical 
management, such as intestinal foreign bodies.  
2.5 Conclusion 
Serum cPE-1 is useful for the diagnosis of severe acute pancreatitis, but less so for 
milder forms of the disease. The diagnosis of milder or more chronic forms of the disease 
remains dependent on histological confirmation for definitive diagnosis. The usefulness of   133 
serum cPE-1 in assessing residual exocrine pancreatic function following acute pancreatitis 
should be further evaluated.      134 
Chapter 3: Association between canine specific pancreatic lipase (Spec-
cPL™) and histological exocrine pancreatic inflammation in dogs: 
assessing specificity 
The following is a modified version of the paper accepted for publication November 2011: 
Caroline S Mansfield, Garry A Anderson, Amanda J O’Hara (in press) Journal of 
Veterinary Diagnostic Investigation  
3.1 Introduction 
Pancreatitis in dogs is a commonly diagnosed condition in veterinary clinics 
worldwide (Cook et al., 1993; Hess et al., 1998; Mansfield and Jones, 2000; Watson, 
2004). Clinically, pancreatitis in dogs results from an acute inflammatory or necrotising 
process centred on the pancreas, with variable systemic complications (Kalli et al., 2009).  
Histologically, acute pancreatitis is defined as a neutrophilic inflammation, without fibrosis 
or exocrine atrophy; and usually is present within the body of the pancreas and/or peri-
pancreatic fat (Newman et al., 2006). The pathological distinction between acute 
pancreatic necrosis, acute pancreatitis, acute peripancreatic necrosis and acute 
peripancreatic steatitis, may reflect a different pathogenesis, however the clinical signs of 
the disease will be similar, as the systemic effects can occur with any of these (Mansfield 
et al., 2008). Chronic pancreatitis is defined as a mononuclear (often lymphocytic) 
inflammation, with disruption of the pancreatic architecture due to concurrent fibrosis 
(Watson et al., 2007). The presence of nodular hyperplasia in the pancreas of dogs is now 
considered an incidental finding, with an increased presence in older dogs (Newman et al., 
2005).  It has also been shown that pancreatic inflammation is present variably throughout 
the pancreas, and so single biopsies may miss the true extent of the disease (Newman et al., 
2004). Histological grading schemes have been published that take into account the uneven 
distribution of the inflammatory changes in categorising exocrine pancreatic disease 
(Newman et al., 2006; Watson et al., 2007).    135 
Recent evidence would suggest that chronic pancreatic inflammation is more 
common than previously thought, but diagnosis is difficult due to a failure of laboratory 
testing or imaging modalities to reliably detect it (Steiner et al., 2008a; Watson, 2004). 
Acute pancreatitis is considered easier to diagnose, but this diagnosis is often reliant on 
ultrasound imaging, something not always available to veterinary surgeons. Acute 
pancreatitis usually presents with acute vomiting and/or diarrhoea, in combination with 
abdominal pain and anorexia. This combination of clinical signs is not pathognomonic for 
acute pancreatitis, and other conditions such as septic peritonitis, acute renal failure, 
intestinal obstruction and others, are also associated with similar clinical signs.  
Spec-cPL™ is a monoclonal enzyme-based assay that was developed from the 
original ELISA test for canine pancreatic lipase immunoreactivity (Steiner et al., 2003) 
(cPLI), and results of each assay are closely correlated (Steiner et al., 2008b). Spec-cPL™ 
has been shown to be virtually undetectable in dogs with exocrine pancreatic insufficiency 
(Steiner et al., 2006), and immunochemical studies have determined it is localized in the 
exocrine pancreas (Steiner et al., 2002). Spec-cPL™ (or originally cPLI) has been reported 
to have a sensitivity ranging from 21-82% for the diagnosis of pancreatitis (Steiner et al., 
2001; Steiner et al., 2008a; Trivedi et al., 2011). The sensitivity appears to be higher in 
studies where the disease is more severe in nature. This sensitivity is comparable to a 
reported sensitivity ranging from less than 50% up to 78% for total lipase, using three 
times the upper reference interval as the diagnostic cut-off point (Cook et al., 1993; Hess et 
al., 1998; Mansfield and Jones, 2000).  One of these studies established a specificity of 
55% for total lipase (Mansfield and Jones, 2000). Dogs with acute renal failure, intestinal 
foreign bodies, acute enteritis and liver disease have all been shown to have increased total 
serum lipase concentration (Mansfield and Jones, 2000; Quigley et al., 2001; Rallis et al., 
1996; Strombeck et al., 1981). A recent paper assessing dogs with no clinical or   136 
histological signs of pancreatitis (essentially healthy dogs) determined a specificity of > 
95% for Spec-cPL™
 (Neilson-Carley et al., 2011). Another study showed specificity of 
100% using the upper cut-off reference interval, however this was only in 7 dogs (Trivedi 
et al., 2011).  
The aim of this study was to determine the specificity, and to a lesser degree the 
sensitivity, of Spec-cPL™ in a population of sick dogs using histological assessment of the 
pancreas as the gold standard for diagnosis.  
3.2 Materials and Methods 
Dogs that were submitted for post-mortem pancreatic examination, regardless of 
the cause of death or ante-mortem diagnosis, at Murdoch University, Perth, Western 
Australia during the period from September 2008 until May 2010, were initially recruited 
for the study. Blood samples were obtained within 6 hours of death, or immediately post 
mortem, and then serum harvested and stored at -20˚C. Informed owner consent was 
obtained for all post-mortem examinations, and if additional serum was needed to be 
obtained for this study, specific consent was also sought. Some owners consented only to 
the pancreas being removed, and not full post-mortem evaluation. The project was 
approved by the Murdoch University Animal Ethics Committee, following National Health 
and Medical Research Council guidelines.  
Post-mortem evaluation when performed was as standard, and in all dogs, samples 
were obtained from the left lobe, right lobe and body of the pancreas and fixed in 10% 
formaldehyde for a minimum of 24 hours. These were then processed routinely through 
graded alcohol into paraffin before sectioning at 5 m and staining with haematoxylin and 
eosin (H&E) for later analysis by the two investigators (CSM and AO’H). Both 
investigators were blinded to the final diagnosis and results of serum testing when   137 
reviewing the histopathology. Samples that were too autolysed for histological 
interpretation were excluded, as were cases where there were not 3 pancreatic samples 
available for assessment.  
Histological grading of the pancreas was adapted from two previous studies (Newman 
et al., 2006; Watson et al., 2007). Inflammation was assessed and assigned a score for each 
of the three pancreatic sections, with a total cumulative score of 12 possible:  
0-  No inflammation present, or <2 small foci mononuclear cells with no disruption of 
the architecture 
1-  <5% neutrophilic or lymphoplasmacytic inflammation  
2-  5- 50% neutrophilic or lymphoplasmacytic inflammation 
3-  > 50% neutrophilic or lymphoplasmacytic inflammation 
4-  Necrosis of pancreatic tissue, or peri-pancreatic necrosis/steatitis  
Additionally, the presence of fibrosis was defined as mature fibrous connective tissue 
replacing the acinar structures or expanding the interstitium. The severity of the fibrosis in 
each section was scaled according to the following numerical system, with a maximum 
cumulative score of 9: 
0-  None evident 
1-  < 20% of each section effaced by mature connective tissue 
2-  20-50% of each section effaced by mature connective tissue 
3-  >50% of each section effaced by mature connective tissue 
If fibrosis could not be definitely differentiated on routine H&E sections, additional 
staining with Sirius Red was performed to characterize this more clearly (Watson et al., 
2007). Other pancreatic changes (in addition to the above) were recorded if present, but not   138 
assigned severity scores: haemorrhage, oedema, hyperaemia, neoplasia and exocrine 
nodular hyperplasia.  
Sera from every dog that was assessed in the study was sent as a batch for 
measurement of Spec-cPL™ at a commercial laboratory. For the purposes of the study, a 
result < 30 µg/L was recorded as 30; and results > 1000 µg/L were recorded as 1000 to 
reflect the limit of quantification of the assay. This assay has previously been shown to 
have good reproducibility with both inter- and intra- assay coefficient of variation < 12% 
(Huth et al., 2010). Current laboratory recommendations are that a result > 400 µg/L is 
consistent with pancreatitis, and a result in the 200-399 µg/L interval should be considered 
to possibly signify pancreatitis (Steiner et al., 2008a,b).  
For the purposes of analysis, dogs with a cumulative inflammatory score of   3 
were considered to have sub-clinical pancreatitis of little to no significance; dogs with a 
cumulative inflammatory score of ≥ 4 had pancreatic inflammation of increasing degrees. 
Concurrently, a cumulative score of ≤ 2 for fibrosis indicated a mild to minimal degree of 
chronicity, whilst ≥ 3 indicated moderate to severe fibrosis.  
Statistical analysis and graphical representation were done using a statistical 
software package (MedCalc 11.6.1, MedCalc software, Mariakerke, Belgium). Statistical 
difference between groups was determined using the Mann-Whitney U test. Spearman’s 
rank correlation coefficient was calculated to determine the association between Spec-
cPL™ concentration and the inflammatory and fibrosis scores, respectively. A two-tailed 
P-value   0.05 was considered to be statistically significant. 
3.3 Results 
There were a total of 54 dogs initially included in the study, but only 32 had all the 
required data and were analysed.  Twenty dogs had a pancreatic inflammation score ≤ 3, 5   139 
dogs had a score of 4-5; 4 dogs had a score 6-8 and 3 dogs had a score ≥ 9. Pictorial 
examples of histological sections from each of these categories are shown in Figure 3.1.  
In the 20 dogs with a pancreatic inflammatory score of ≤ 3, the cause of death or 
euthanasia was determined in 17 and included dog attack (2), and 1 each of the following: 
vasculitis/coagulopathy, disseminated intravascular coagulation due to anaphylaxis, 
congestive heart failure, hepatic necrosis, intestinal infarct secondary to NSAID overdose, 
osteosarcoma, heart base mass, multiple endocrine neoplasia, lung carcinoma, septic 
peritonitis (stick foreign body), splenic haemangiosarcoma, metastatic malignant 
melanoma, snake envenomation, islet cell neoplasia, and metastatic nephroblastoma. In the 
12 dogs with a pancreatic inflammatory score > 3, the primary cause of death was 
identified in 11, and included acute pancreatitis (2), and 1 each of splenic 
haemangiosarcoma, haemabdomen secondary to splenic haematoma, small intestinal 
foreign body, multicentric lymphoma, metastatic carcinoma, pituitary tumour (non-
functional), pneumonia, septic peritonitis (secondary to hepatic abscessation) and extra-
hepatic bile duct obstruction due to chronic pancreatitis.  
The descriptive statistics for Spec-cPL™ are shown in Table 3.1. There was a 
statistical difference in Spec-cPL™ concentration between dogs with a pancreatic 
inflammation score of ≤ 3 and those with a score of > 3 (P=0.011), as demonstrated in 
Figure 3.2.  
Seventeen dogs had a fibrosis score of ≤ 2, 10 of which had no observed fibrosis. 
Thirteen dogs had a moderate (score 3-6) degree of fibrosis, and 2 had severe (score   7) 
fibrosis (Table 3.1). There was no statistical difference in Spec-cPL™ concentration 
between dogs with a pancreatic fibrosis score of ≤ 2 and those > 2 (P=0.055). 
Haemorrhage was observed in samples from 8 dogs, all with pancreatic inflammation   140 
scores ≤ 3. Haemorrhage was not observed uniformly through all sections in each dog. 
Additionally nodular exocrine hyperplasia was identified in 2 dogs. No oedema was noted.  
Spearman’s rank correlation coefficient between pancreatic inflammation score and 
Spec-cPL™ was significant (rs = 0.47; 95% CI 0.15 - 0.71; P = 0.0060), as demonstrated in 
Figure 3.3, while there was no correlation between pancreatic fibrosis and Spec-cPL™ ( rs 
= 0.30; 95% CI -0.05 to 0.59; P = 0.091). 
When using 400 µg/L as a diagnostic cut-off for Spec-cPL™, and a pancreatic 
inflammation score of ≤3 to indicate no histological pancreatitis, there were 2 false 
positives. These 2 dogs had Spec-cPL™ concentrations of 914 and 568 µg/L, both with 
pancreatic inflammation and fibrosis scores of 1 and 3 respectively. No other pancreatic 
abnormalities were observed. When using a diagnostic cut-off for Spec-cPL™ of 200 
µg/L, there were 4 false positives. The additional 2 dogs had Spec-cPL™ concentrations of 
270 and 255 µg/L, with pancreatic inflammation and fibrosis scores of 3,3 and 1,3 
respectively. This correlates to a specificity of 90% (95% CI 68 - 99%) using a Spec-
cPL™ cut-off value of 400 µg/L and 80% (95% CI 56 - 94%) using a cut-off value of 200 
µg/L. The area under the receiver operating characteristic (ROC) curve was 0.77 (95% CI 
0.59 – 0.90). 
There were 12 dogs in this study that had a histological diagnosis of pancreatitis (a 
pancreatic inflammation score ≥ 4). By using 400 µg/L as a diagnostic cut-off 
concentration for Spec-cPL™ there were 4 true positives (4/12, sensitivity of 33%, 95% CI 
10 - 65%), whilst using the diagnostic cut-off value of 200 µg/L, there were 7 true 
positives (7/12, sensitivity 58.3%, 95% CI 28 - 85%). Three of these dogs had peri-
pancreatic fat necrosis present, but minimal to no inflammation present within the 
pancreatic interstitium. On analysis of these 11 dogs with histological pancreatitis and a 
known cause of death, only 3 had pancreatitis as the primary cause of their clinical signs.    141 
 
 
Figure 3.1 Haematoxylin & Eosin stained sections from four dogs with variable 
pancreatic inflammatory scores (PIS); A: nil or minimal pancreatic inflammation (PIS < 
3; Fibrosis <3; 200x magnification); B: Mild to moderate pancreatic inflammation (PIS 4-
5; fibrosis 3; 200x magnification); C: Moderate to severe pancreatic inflammation (PIS 8; 
Fibrosis 3; 200x magnification); D: Severe pancreatic inflammation, including peri-
pancreatic necrosis (PIS ≥ 9; 40x magnification).  
 
Table 3.1 
  Pancreatic Inflammation 
Score 
Pancreatic Fibrosis Score 
Grading  ≤ 3  4+  ≤ 2  3+ 
Number  20  12  17  15 
Mean  144.1  347.5  151.6  298.3 
Median  39  327  41  268 
Standard Deviation  225.3  290.5  234.3  261.2 
Minimum  30  30  30  30 
Maximum  914   1000  1000  914 
 
 Statistical summary of Spec-cPL™ results (µg/L) for each pancreatic inflammatory and 
fibrosis group.   142 
 
Figure 3.2  Results of Spec-cPL™ concentrations in 20 dogs with minimal to no 
pancreatic inflammation (Pancreatic inflammation score ≤3) and in 12 dogs with scores of 
4+. The median concentration is represented by the short horizontal bar. 
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Figure 3.3  Scatterplot of pancreatic inflammation score and Spec-cPL™ 
concentrations in 32 dogs. Spearman’s rank correlation coefficient 0.47 (P=0.0060). 
 
3.4 Discussion 
The pathogenesis of clinical pancreatitis is complex and multi-factorial. The 
clinical signs from acute pancreatitis may result purely from the local effects of the 
pancreatic digestive enzymes released into the cranial abdomen when trypsinogen is 
activated to trypsin within the pancreatic acinar cell (Rinderknecht, 1986). Pancreatic 
safeguards such as pancreatic secretory trypsin inhibitor (PSTI) can become overwhelmed, 
allowing trypsin activation to spill into the interstitium (Fernandez-del-Castillo et al., 
1994). Circulating anti-proteases (such as α-macroglobulin or α1–protease inhibitor) are 
responsible for binding to proteases and clearing them through the reticuloendothelial 
system, but these too may become overwhelmed in individual animals (Lasson and   144 
Ohlsson, 1984).
  Circulating pancreatic proteases are then capable of inciting inflammation 
systemically via activation of free radical, coagulation, complement and kinin cascades 
(Ruaux, 2000). The generation of chemokines and cytokines leads to further tissue 
inflammation and injury, which in turn may cause multi-organ failure and death.  As such, 
determination of histological severity alone cannot conclusively determine if an animal has 
clinically severe pancreatitis. Additionally, it is possible that mild pancreatic inflammation 
may be along the spectrum of normal in dogs, and it is the way the body responds to that 
inflammation that determines if clinical disease is manifested or not.  
Along those lines, this study demonstrates the difficulty in truly defining clinical 
pancreatitis based on histological grading alone. One post-mortem survey identified 92% 
of dogs in a referral institution to have pancreatic inflammation (Newman et al., 2006), 
whilst another study found approximately 34% of dogs surveyed in a first opinion clinic to 
have chronic pancreatitis (Watson et al., 2007). As it seems highly unlikely that 90% of 
sick dogs will be sick due entirely to pancreatitis, it can be surmised that histological 
pancreatitis does not always translate to clinically important pancreatitis. It has not been 
established what percentage of the pancreas needs to have inflammation present before it 
can be truly categorised as having clinically important pancreatitis. It is interesting to note 
that in our study, of the 11 dogs with histological pancreatitis (an inflammation score > 3) 
and a known cause of death, only 3 had pancreatitis as the primary cause of their clinical 
presentation. This highlights the need to consider the pancreas as a participant in many 
presentations, rather than always as an instigator.  
The use of the current scheme was an attempt by the authors to correct for this 
potential discrepancy between histological and clinical pancreatitis. Whilst it is possible 
that a dog with a pancreatic inflammation score ≥ 4 in this study did not have clinical 
pancreatitis, the 8 dogs that were designated to be false negatives all had inflammation   145 
scores ≥ 5, and had clinical signs of pancreatitis. The possible reason for this discrepancy 
is that 4 of the 8 had predominantly peri-pancreatic fat necrosis, with little to no 
inflammation or necrosis of the pancreatic interstitium. One possible explanation for this is 
that the disease may have initiated in the peri-pancreatic fat, and inflammation centred on 
the pancreas itself had yet to develop. This may have resulted in less stimulation of the 
pancreatic enzyme cascade than if it had involved the interstitium. This also raises an 
interesting alternative conjecture in that this sub-group of dogs may not have true 
pancreatitis as is currently understood (where trypsinogen is activated within the acinar cell 
as the initiating event). Rather, the disease may actually be initiated in fat within the 
abdomen and extend towards the pancreas. The role of adipokines in initiating 
inflammation is increasingly being recognised in the human and veterinary field (Martínez-
Clemente et al., 2011; Radin et al., 2009a). Clinically, these 2 possibilities would be 
impossible to differentiate. As 3 of these 4 dogs had clinical signs (abdominal pain, 
vomiting) for more than 3 days, lack of opportunity for inflammation to develop seems 
unlikely.   
When using a cut-off value of 400 µg/L, the specificity of Spec-cPL™ in this study 
was 90%, and when using a cut-off value of 200 µg/L, the specificity was 80%. Caution 
should be taken when interpreting these results however, as the post-mortem nature of this 
study biased the selection of cases. By the very nature of requiring the pancreas in its 
entirety, the study is pre-selecting for dogs with severe disease. Additionally, this study 
only assessed dogs presented for post-mortem at a referral institution. Dogs with diseases 
that have similar clinical signs to pancreatitis (intestinal foreign body, acute gastroenteritis) 
are more likely to be treated at a general veterinary practice, or survive their illness. This, 
combined with a lack of a non-invasive gold standard, makes it extremely difficult to   146 
assess the true clinical specificity of Spec-cPL™ in a large population of dogs with acute 
gastrointestinal signs.  
The dogs in this study with false positive results had a number of underlying causes 
of death or euthanasia, and none was considered likely to have pancreatitis as a primary 
problem. That being said, it is possible that the inflammation score determined in this study 
did not accurately reflect changes throughout the pancreas. Previous studies have identified 
that histological changes in the pancreas are not uniformly distributed throughout the organ 
(Newman et al., 2004). This study assessed samples from the left and right lobe, as well as 
the body of the pancreas. Although the entire pancreas was not sectioned, the authors felt 
this was representative of an overall inflammatory assessment. Other possible reasons for 
the false positive results includes cross-reactivity with other lipases (which seems unlikely 
based on previous work), excessive production of pancreas-specific lipase by the pancreas 
in the absence of pancreatic inflammation, or production of this isoenzyme of lipase in an 
organ(s) other than the pancreas. It is not possible from the current information to postulate 
on the most likely cause.  
This study did not include any dogs with renal failure, and increased total lipase has 
been identified in dogs with renal failure (Mansfield and Jones, 2000; Strombeck et al., 
1981). Further work assessing Spec-cPL™ and pancreatic inflammation in dogs with renal 
failure is required before conclusions can be made regarding this particular aspect.  
A recent study has established similar sensitivities for measurement of serum 
canine pancreatic-elastase-1(cPE-1) (Mansfield et al., 2011b, Chapter 2) to what has 
previously been reported for Spec-cPL™ (Steiner et al., 2008a). Again, with both analytes 
the sensitivity increases when more severe forms of pancreatitis are assessed. This current 
study actually reported a much lower sensitivity for Spec-cPL™ of 33-58% than what had 
previously been reported, however caution should be had in over interpreting this aspect   147 
due to the very small numbers of animals with true disease. The dogs in this study were 
presented for post-mortem evaluation, and were not necessarily considered likely to have 
pancreatitis.  The specificity for cPE-1 was also reported to be approximately 92%
 
(Mansfield et al., 2011b, Chapter 2), again similar to the result reported for Spec-cPL™ in 
this study.  
The specificity identified in this study is similar, but slightly lower than another 
study published assessing the histological and gross appearance of the pancreas (Neilson-
Carley et al., 2011). The slightly lower value in our study may be due to only sick dogs 
being assessed, whilst almost two thirds of the dogs without pancreatitis were clinically 
healthy. To date, the current sensitivity and specificity for clinical suspicion combined with 
imaging findings to diagnose pancreatitis in dogs is not known. It can certainly be 
extrapolated that no single laboratory test will replace good clinical acumen and imaging 
of the abdomen, but rather can serve to enhance it.  
3.5 Conclusion 
In this study of pancreatic histology obtained post-mortem in dogs, Spec-cPL™ 
had a specificity ranging from 80-90%, dependent on which value (200 µg/L and 400 µg/L 
respectively) was used as the lower limit in the analysis. The sensitivity for this test ranged 
from 33-58% (using 400 µg/L and 200 µg/L respectively), which is less than previously 
reported. The authors recommend additional testing, especially abdominal imaging, should 
aid in the diagnosis of the primary problem in dogs presenting with vomiting and/or 
abdominal pain.  
Although both pancreatic elastase and pancreatic lipase are released by the 
pancreas in response to inflammation, they appear to be unable to predict the severity of 
clinical disease.  The next section of this thesis relates to the development of a clinical   148 
severity scoring index that would be useful in dogs to allow assessment of treatment 
modalities.      149 
Chapter 4: Development of a clinical severity index for dogs with acute 
pancreatitis  
The following is a modified version of the published paper: Caroline S Mansfield, Fleur E 
James & Ian D Robertson (2008) Journal of the American Veterinary Medical Association 
233: 936-944.  
4.1 Introduction 
Pancreatitis is a major disease of dogs, and acute necrotising inflammation is the 
most common form of pancreatitis that is diagnosed in dogs (Hess et al., 1998; Watson, 
2004). Pancreatitis may result in a wide range of clinical signs of differing severity and 
cause multisystem inflammation in dogs (Ruaux, 2000). The mortality rate among dogs 
with acute pancreatitis is often high because of the systemic effects of the disease, and 
surviving animals usually require intensive treatment and hospitalization (Mansfield et al., 
2003; Ruaux and Atwell, 1998a; Ruaux and Atwell, 1998b; Williams, 1994). Studies in 
people with acute pancreatitis have identified that the optimal therapeutic window is 
approximately 48 to 72 hours after the first onset of pain (Norman, 1998). Prediction of 
which dogs with acute pancreatitis will develop fatal complications is problematic, 
although a significant association between acute pancreatitis-related death and concurrent 
disease, such as diabetes mellitus, epilepsy, or hyperadrenocorticism, has been reported 
(Cook et al., 1993; Hess et al., 1998; Strombeck et al., 1981).  
To date, no readily available blood test has been shown to differentiate mild from 
severe disease in dogs with acute pancreatitis (Hess et al., 1998; Mansfield et al., 2003; 
Ruaux and Atwell, 1998b; Strombeck et al., 1981; Williams, 1994). Thus, there is a 
singular lack of objective criteria that correlate with the severity of acute pancreatitis in 
affected dogs. Traditional biochemical methods of diagnosing pancreatitis, such as high 
serum amylase and lipase activities, are poor predictors of death (Mansfield et al., 2003; 
Strombeck et al., 1981).
 Much attention in veterinary medicine has been focused on   150 
measurement of circulating concentrations of acute-phase proteins, especially CRP, in the 
diagnosis and prognostication of acute and chronic inflammatory conditions. Acute-phase 
proteins are part of a complex and nonspecific reaction that occurs immediately after tissue 
injury to restore homeostasis and remove the cause of its disturbance (Ceron et al., 2005). 
Production of CRP is stimulated by inflammatory cytokines such as IL-6, IL-1, and tumor 
necrosis factor-α (Ceron et al., 2005). The main biologic functions of CRP appear to be 
promotion of bacterial phagocytosis, induction of other cytokines, inhibition of 
chemotaxis, and modulation of neutrophil function (Ceron et al., 2005). C-reactive protein 
is stable and increases in association with several inflammatory conditions in dogs, 
including pancreatitis (Berghoff et al., 2006; Chan et al., 2006; Holm et al., 2004; Merlo et 
al., 2006; Spillman et al., 2002).  
Extrapolation of a clinical findings-based classification scheme for acute 
pancreatitis in humans (Bradley, 1993),
 would mean a severe pancreatitis in dogs requires 
2 or more of the following findings: necrosis of pancreatic acinar tissue, systemic 
complications (e.g., disseminated intravascular coagulation or acute respiratory distress 
syndrome), severe clinical signs causing profound obtundation or death, or development of 
abdominal complications.
 This classification scheme relies heavily on histological 
confirmation of pancreatic necrosis; such confirmation is seldom obtained ante-mortem in 
most dogs with acute pancreatitis, and the system is therefore not easily applied to canine 
patients. Among dogs with pancreatic necrosis, there is widespread degree of severity of 
disease, dependent on the dogs’ systemic response to pancreatic inflammation and 
activation of pancreatic proteases (Mansfield and Jones, 2000; Ruaux, 2000; Watson, 
2004). The use of such a classification scheme is also highly subjective and does not allow 
for standardization of less objective criteria.    151 
A clinicopathological abnormality-based scheme for classification of pancreatitis in 
dogs has also been described (Ruaux and Atwell, 1998b); on the basis of that scheme, 
classification of severity correlates with outcome. However, the devised scoring scheme 
did not assess definitively confirmed cases of pancreatitis and did not take into account 
non-clinicopathological abnormalities. Development of a clinical severity index for acute 
pancreatitis in dogs which take into account multiple body systems, clinicopathological 
abnormalities, and local pancreatic complications will allow comparisons of data among 
practices and objective assessment of various treatments of this disease. The purpose of 
the study reported here was to establish a clinical severity index that correlates severity of 
body system abnormalities with outcome in dogs with acute pancreatitis as well as 
determines the usefulness of serum CRP concentration as an objective measure of acute 
pancreatitis severity. The wider context was to provide a method of ensuring dogs with 
acute pancreatitis assessed in later studies had similar degrees of disease severity.  
4.2 Materials and Methods 
4.2.1 Inclusion criteria  
Records of dogs that were evaluated at a primary emergency center (Murdoch Pet 
Emergency Centre) and a referral veterinary teaching hospital (Murdoch University 
Veterinary Teaching Hospital) between 1999 and 2006 and for which a diagnosis of 
pancreatitis was recorded were reviewed. As no clients were contacted, or interventional 
studies performed, no institutional animal ethics approval was required for the 
retrospective study. Client permission was obtained when extra blood sampling was 
required, under approval of Murdoch University Animal Ethics Committee, for the 
prospective study. Inclusion criteria included evidence of acute pancreatitis detected via  
abdominal ultrasonography or histological examination of surgical or necropsy tissue   152 
samples, admission to hospital for treatment, complete daily clinical records (physical 
examination findings), and results of full clinicopathological evaluation (haematological 
and serum biochemical analyses and urinalysis as minimum) performed within 12 hours of 
admission. Ultrasonography was performed by a board-certified (or equivalent Australian 
qualification) radiologist, using a curvilinear 8 MHz or linear 15 MHz probe (Sequioa 512, 
Acuson, Munich, Germany). A diagnosis of acute pancreatitis was made if there was 
evidence of a large pancreas with patchy echogenicity or hyperechoic mesentery. Dogs 
were excluded if they were not admitted for treatment or were euthanatized for nonmedical 
reasons. Signalment, interval between onset of clinical signs and evaluation, and interval 
from hospital admission until outcome (considered to be death or discharge from the 
hospital; designated as days until outcome) were recorded for each dog that fulfilled the 
inclusion criteria.  
4.2.2 Development of the severity scoring index 
Several body systems were evaluated in the study animals to develop an 
appropriate clinical severity index scheme (Table 4.1). Abnormalities of the endocrine 
system (e.g. diabetes mellitus or diabetic ketoacidosis) and hepatic system (e.g. high serum 
activities of hepatocellular and cholestatic enzymes) were included and graded as part of 
the index on the basis of their inclusion in a previously published severity scheme (Ruaux 
and Atwell, 1998b). Other systems were included on the basis of criteria developed for 
critically ill patients (King et al., 2001); these included the haematopoietic system to 
evaluate for signs of inflammation (high WBC count and moderate left-shift), development 
of systemic inflammatory syndrome (severe leucocytosis or leucopenia), or development 
of disseminated intravascular coagulation. Coagulation abnormalities included 
prolongation of prothrombin time, activated partial thromboplastin time, or activated   153 
clotting time and high plasma concentration of fibrinogen degradation products. Other 
critical care factors evaluated were the presence of cardiac arrhythmias (graded in 
ascending order according to whether relatively benign or potentially malignant), 
respiratory complications (graded in ascending order to reflect possible development of 
acute respiratory distress syndrome), renal disease (severe azotaemia or anuria), and 
altered vascular forces (graded in ascending order to reflect changes in serum albumin 
concentration and systolic arterial blood pressure). On the basis of the human and 
veterinary medical literature, local pancreatic complications were also considered and 
included peritonitis that extended beyond the peripancreatic region and presence of a 
pancreatic acute fluid collection (also known as a pseudocyst), or pancreatic abscess. Poor 
enteral health or altered intestinal integrity was also graded if there was poor intestinal 
motility (defined as an absence of intestinal sounds during   3 auscultations of the left and 
right sides of the abdomen during a 24-hour period), development of regurgitation 
(presumed to be the result of reflux oesophagitis), altered intestinal integrity (evidence of 
bleeding into gastrointestinal tract, such as melena or haematochezia), or a prolonged 
period of anorexia (> 3 days), regardless of whether this was prior to or during 
hospitalisation.  
Each of these scored factors was evaluated for significance (i.e. whether it 
contributed to survival) by use of a Pearson 
2 and Fisher exact test; a value of P < 0.05 
was considered significant. Factors were retained for evaluation if they were significant. A 
clinical severity index based on the significant factors was determined for each dog by 
assessment of the medical record data collected within the first 24-hour period after 
admission to the hospital. An organ score based on clinicopathological variables was also 
calculated for each dog from laboratory information obtained within the first 24-hour   154 
period after admission to the hospital, according to a previously published method (Ruaux 
and Atwell, 1998b). In that organ scoring scheme, 1 point is allocated for abnormalities 
associated with the leucogram (> 10% band neutrophils or WBC > 24 X 10
9 cells/L); 
kidneys (serum urea concentration > 14 mmol/L [39.2 mg/dL] and serum creatinine 
concentration > 300 μmol/L [3.3 mg/dL]); liver (serum alanine transferase activity > 240 
U/L, serum aspartate aminotransferase activity > 240 U/L, or serum alkaline phosphatase 
activity > 420 U/L); acid-base buffering (blood bicarbonate concentration > 26 mmol/L or 
< 13 mmol/L or anion gap < 15 mmol/L or  > 38 mmol/L); and the endocrine pancreas 
(blood glucose concentration > 13 mmol/L [234 mg/dL] or serum  -hydroxybutyrate 
concentration > 1 mmol/L).  
4.2.3 Serum CRP concentration measurement 
During a 3-month period, dogs admitted to Murdoch University Veterinary 
Teaching Hospital that had a diagnosis of acute pancreatitis (confirmed via 
ultrasonographic or histological evaluation of the pancreas as described) were also 
evaluated prospectively. The dogs were admitted and treated as considered appropriate by 
attending veterinarians and none were euthanatized for nonmedical reasons. Severity 
scores were determined as described and treatment data were recorded. From each dog, a 
blood sample (2 mL) was obtained via jugular or cephalic venipuncture within 24 hours of 
admission, with informed owner consent. Serum was harvested within 30 to 60 minutes of 
blood collection and frozen at -20˚C. Samples were then transported on dry ice and CRP 
concentration was measured by use of a solid-phase sandwich immunoassay (Tridelta 
Phase Canine CRP Assay, Tridelta Diagnostics Inc, Morris Plains, NJ). The reference 
interval for this assay in healthy dogs has been determined as 0 to 7.6 mg/L (Berghoff et 
al., 2006).    155 
4.2.4 Statistical analysis 
Correlation between the 2 severity scoring systems (the clinical severity index and 
clinicopathological variable-based organ scoring scheme) and survival in all dogs was 
determined via Spearman rho calculation (a value of P < 0.05 was considered significant) 
and an ANOVA. Correlation between the 2 severity scoring systems and days until 
outcome in all cases was also determined by use of the Spearman rho (non-parametric) 
analysis, because data were not distributed normally. Spearman rho analysis was also used 
to determine the correlation between serum CRP concentration and each of the severity 
scoring schemes, between serum CRP concentration determined within 2 days of onset of 
clinical signs and outcome (survival to discharge from the hospital or death), and between 
serum CRP concentration determined at any time and outcome (survival to discharge from 
the hospital or death). For all analyses, a value of P < 0.05 was considered significant. 
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System  Finding  Point 
allocation 
Endocrine  0-    No abnormalities   0 
  1-    Pre-existing diabetes mellitus   1 
  2-    Diabetes ketoacidosis (glycosuria/hyperglycaemia+ ketonuria or 
incincreased beta-hydroxy butyrate) 
2 
Hepatic  No abnormalities  0 
  ≥ 2.5-fold increase (compared with upper limit of reference range) in 
at least 2 of the following: serum alkaline phosphatase, alanine 
transferase, and aspartate aminotransferase activities   
1 
  ≥ 5-fold increase (compared with upper limit of reference range) in at 
least 2 of the following: serum alkaline phosphatase, alanine 
transferase, and aspartate aminotransferase activities   
2 
         Extra-hepatic bile duct obstruction  3 
Renal  No   No abnormalities     
  Azotaemia (  1.5-fold increase [compared with upper limit of 
reference range] in serum urea and creatinine concentration  
1 
  Anuria or azotaemia (  1.5-fold increase [compared with upper limit 
of reference range] in serum urea and creatinine concentration) 
2 
Haematopoietic  No abnormalities  0 
  0-  WBC count ≥ 20.0 X 10
9 cells/L or ≤ 4.0 X 10
9 cells/L, with ≤ 10% 
band neutrophils 
1 
  1-  WBC count ≥ 20.0 X 10
9 cells/L or ≤ 4.0 X 10
9 cells/L, or neutrophil 
count ≤ 1.0 X 10
9 cells/L, or ≥ 10% band neutrophils 
2 
  2-  Clinicopathological evidence of hypercoagulability or coagulation 
abnormalities 
3 
  3-  Clinical evidence of disseminated intravascular coagulation or 
bleeding diathesis 
4 
Local complications  0-  No abnormalities   0 
  1-  Peritonitis extending beyond peripancreatic area  1 
  2-  Pseudocyst or other acute fluid accumulation   2 
  3-  Pancreatic abscess  3 
Cardiac  0-  No abnormalities   0 
  1-  < 60 ventricular premature complexes/24-hour period or heart rate > 
180 beats/min 
1 
  2-  Paroxysmal or sustained ventricular tachycardia  2 
Respiratory  0-  No abnormalities   0 
  1-  Clinical evidence of dyspnoea or tachypnoea (> 40 breaths/min)  1 
  2-  Clinical evidence of pneumonia or acute respiratory distress syndrome  2 
Intestinal integrity  0-  No abnormalities   0 
  1-  Intestinal sounds not detected during > 3 auscultations in 24-hour 
period 
1 
  2-  Haematochezia, melena, or regurgitation  2 
  3-  No enteral food intake for > 3 days  3 
  4-  No enteral food intake for > 3 days and at least 2 of the following: 
haematochezia, melena, and regurgitation  
4 
Vascular forces  0-  No abnormalities   0 
  1-  Systolic arterial blood pressure < 60 or > 180 mm Hg or serum 
albumin concentration < 18 g/L 
1 
  2-  Systolic arterial blood pressure < 60 or > 180 mm Hg and serum 
albumin concentration < 18 g/L 
2 
   
Full details of all aspects reviewed and points allocated when initially determining 
which factors would correlate to survival.  
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4.3 Results 
4.3.1 Animals 
From the medical records, 68 dogs for which a diagnosis of pancreatitis had been 
made during the period of 1999 to 2006 were identified. Sixty-one dogs fulfilled the 
inclusion criteria and were admitted for treatment; in 12 of these dogs, serum CRP 
concentration was measured. Seven dogs were excluded because they were euthanatized 
due to financial reasons alone or had incomplete medical records. In the study group, there 
were 36 females (of which 35 were spayed and 1 was sexually intact) and 25 males (of 
which 17 were neutered an 8 were sexually intact). Mean age of all dogs was 8.5 years 
(range, 1 to 16 years). Breeds included Terrier-breeds (n = 12), Australian Kelpie or 
Australian Kelpie crossbreeds (8), Border collie or Border collie crossbreeds (7), 
Australian cattle dog (6), Bull terrier (4), Miniature schnauzer (3), Miniature poodle (3), 
Rottweiler (2), Corgi (2), Golden retriever (2), and Lhasa Apso (2). The other 10 dogs 
were mixed breeds.  
4.3.2 Clinical severity index and organ scoring scheme 
The medical records for each dog were reviewed and the system factors used in the 
clinical severity index were assessed (Table 4.1). Statistical analysis of those data revealed 
an association between outcome and each of 4 body system classifications: the cardiac and 
respiratory system factors (P ≤ 0.044 and P ≤ 0.035, respectively), intestinal integrity (P ≤ 
0.009), and vascular forces (P ≤ 0.003) (Table 4.2). There was no statistically significant 
association between outcome and the renal, haematopoietic, hepatic, endocrine, or local 
complication factors. Therefore, those classifications were excluded from the clinical 
severity index. Further evaluation of the local complication and haematopoietic systems 
also failed to identify a significant association between outcome and scores of 2 or 3 and 3   158 
or 4, respectively. Therefore, in the final clinical severity index, the total maximum score 
was 10 points (maximum score of 2 for the cardiac, respiratory, and vascular forces 
systems and a maximum score of 4 for the intestinal integrity system).  
Of the 61 dogs, 47 survived to discharge from hospital and 14 died or were 
euthanatized for pancreatitis-associated medical reasons; the overall mortality rate was 
23%. On the basis of severity scores (maximum of 10 points) derived by use of the clinical 
severity index, dogs were grouped into categories of 0, 1, 2, 3, 4, 5, and ≥ 6 scores (no 
score was > 6) and the outcomes for each category were examined (Figure 4.1a). The 
numbers of dogs in each score category were 15 (24.6%), 15 (24.6%), 6 (9.8%), 8 (13.1%), 
12 (19.7%), 4 (6.5%), and 1 (1.7%) respectively. The mortality rate for dogs that had a 
clinical severity index   4 was 53%, compared with the overall mortality rate among all 
dogs of 23%. On the basis of the organ scoring scheme, dogs were grouped into categories 
of 0, 1, 2, 3, or 4 scores and the outcomes for each category were also examined. The 
numbers of dogs in each score category were 15 (24.6%), 17 (27.9%), 19 (31.1%), 7 
(11.5%), and 3 (4.9%), respectively (Figure 4.1b).  
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Number and percentage in brackets of dogs with the various point allocation in the 
severity index calculation. The factors considered significant on analysis and included in 
the clinical severity index are highlighted. Comparison between survival for each factor is 
also demonstrated in the 4
th column.  
 
The score derived by use of the clinical severity index had a significantly greater 
correlation with survival (Spearman correlation coefficient = –0.437; P = 0.000) than the 
score derived by use of the organ scoring scheme (Figure 4.2). Scores using the latter 
system had no significant correlation with outcome in the cohort of the present study 
(Spearman correlation coefficient = –0.096; P = 0.460). The mean score derived by use of 
the clinical severity index for the 47 survivors (1.62) was significantly lower than the mean 
score for the 14 dogs that died or were euthanatized (3.4). The ANOVA revealed that death 
System  Point allocation  No. of dogs (%)  No. of Survivors (Non-
Survivors) 
Endocrine  0  49 (80.3%)  39 (10) 
  1  4 (6.6%)  3 (1) 
  2  8 (13.1%)  5 (3) 
Hepatic  0  22 (36.3%)  19 (3) 
  1  14 (22.9%)  10 (4) 
  2  9 (14.8%)  6 (3) 
  3  16 (26.2%)  12 (4) 
Renal  0  51 (83.6%)  39 (12) 
  1  7 (11.5%)  6 (1) 
  2  3 (4.9%)  1 (2) 
Haematopoietic  0  17 (27.9%)  15 (2) 
  1  19 (31.1%)  14 (5) 
  2  18 (29.5%)  14 (4) 
  3  5 (8.2%)  4 (1) 
  4  2 (3.3%)  1 (1) 
Local complications  0  19 (31.1%)  14 (5) 
  1  36 (59%)  29 (7) 
  2  5 (8.2%)  4 (1) 
  3  1 (1.7%)  0 (1) 
Cardiac  0  47 (77%)  38 (9) 
  1  14 (23%)  9 (5) 
  2  0  - 
Respiratory   0  57 (93.4%)  45 (12) 
  1  4 (6.6%)  2 (2) 
  2  0  - 
Intestinal integrity  0  22 (36.1%)  21 (1) 
  1  13 (21.3%)  9 (4) 
  2  5 (8.2%)  3 (2) 
  3  20 (32.7%)  13 (7) 
  4  1 (1.7%)  1 (0) 
Vascular forces  0  45 (73.7%)  41 (4) 
  1  15 (24.6%)  8 (7) 
  2  1 (1.7%)  0 (1) 
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was more likely to occur in dogs with higher clinical severity index scores(P = 0.008). 
There was generally a fair degree of correlation within individuals between scores derived 
by both schemes; however, there were some outliers with poor correlation (Table 4.3). Six 
dogs had significantly lower organ scores, compared with their clinical severity index 
scores (P < 0.05); 5 of these dogs died or were euthanatized as a result of their disease, and 
the dog that survived had a prolonged hospitalisation period. There was a high rate of 
abnormalities in vascular forces or evidence of severely altered intestinal integrity in all 6 
dogs (Table 4.4).  
Among all 61 dogs, the mean   SD interval from onset of clinical signs until 
outcome (i.e. days until outcome, namely death or discharge from the hospital) was 5.7   
3.12 (range, 1 to 15 days). Results of the ANOVA indicated that there was no significant 
(P = 0.329) difference in days until outcome between survivors (mean, 5.9 days   3.23, 
range 2-15; n = 47) and non-survivors (mean, 5.0 days   2.69, range 1-10; 14). However, 
there was a highly significant correlation (Spearman correlation coefficient = 0.554; P = 
0.000) between the days until outcome and the clinical severity index score. There was also 
a significant correlation (Spearman correlation coefficient = 0.278; P = 0.03) between days 
until outcome and the organ score.  
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Figure 4.1 Distribution of dogs with acute pancreatitis that survived to discharge from the 
hospital (black bars; n = 47) versus those that died or were euthanatized for reasons 
related to acute pancreatitis (grey bars; 14) according to scores derived by use of a 
clinical severity index (A) or an organ scoring scheme (B).  
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Figure 4.2   Individual scatter plot comparing results for each individual dog using the 
laboratory organ scoring system and the clinical severity index (numbers above crosses 
indicate number of animals with that combination of results). 
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Comparison of severity scores for individual dogs assessing the organ score and clinical 
severity index evaluated in this chapter.  
*The correlation between the two scoring systems for these dogs was poor (i.e., organ 
score was significantly [P < 0.05] lower than the clinical severity index score) using 
Spearman rho analysis.  
 
 
 
 
 
 
 
  Clinical severity index score 
Organ score  0  1  2  3  4  5  6 
   0  7  4  2  0  1*  0  1* 
   1  6  4  2  2  1*  2*  0 
   2  2  6  2  4  4  1*  0 
   3  0  1  0  1  4  1  0 
   4  0  0  0  1  2  0  0   163 
Table 4.4  
 
  Dog 
Variable   1  2  3  4  5  6 
Signalment             
Breed  Australian 
Cattle Dog 
Border Collie  Corgi  Australian 
Cattle Dog 
Border 
Collie 
Tibetan 
Terrier 
 Sex  
(reproductive 
status) 
Male (N)  Female (N)  Male (N)  Male (SI)  Female 
(N)  
Female 
(N) 
 Age (y)  9  7  12  10  6  13 
Clinical severity index point allocations 
    Cardiac  1  0  1  0  1  1 
    Respiratory  0  0  1  0  1  0 
    Intestinal 
integrity 
3  3  3  4  2  3 
    Vascular 
forces 
1  2  1  0  1  0 
    Total clinical 
severity  index 
score 
5  5  6  4  5  4 
Laboratory 
organ score 
1  1  0  0  2  1 
Serum  CRP 
concentration  
(mg/L) 
48.8  ND  ND  ND  ND  ND 
Outcome  ERD  ERD  Died  Recovered  Died  ERD 
Days  until 
outcome  from 
initial  onset  of 
signs  (from 
hospitalization 
at study centre)  
10 (6)  6 (5)  10 (8)  12 (10)  3 (1)  5 (3) 
Potential 
underlying 
cause  
Post surgery 
complication 
Suspected 
dietary 
indiscretion 
Unknown  Unknown  Unknown  Unknown 
 
Data obtained from 6 dogs with acute pancreatitis for which the scores derived by use of 
the final clinical severity index and organ scoring scheme were poorly correlated. N = 
Neutered. SI = Sexually intact. ND = Not done. ERD = Euthanatized as a result of disease. 
 
4.3.3 Assessment of serum CRP concentration 
In 12 dogs with acute pancreatitis, serum CRP concentration was prospectively 
evaluated within 24 hours of hospital admission. Three of these dogs had hyperlipidaemia 
at the time of sample collection. Concurrent diseases in this group included idiopathic 
epilepsy (n = 2), suspected hyperadrenocorticism (2), and atopic dermatitis that was   164 
controlled with prednisolone (n = 2). All 12 dogs had high serum C-RP concentration; the 
mean   SD value was 111.02   103.93 mg/L (range, 24.2 to 374.51 mg/L [reference 
interval, 0 to 7.6 mg/L]). There was poor correlation between serum CRP concentration 
and scores derived by use of the clinical severity index (Spearman correlation coefficient = 
–0.057; P = 0.859) or organ scoring scheme (Spearman correlation coefficient = 0.026; P = 
0.936). The mean CRP concentration for survivors (89.2 mg/L   71.8, range 24.2-200.32 
mg/mL; n = 9) did not differ significantly from the value for non-survivors (176.4 mg/L   
173.9, range 48.8-374.51 mg/mL; n = 3). There was no significant correlation (Spearman 
correlation coefficient = –0.362; P = 0.247) between outcome and serum CRP 
concentration. When serum CRP concentration measured within 2 days of the onset of 
clinical signs and outcome were analyzed, findings for survivors and non-survivors 
differed significantly (mean serum CRP concentration, 90.6 mg/L   75.2, range 26.77-
200.32 [n = 7] and 374.5 mg/L [n = 1]; P = 0.012) but this difference did not represent a 
significant correlation between serum CRP concentration and outcome (Spearman 
correlation coefficient = –0.577; P = 0.134).  
4.4 Discussion 
In dogs, the morbidity and mortality rates associated with acute pancreatitis are 
high (Watson, 2004). In affected dogs, circulating pancreatic proteases are capable of 
inciting inflammation systemically and, subsequently, various free-radical, coagulation, 
complement, and kinin cascades can become activated (Ruaux, 2000). The generation of 
chemokines and cytokines leads to further tissue inflammation and injury, which in turn 
may cause multi-organ failure and death. In particular, IL-6, -8, tumor necrosis factor-α, 
and CRP have been associated with a poor prognosis in people with pancreatitis, whereas 
platelet-activating factor has been specifically implicated in the development of lung-  165 
associated injury (Chen et al., 1999a; Formela et al., 1994; Mentula et al., 2005). Of these 
cytokines, it would appear that the circulating concentration of IL-6 has the best predictive 
value for organ failure in humans with severe pancreatitis (Chen et al., 1999a; 
Sathyanarayan et al., 2007). 
In the present study, serum CRP concentration was measured as previously 
described (Berghoff et al., 2006; Kjelgaard-Hansen et al., 2003), by use of an ELISA
 that is 
specific for canine CRP and accurate for samples stored at temperatures less than –10
oC 
for 3 months. For analysis of canine serum samples, the inter- and intra-assay coefficients 
of variation of the ELISA have been reported by the manufacturer (Tridelta Phase
 Canine 
CRP Assay, Tridelta Diagnostics Inc, Morris Plains, NJ) as 8% and 6.7%, respectively, 
well within accepted limits for an ELISA. All 12 dogs in which serum CRP concentration 
was measured in our study had values that were markedly greater than the upper limit of 
the established reference interval. This finding is consistent with other data reported for 
other dogs with acute and chronic illnesses, including dogs with acute pancreatitis 
(Berghoff et al., 2006; Burton et al., 1994; Chan et al., 2006; Holm et al., 2004; Merlo et 
al., 2006; Ohno et al., 2006; Rush et al., 2006; Spillman et al., 2002; Tecles et al., 2005). 
None of the 12 dogs evaluated for CRP in our study had evidence of concurrent 
inflammatory or neoplastic disease with the exception of mild atopic dermatitis, and it 
would seem unlikely that atopic dermatitis would have contributed to the high serum CRP 
concentration in the 2 affected dogs. Serum CRP concentration is unaffected by treatment 
with prednisolone (Martinez-Subiela et al., 2004; Merlo et al., 2006); thus, the 
administration of that drug to the 2 dogs with atopic dermatitis was unlikely to have altered 
the concentrations. Lipaemia was detected present in 3 of the 12 dogs in which serum CRP 
concentration was assessed. Although lipaemia can artefactually increase serum CRP   166 
concentration, it has minimal impact on clinical interpretation of those values (Ceron et al., 
2005; Kjelgaard-Hansen et al., 2003). 
In the present study, we failed to identify a correlation between serum CRP 
concentration and outcome or clinical severity index score. This is in contrast to results of 
a study in which a difference in serum CRP concentration between dogs with pancreatic 
necrosis (n = 9) and dogs with oedematous pancreatic inflammation (5) was detected 
(Spillman et al., 2002). A likely explanation for this disparity is that dogs in our study were 
probably more severely affected than the dogs evaluated in the previous study, and would 
all likely have fallen into the pancreatic necrosis group. In another recent study, findings 
were similar to results of our study, in that although serum CRP concentration was 
relatively increased in dogs with pancreatitis, all dogs that were critically ill had similar 
concentrations and it was not possible to differentiate between survivors and non-survivors 
on the basis of a single CRP value (Chan et al., 2006). The reason that serum CRP 
concentration may not correlate strongly to outcome may be dependent on the stage of the 
disease process during which the assessment was made. Serum concentration of CRP 
sequentially decreases in dogs during treatment for pancreatitis
 and in humans with acute 
pancreatitis after 2 days from the onset of clinical signs (Chen et al., 1999a; Holm et al., 
2004).
  
Serum CRP concentration in samples that were obtained within 2 days of the onset 
of clinical signs had a greater correlation with outcome in the present study than serum 
CRP measured after 2 days of clinical signs developing, although fewer dogs were 
assessed. The delay between onset of clinical signs and admission to the hospital in our 
study appeared to be attributable to the facts that some dogs were treated by their 
veterinarians before being hospitalised and the owners of others did not seek veterinary 
care immediately. This period of delay probably provides a true representation of the   167 
attendant times of admission and diagnosis of acute pancreatitis at a veterinary hospital in 
the general dog population.  
 
Although the number of dogs in which serum CRP concentration was evaluated 
was small, the results of the present study suggest that assessment of this variable in dogs 
with acute pancreatitis at the earliest possible time should be considered in conjunction 
with application of a clinical severity index for acute pancreatitis in dogs, rather than as a 
stand-alone test to determine disease severity. However, if a serum sample is obtained 
within 2 days of the onset of clinical signs and is greatly increased, then a poorer prognosis 
could be given. Sequential assessment of serum CRP concentration may also be an 
effective and objective method for monitoring response to treatment.  
Many clinical classification schemes for acute pancreatitis in humans have been 
assessed. The acute physiology, age, chronic health evaluation (APACHE) scheme, 
Ranson scheme, and Balthazar computed tomography severity index have been used with 
mixed results (Chatzicostas et al., 2003; Eachempati et al., 2002; Williams and Simms, 
1999; Yeung et al., 2006). In people, the development of pancreatic infection is considered 
the worst prognostic indicator, but such infections do not appear to develop in dogs with 
acute pancreatitis (Bradley, 1993; Isenmann et al., 1999; Williams, 1994). Clinical severity 
scoring schemes have been developed for assessment of inflammatory bowel disease in 
dogs and as a survival prediction index in dogs admitted to intensive care units but the 
latter fails to take into account complications specific to pancreatitis (Jergens et al., 2003; 
King et al., 2001). A previously published severity score for pancreatitis was calculated on 
clinicopathological abnormalities determined from sample submissions to a clinical 
pathology laboratory (Ruaux and Atwell, 1998b). For purposes of that scheme, a diagnosis 
of pancreatitis was made solely on the basis of whether dogs had increased serum lipase or 
amylase activity (Ruaux and Atwell, 1998b). As such, that scheme may have included dogs   168 
that did not truly have pancreatitis, because the rate of false-positive diagnosis associated 
with assessment of those biochemical variables alone is fairly high (Mansfield and Jones, 
2000). The mortality rate for our cohort of dogs that scored 3 and 4 using this laboratory-
based organ score were much lower than those reported in the original study (Ruaux and 
Atwell, 1998b).
 The reported mortality rate in the study involving the clinicopathological 
scheme may also be inaccurate because of the possibility that dogs from which samples 
were derived did not have pancreatitis, as well the possibility that some dogs that did have 
pancreatitis were excluded because the samples did not contain high serum lipase and 
amylase activities. Additionally, dogs that were euthanatized as a result of nonmedical 
reasons or that did not receive an optimal standard of care may have been included (Ruaux 
and Atwell, 1998b). In the present study, scores derived by use of the organ scoring 
scheme that was based on clinicopathological variables were not significantly correlated 
with outcome.  
Interestingly, scores for all but one of the organ systems evaluated for the organ 
score (i.e. the endocrine pancreas, leucogram, renal, and hepatic systems) were not 
significantly associated with outcome in our study. The remaining system, acid-base 
buffering, was not thoroughly assessed in our study because of a lack of consistent blood 
gas analysis among dogs during the study period.  
The clinical severity index score had a significant correlation with outcome, 
although days until outcome were equally associated with severity by use of either 
classification scheme. When considering this association in a retrospective manner, it is 
difficult to determine if the days until discharge were determined by factors other than 
medical reasons. It may be that some dogs were discharged prior to full recovery due to 
financial reasons, or that client factors may have precluded prompt discharge. In future   169 
studies, the determination of level of illness (i.e. able to be cared for in a ward situation or 
in an intensive care unit is likely to be a better assessment than duration of hospitalisation.  
In people, the development of severe peritonitis or infected pancreatic necroses is 
strongly indicative of a poor prognosis, whereas in dogs, pancreatic lesions (abscesses, 
acute fluid accumulations, or pseudocysts) have been similarly implicated (Edwards et al., 
1990; Johnson and Mann, 2006; Salisbury et al., 1988). Interestingly, among the 61 dogs 
with acute pancreatitis in the present study, local complications, even those considered 
severe, did not have an impact on outcome. This may reflect the large number of dogs 
(both survivors and non-survivors) that were recorded as having widespread peritonitis. Six 
dogs were recorded as having a score ≥ 2 in this category, and 5 of those dogs survived to 
discharge from the hospital; there was no significant association of scores ≥ 2 with 
outcome. This probably reflects both the low incidence of pancreatic abscess formation in 
dogs with acute pancreatitis and the recent trend in human gastroenterology toward 
conservative treatment of uninfected pancreatic lesions instead of surgical correction 
(Isenmann et al., 1999). The 5 dogs with pancreatic pseudocysts or acute fluid 
accumulations that survived were all conservatively treated. Follow-up information was 
available for 3 of those dogs; in all, the original lesion had resolved within 4 to 6 months.  
The development of systemic inflammatory response syndrome has also been 
identified as a strong indicator of poor prognosis in dogs with any illness, and diagnosis is 
often made on the basis of WBC abnormalities and high respiratory or heart rates (Okano 
et al., 2002). Coagulation abnormalities were also included in our initial body-system 
based score because disseminated intravascular coagulation and thromboembolic 
complications are potentially devastating consequences of severe acute pancreatitis 
(Ruaux, 2000). However, the haematopoietic complications initially considered 
(development of systemic inflammatory response syndrome or thromboembolic disease)   170 
were not correlated with survival in our study. This is despite strong links between these 
conditions and prognosis for other critical illnesses in dogs (King et al., 2001; Okano et al., 
2002). A large percentage of dogs in our study had abnormalities in the haematopoietic 
category, supporting the notion that virtually all dogs with acute pancreatitis have some 
degree of inherent systemic inflammation. Stratification within the haematopoietic system 
category was also assessed, and thromboembolic disease (either overt or subclinical) was 
not significantly correlated with prognosis. Seven dogs had scores ≥ 3 in this category, and 
5 of those dogs recovered. Causes of death of the 2 dogs that died were not recorded as 
potentially being attributable to thromboembolic complications; therefore, thromboembolic 
disease does not appear to play an important role in determination of acute pancreatitis 
severity in dogs. It was not possible to determine the effect of treatment on these 
haematopoietic factors, but no anti-coagulant therapy was used.  
Several factors may have contributed to the greater correlation of outcome with the 
scores derived by use of the clinical severity index developed in the present study, 
compared with findings in studies involving previously identified methods. What appears 
to be of most importance in dogs with acute pancreatitis is intestinal health, in particular 
during the period in which direct enteral nutrition is lacking, whether this is an intentional 
occurrence as part of the treatment or a disease-related complication. During starvation, 
inflammatory cytokines are produced by enterocytes and there is an increased incidence of 
bacterial translocation as a result of altered intestinal permeability, both of which have 
been shown to occur in naturally occurring acute pancreatitis in humans and 
experimentally induced acute pancreatitis in dogs (Abou-Assi et al., 2002; Ammori et al., 
1999; Kalfarentzos et al., 1997; Mohr et al., 2003; Powell et al., 2000; Qin et al., 2002a; 
Windsor et al., 1998). Restoration or maintenance of intestinal health is of potentially great 
importance when developing treatment strategies for dogs with acute pancreatitis, and   171 
provision of enteral nutrition early in the disease process may prove to be a prime factor in 
treatment of this condition.  
The clinical severity index established in the present study was developed to 
incorporate easily measurable variables that are most likely to contribute to the overall 
wellness of a dog with acute pancreatitis. Initial evaluation of this index revealed a 
significant negative correlation with outcome—as the clinical severity index score 
increased, the chance of survival decreased. A similar significant negative correlation with 
outcome was not identified for the organ scoring scheme. The strength of the clinical 
severity index, compared with the organ scoring scheme, is highlighted by the 6 dogs for 
which clinical severity index scores were high (mainly because of severely altered 
intestinal integrity or vascular forces) and poorly correlated with the organ scores. Without 
inclusion of factors relating to intestinal integrity or vascular forces, these dogs would have 
been assigned a low clinical severity index score indicative of mild disease.  However, 5 of 
the 6 dogs died or were euthanatized as a result of their disease despite intensive treatment. 
Serum CRP concentration was measured in 1 of these dogs; and that assessment alone 
would not have correlated with acute pancreatitis severity or outcome. Further analysis of 
additional dogs with acute pancreatitis from other veterinary hospitals may result in 
ongoing modification of the clinical severity scoring index, eventually allowing 
development of the most robust system possible for severity assessment. 
On the basis of sex and age distributions, the group of dogs evaluated in the present 
study was fairly similar to those evaluated in other studies (Cook et al., 1993; Hess et al., 
1998; Mansfield and Jones, 2000)
 of pancreatitis in dogs, although the breed representation 
in our study may be geographically unique.
 Reported rates of mortality in dogs with acute 
pancreatitis range from 27% to 42%, (Cook et al., 1993; Hess et al., 1998; Mansfield and 
Jones, 2000; Mansfield et al., 2003; Ruaux and Atwell, 1998b) which suggests that the   172 
group of dogs in our study was representative of the general population of dogs with acute 
pancreatitis, that treatment was essentially appropriate, and that there was no pre-selection 
for the most severe cases (no dogs with chronic pancreatitis were knowingly included). 
The inclusion criteria in our study allowed dogs with ultrasonographic evidence of 
pancreatitis (with supportive clinical findings and clinicopathological abnormalities) to be 
assessed. In 1 study,
 the sensitivity of
 ultrasonography for diagnosis of pancreatitis in dogs 
was approximately 62% (Mansfield and Jones, 2000). Although this sensitivity is relatively 
low, dogs with acute and chronic pancreatitis were evaluated in the study; thus the true 
diagnostic value of ultrasonography in dogs with acute pancreatitis is probably much 
higher. In dogs, the typical ultrasonographic changes associated with acute pancreatitis 
include a large pancreas with a hypoechoic appearance and cavitatory lesions, dilated 
pancreatic duct, and hyperechoic mesentery (Lamb, 1989; Lamb and Simpson, 1995; 
Murtaugh et al., 1985; Williams, 1994). In comparison to the situation in people, advanced 
imaging such as contrast-enhanced computed tomography may have no advantage over 
ultrasonography for the diagnosis of acute pancreatitis in dogs (Jaeger et al., 2003). This 
likely reflects the fact that infected pancreatic necrosis (for which computed tomography is 
considered the gold standard diagnostic tool) develop less frequently in dogs than in people 
(Isenmann et al., 1999). In the present study, it is possible that some dogs with pancreatitis 
were evaluated at the hospital but were not included in the analyses because the diagnosis 
was not confirmed ultrasonographically. The rate of false-positive diagnosis of pancreatitis 
via ultrasonography is likely to be low with experienced operators, so it was assumed that 
all dogs that were included in our study did in fact have acute pancreatitis. The 
classification of pancreatitis is confusing and problematic, but in dogs and people, it is 
assumed that the acute form involves some degree of necrosis (Bradley, 1993; Charles, 
2007; Watson, 2004). Although ultrasonography cannot determine the cellular process   173 
within the pancreas, pancreatic neoplasia is considered unlikely in the dogs included in the 
present study because the outcome for each individual is known. Often the presence of 
pancreatic neoplasia is accompanied by pancreatic inflammation and necrosis; thus, the 
definitive differentiation of neoplasia and inflammation in the short term would have little 
bearing on our study results (Williams, 1994). Ultrasonography is also considered a highly 
sensitive technique for detection of pancreatic complications such as pseudocysts, acute 
fluid accumulations, or abscesses (Johnson and Mann, 2006; Murtaugh et al., 1985; 
Rutgers et al., 1985; Schaer, 1979; Williams, 1994). 
4.5 Conclusion 
For dogs with acute pancreatitis, use of a clinical severity scoring index, such as 
that developed in the present study, along with sequential measurement of serum CRP 
concentration appears to be helpful in prognostic determination. Nevertheless, the clinical 
severity index score should not be used as the sole criterion on which treatment or 
prognosis in acute pancreatitis -affected dogs is determined at present, because some dogs 
in our study that had high scores survived to discharge from the hospital and others that 
had lower scores died or were euthanatized. The clinical severity index may be useful in 
allowing multicenter comparison of treatments of dogs with severe naturally occurring 
acute pancreatitis. As new treatments based on an improved understanding of the 
pathophysiology of this disease are developed, use of this index may allow objective 
assessments of the usefulness of particular treatment options to be made.  
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Chapter 5: Retrospective analysis of the effect of plasma and 
microenteral nutrition administration on mortality and morbidity in 
dogs with acute pancreatitis  
This chapter has not been submitted for publication.  
5.1 Introduction 
Most treatment recommendations for canine acute pancreatitis are based on general 
supportive principles or extrapolated from human and experimental studies in species other 
than dogs.  Plasma transfusion is currently recommended in the veterinary literature for the 
treatment of this disease (Logan et al., 2001; Snow et al., 2010; Williams and Steiner, 
2005). Purported benefits include replacement of circulating α-macroglobulins, 
replacement of coagulation factors and treatment of systemic inflammatory response 
syndrome (SIRS) with anti-inflammatory factors (Weatherton and Streeter, 2009). 
Depletion of α-macroglobulin has been documented in an experimental model of canine 
pancreatitis, and correlated with severity of pancreatic inflammation (Murtaugh and 
Jacobs, 1985). Systemic effects of the pancreatic inflammation were not assessed in that 
study, nor whether there would have been amelioration with administration of plasma. It is 
unlikely that any benefit seen with plasma will be due to colloid like properties, as fresh 
frozen plasma (FFP) has only about 20-30% of the oncotic properties of colloids (Iazbik et 
al., 2001; Yaxley et al., 2010). However, haemostatic proteins are well preserved in FFP, 
regardless of whether freeze-thawed or not (Iazbik et al., 2001; Yaxley et al., 2010).  
There are no published prospective studies in naturally occurring acute pancreatitis 
to support many of the current treatment recommendations such as plasma transfusion in 
dogs. One retrospective study identified a negative correlation between plasma 
administration and survival (Weatherton and Streeter, 2009). As the dogs included in that 
study were not stratified according to severity, it is difficult to elucidate whether more   175 
severely affected dogs were selectively administered plasma to start with, contributing to 
the poor mortality.  
Nutritional intervention in acute pancreatitis and other diseases necessitating 
critical care are beginning to be evaluated in the veterinary literature (Chan et al., 2006; 
Chan et al., 2002; Freeman et al., 1995; Mansfield et al., 2011a; Mansfield et al., 2011b; 
Chapter 7; Mohr et al., 2003; Queau et al., 2011). Historically, the recommendation in 
canine pancreatitis is to rest the pancreas, and provide no nutrition via the gut (Simpson 
and Lamb, 1995; Williams and Steiner, 2005). This paradigm is being challenged in human 
gastroenterology, where current consensus opinion is to feed in people with severe acute 
pancreatitis as early as possible (Johnson, 2005; Meier et al., 2006). This shift was based 
on experimental observations that fasting led to mucosal atrophy, changes in the goblet cell 
function within the intestine, and decreased glutamine transportation, potentially leading to 
oxidative stress (Hernandez et al., 1999; King and Kudsk, 1997; Sarac et al., 1994; Sharma 
and Schumacher, 1995).  
Interventional nutrition in the form of feeding tubes is sometimes difficult to apply 
in veterinary practice. A relatively easy method by which to accomplish nutrition delivered 
into the gut is by insertion of a naso-oesophageal feeding tube, a procedure which does not 
require sedation or general anaesthesia. The drawback with this methodology is the tubes 
normally able to be inserted by this method are very narrow gauge and so only very liquid 
formulations can be delivered. In Australia, no veterinary liquid diet is available that is of 
the appropriate consistency, and so one potentially useful method is to trickle in a balanced 
electrolyte solution that contains glucose to try and go some way to overcoming the 
negative nitrogen balance that occurs in pancreatitis (Abou-Assi and O'Keefe, 2001). For 
the purposes of this study, this is referred to as microenteral nutrition (MEN). Whether 
there is potential for MEN to also directly counteract gut mucosal atrophy is unknown.      176 
The aim of this project is to assess whether plasma administration or MEN 
administration is beneficial, when stratified according to the severity criteria developed in 
Chapter 4.  
5.2 Materials and Methods  
5.2.1 Animal selection 
A database review of cases seen at Murdoch University (primary emergency 
accession centre and referral hospital) for the period between 1999 and 2006 was 
performed. Search terms included pancreatitis, acute pancreatitis, pancreatic necrosis or 
suspected pancreatitis. Inclusion criteria were evidence of acute pancreatitis detected via  
abdominal ultrasonography or histological examination of surgical or necropsy tissue 
samples, admission to hospital for treatment, complete daily clinical records (including all 
medical treatments), and known outcome, as per Chapter 4. Ultrasonography using a 
curvilinear 8 MHz or linear 15 MHz probe (Sequioa 512, Acuson, Munich, Germany) was 
performed by a board-certified (or equivalent Australian qualification) radiologist. A 
diagnosis of acute pancreatitis was made if there was evidence of a large pancreas with 
patchy echogenicity or hyperechoic mesentery. Dogs were excluded if they were not 
admitted for treatment, received TPN or full EN or were euthanatized for nonmedical 
reasons.  
5.2.2 Data collection 
  For each dog that fulfilled the inclusion criteria, duration of hospitalisation and 
outcome (died, euthanatized due to medical reasons or survived to discharge) was 
recorded, along with the clinical severity index as previously described in Chapter 4 based 
on data collected within 12 hours of admission (Mansfield et al., 2008). The administration 
of plasma or MEN was also recorded, if given within 72 hours of the clinical severity   177 
index calculation. For the purposes of this study, MEN was defined as a trickle electrolyte 
solution (Lectade
®, Jurox Pharmaceuticals, Rutherford NSW, Australia) delivered via a 
naso-oesophageal tube at 0.5 mL/kg/hour 
5.2.3 Statistical Analysis 
Association between plasma treatment and survival, and between use of MEN and 
survival in all cases was calculated using Fisher’s exact test. Association between plasma 
treatment or use of MEN and survival in cases with a modified clinical severity index 
greater than or equal to two was also calculated using Fisher’s exact test.  A Mann-
Whitney test was used to compare modified clinical severity scores between two groups. A 
P value < 0.05 was considered significant. Stata v12.0 (StataCorp, Texas, USA) was used 
for statistical analyses. 
5.3 Results 
Analysing all data, there were 59 dogs that fulfilled the inclusion criteria.  Two of 
the previously identified dogs in Chapter 4 were excluded due to administration of TPN.  
The treatment group, outcome, duration of hospitalisation and clinical severity 
index on admission of these 59 dogs identified on retrospective review of medical records 
are detailed in Table 5.1. Of the dogs with a clinical severity index  ≥2, four received MEN 
plus plasma and supportive care, but no other form of interventional nutrition in the first 3 
days of admission. All 4 dogs survived, with a range in duration of hospitalisation from 6-
10 days (median 8 days). Six dogs received plasma treatment, but no MEN or other 
nutritional support. Three of these dogs died, with a hospitalisation duration ranging from 
3-10 days (median 6 days). One dog had nutritional support in the form of MEN, but did 
not receive any plasma. This dog survived with a hospitalisation of 11 days.   178 
Thirteen dogs were treated with plasma and 10 (76.9%) recovered, compared to 46 
dogs that received no plasma, of which 37 (80.4%; P=0.72) recovered. When only dogs 
with a modified clinical severity index ≥ 2 were analysed, there was still no effect of 
plasma treatment on survival. Ten of these dogs were treated with plasma and 7 (70%) 
recovered, whilst 20 of these dogs were not treated with plasma, of which 12 (60%) 
recovered. The P value using Fisher’s exact test was 0.70, indicating no statistically 
discernible benefit in giving plasma.  
If dogs with a clinical severity index  ≥ 2 that were administered plasma but also 
received MEN were excluded, there was no difference in survival (3/6 dogs given plasma 
survived vs. 11/19 dogs not given plasma survived; P = 1.0). It was not possible to 
determine from the retrospective case records the clinician’s reasoning for administering 
plasma to individual dogs. There was no individual factor of the clinical severity index that 
appeared to be related to this.  
  When all dogs that had received plasma transfusions (regardless of other 
treatments) were compared to all other treatment groups (excluding total parenteral 
nutrition) there was no difference in outcome (P = 0.72), however there was a difference in 
initial clinical severity index  (P = 0.0039). The median (range) of the clinical severity 
index in the 13 dogs given plasma was 4 (0-6) and the median in the dogs not given plasma 
was 1 (0-5). 
When all dogs that had received MEN (regardless of other treatments) were 
compared to all treatment groups there was no statistical difference in initial clinical 
severity index (P = 0.078). The difference in outcome between all dogs that received MEN 
(8/8; 100%) and those that didn’t (39/51; 76%) was not statistically significant (P = 0.19). 
Analysis of dogs with an initial clinical severity index ≥ 2 showed that all 5 dogs receiving   179 
MEN survived and 14 of 25 (56%) dogs not receiving MEN survived (P = 0.13). MEN had 
only been instituted in 2001.  
  Assuming a survival rate of 70% without extra treatment such as nutrition or 
plasma, sample sizes required to prove a 10%, 20% and 25% improvement in mortality 
with each treatment are 313, 69 and 39 respectively. This is with 80% power and Type I 
error of 5%.  
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Table 5.1  
Treatment 
group 
Breed  Age 
(years) 
Sex  CSI 
admission 
LOH  Outcome 
MEN + plasma 
  Bull terrier X  9  MN  4  6  Survived 
  Australian cattle dog X  7  FN  4  10  Survived 
  Border collie  9  MN  4  8  Survived 
  Jack Russell terrier  3  FN  5  8  Survived 
MEN only 
  Miniature poodle  9  FN  4  11  Survived 
  Miniature schnauzer  9  FE  1  5  Survived 
  Miniature schnauzer  11  MN  1  5  Survived 
  Bull terrier X  4  FN  1  4  Survived 
Plasma only 
  Kelpie X  3  ME  4  6  Survived 
  Border collie  7  FN  5  6  Died 
  Corgi  8  MN  6  10  Died 
  Collie X  6  FN  1  7  Survived 
  Shih Tzu  5  MN  3  8  Survived 
  Bull terrier  8  FN  4  3  Died 
  Flat Coat retriever  9  ME  1  5  Survived 
  Miniature schnauzer  2  FN  3  6  Survived 
  West Highland White 
terrier 
9  FN  0  3  Survived 
 
Details of dogs that were retrospectively identified to have received micro-enteral nutrition 
(MEN) and/or plasma transfusion for the treatment of severe pancreatitis, but no other 
nutritional intervention, at Murdoch University Veterinary Hospital in the period 1999-
2006. CSI= clinical severity index; LOH= length of hospitalisation (days). 
5.4 Discussion 
Plasma treatment alone was shown to have no beneficial treatment in all dogs and 
in all dogs with a clinical severity index ≥ 2 in our study. Controlled studies in people 
would also suggest that there is no benefit of fresh frozen plasma over albumin infusion, at 
either a high or low dose rate (Leese et al., 1991; Leese et al., 1988). The main clinical 
rationale for the use of fresh frozen plasma in our study population appears to have been 
for prevention of complications such as disseminated intravascular coagulation or other   181 
inflammatory-mediated syndromes rather than to provide oncotic support. Although this 
study only evaluated a small numbers of dogs, and therefore only had power to detect large 
improvements in mortality, it is suggestive that plasma administration may not actually be 
beneficial in canine acute pancreatitis. This reflects the current trends in veterinary 
medicine, and also a recent retrospective report (Snow et al., 2010; Weatherton and 
Streeter, 2009). 
All cases that received plasma transfusion also received concurrent treatment such 
as analgesia, intravenous crystalloid fluid therapy and anti-emetic treatment considered 
standard for acute pancreatitis, and thus do not reflect a sub-group of the population that 
received sub-optimal treatment in other regards. However, the treatment was not 
standardised amongst dogs, which along with the low numbers is a major limitation of this 
type of study. It is these flaws that limit the clinical conclusions that can be drawn from 
this study, but do suggest large scale studies (with 319 dogs in the treatment group) would 
be necessary to show a 10% improvement in survival.  
The most recent new treatment protocol introduced into the hospital during the 
period of analysis (in 2001) was the introduction of early MEN in all cases of acute 
pancreatitis. Eight dogs with acute pancreatitis received MEN, whilst 4 of these also 
received a plasma transfusion. Potential reasons for benefit of MEN include improvement 
of enterocyte health, general reversal of a catabolic state, decreasing incidence of bacterial 
translocation and reduction of systemically circulating inflammatory cytokines, although 
these are purely speculative.  
The potential benefit of MEN did not translate to a discernible statistical benefit in 
our analysis. Effectively, this type of ‘nutrition’ doesn’t supply any direct nutrients except 
glucose and electrolytes, and so is unlikely to contribute to caloric intake to any discernible 
degree. It is unknown what direct effect (if any) these would have on the enterocytes. It   182 
may be more relevant to study trickle nutrition containing glutamine, due to the potential 
for glutamine to be directly beneficial to the enterocytes (De Beaux et al., 1998, Furst et 
al., 1997). Further studies may prove MEN to be of no benefit, and full enteral nutrition 
may provide the only discernible impact on this disease. There was however a very low 
number of dogs given MEN in this study.  
There are obviously a large number of flaws in this study. Namely, the 
retrospective nature leads to selection bias, there is no control group, and the study size is 
small. By correlating treatment decision to the clinical severity index, this flaw became 
apparent as plasma administration was given to dogs with more severe disease overall. 
This is likely to reflect the views of clinicians who felt that plasma would be of most 
benefit in severe animals. Despite this flaw, when comparing severely affected dogs only, 
no benefit of plasma on survival was discernible. Prospective, well controlled trials are 
necessary to further investigate the potential benefit, or lack thereof, for plasma 
administration in dogs.  
5.5 Conclusion  
Currently, given the high cost of plasma it would not appear that there is strong 
clinical evidence for its use in canine acute pancreatitis. However, large multi-center 
studies are required before this can be conclusively shown, with a minimum number of 313 
in each treatment group required to show a 10% improvement in survival. To be truly 
clinically significant, such a trial would need to be randomized and controlled.  
Additionally, it would appear that MEN without other interventional nutrition has little to 
no effect, albeit this is based on very small numbers and only assessed a colution 
containing electrolytes and glucose, not amino acids like glutamine that may be directly 
beneficial to the gut.      183 
Chapter 6: Pancreatic response in healthy dogs fed diets of various fat 
compositions 
The following is a modified version of the paper: Fleur E. James, Caroline S. Mansfield, 
Jörg M. Steiner, David A. Williams & Ian D. Robertson (2009) Journal of the American 
Veterinary Medical Association 70: 614-618. The author of this thesis designed the study, 
as well as contributed to sample and data collection, data analysis, and equally to the 
writing  of  the paper.  It is  included in this thesis  to  give a clear understanding  of the 
reasoning behind the nutritional intervention in the following chapter.  
6.1 Introduction 
Canine  acute  pancreatitis  can  be  a  challenging  disease  to  manage  and  may  be 
associated  with  high  morbidity  and  mortality  rates.  Part  of  the  traditional  treatment 
recommendation in the management of this disease has been to withhold food from dogs 
followed  by  feeding  an  ultra–low-fat  diet.  Results  of  recent  studies  in  humans  and 
experimental studies in dogs indicate that provision of enteral nutrition early in the course 
of the disease improves survival and decreases complication rates, but the ideal diet has 
never been determined (Meier and Beglinger, 2006; Qin et al., 2002a; Weber and Adler, 
2003). 
Serum  canine  trypsin-like  immunoreactivity  (cTLI)  concentration  is  a  specific 
marker  of  exocrine  pancreatic  mass;  assessment  of  this  variable  has  a  relatively  low 
sensitivity for detection of pancreatitis yet is the most sensitive and specific test for the 
diagnosis of exocrine pancreatic insufficiency in dogs (Hess et al., 1998; Mansfield and 
Jones,  2000;  Williams  and  Batt,  1988).  Because  measurement  of  serum  cTLI 
concentration  includes  all  circulating  cationic  trypsinogen  and  approximately  80%  of 
cationic trypsin, it may also be used to assess pancreatic adaptation or function (Watson, 
2004). Compared with total serum lipase activity, assessment of serum canine pancreatic 
lipase  immunoreactivity  (cPLI)  activity  appears  to  have  improved  sensitivity  and 
specificity as a commercially available laboratory test for diagnosis of pancreatitis in dogs; 
moreover,  serum  cPLI  concentration  is  unaffected  by  prednisolone  administration  or   184 
concurrent renal failure (Steiner, 2003; Steiner et al., 2001; Steiner et al., 2003).
 Serum 
cPLI concentration is reduced in dogs with exocrine pancreatic insufficiency and may also 
be a useful marker to indirectly determine the degree of pancreatic adaptation or response 
within an individual dog (Steiner et al., 2006).  
In the gastric antrum, G-type cells secrete gastrin in response to gastric distension 
and ingestion of protein (Williams, 1996).  The main forms of gastrin secreted in dogs are 
gastrin 34, 17, and 14; collectively, they have a short circulating half-life of 3 to 9 minutes 
(Williams,  1996).  The  presence  of  gastrin,  other  gastrointestinal  hormones  such  as 
cholecystokinin  (CCK),  and  enteric  neuropeptides  stimulate  pancreatic  acinar  cells  to 
release lysosomes and zymogens in response to food (Williams, 1996).  This response to 
food occurs both by the anticipation and smell of food, mediated via neural pathways, as 
well as the presence of food in the stomach and small intestine, mediated via hormonal 
pathways (Williams, 1996).  Thus, measurement of serum gastrin concentration may serve 
as an indirect measure of one aspect of pancreatic stimulation. 
The purpose of the study reported was to determine whether amounts of dietary fat 
or addition of pancreatic enzymes and MCTs to diets alters concentrations of cTLI, cPLI, 
and gastrin in healthy dogs. 
 
6.2 Materials and Methods  
6.2.1 Analytical validation of an assay for gastrin 
An  automated  chemiluminescent,  enzyme-labeled  immunometric  assay 
(Immunolite 2000, Diagnostic Products Corporation, Los Angeles, California, USA) was 
used.
 The assay
 was based on a ligand-labeled murine monoclonal capture-antibody that 
was  specific  for  gastrin  and  involved  separation  by  use  of  an  anti–ligand-coated  solid   185 
phase  (DPC,  2005).  To  analytically  validate  this  assay  for  use  in  dogs,  the  interassay 
variability was assessed via measurement of the coefficient of variation (CV) and the intra-
assay variability was assessed via measurement of the CV and linearity.  A blood sample 
(3 mL) was collected via jugular venipuncture from 3 healthy dogs (designated as dogs A, 
B, and C; dogs B and C also participated in the analytical part of the study), that each 
weighed > 9 kg and all had body condition scores <6/9, and serum was obtained.  For each 
dog,  serum  gastrin  concentration  was  measured.  On  the  basis  of  findings,  dog  A  was 
classified as having low (< 8.0 pg/mL), dog C as medium (8.0 – 13.0 pg/mL), and dog B as 
high  concentration  of  gastrin  (>  13.0  pg/mL).    A  second  blood  sample  (20  mL)  was 
collected from dog A after food was withheld for 12 hours. Dogs B and C were each fed 
one of the experimental diets to stimulate gastrin release (diet A that contained 16% crude 
fat per dry matter ) and the second blood sample (12.5 mL) was collected 5 to 10 minutes 
after  feeding.  Blood  samples  were  placed  on  ice  and  allowed  to  clot,  prior  to 
centrifugation; serum was separated promptly by use of a refrigerated centrifuge at 10
oC 
and immediately divided into aliquots of 100 to 250 μL that were stored at –18
oC.   
Aliquots of serum were used to prepare 3 batches for analysis (30 replicates per 
batch).  Batch  1  consisted  of  28  replicates  of  dog  A  serum  (low-concentration  control 
samples) and 2 replicates of dog B serum (high-concentration control samples).  Batch 2 
consisted of 2 replicates of dog A serum, 2 replicates of dog B serum, and 26 replicates of 
dog C serum (medium-concentration control samples). Batch 3 consisted of 3 replicates of 
dog A serum, 6 replicates of dog B serum, and 3 replicates of dog B serum for each of the 
following dilutions: 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, and 1:128.  Serum from dog A was used 
as the diluent. Each batch was tested as an entire batch and separate from other batches.      
The  specificity  of  the  assay  for  detection  of  gastrin  in  human  serum  had  been 
determined by the manufacturer on the basis of results of assays of samples with high   186 
concentrations of mini-gastrin; low, medium, and high concentrations of sulphated gastrin 
G-17 (type II); low, medium, and high concentrations of both sulphated (type II) and non-
sulphated (type I) gastrin G-34; medium and high concentrations of non-sulphated (type I) 
gastrin G 1-13; low, medium, and high concentrations of pentagastrin; and low, medium, 
and  high  concentrations  of  cerulein  (DPC,  2005).  The  assay  antibody  interacts 
predominantly  with  G-17,  with  lesser interaction with  G-34, mini-gastrin, and cerulein 
(DPC, 2005).  Recovery studies were performed by the manufacturer and results indicated 
mean recoveries for G-17 type II and G-17 type I of 119% and 116%, respectively (DPC, 
2005).  Haemolysis did not appear to interfere with the test (DPC, 2005). It was reported 
that bilirubin at concentrations > 85.5 µmol/L may interfere with the test, and that serum 
triglyceride concentrations > 11 mmol/L results in degradation of values (DPC, 2005).  
The assay range was 5 to 1,000 pg/mL, and results < 5 pg/mL were recorded as 0 pg/mL.   
6.2.2 Study protocol 
The study was approved by the Animal Ethics Committee at Murdoch University, 
fulfilling requirements of the National Health and Medical Research Council.  Healthy 
staff-owned dogs that weighed > 9 kg were recruited into the study with owner consent. 
The  dogs  had  no  prior  history  of  pancreatitis  or  clinically  important  gastrointestinal 
disease.    All  dogs  were  determined  to  be  healthy  on  the  basis  of  results  of  physical 
examination,  haematology,  serum  biochemical  analyses,  urinalysis,  and  assessments  of 
serum  amylase  and  lipase  activities.    No  dogs  were  considered  to  be  more  than  10% 
overweight. 
Four experimental diets were used in the study, and each dog was fed all 4 diets 
once in random order using a Latin square design at 1-week intervals. Between dietary 
treatments, dogs were fed their normal diet, which did not exceed 24% dry matter in any   187 
individual dog.  Diet A was a maintenance commercial dog food (PurinaONE, adult dog 
chicken and rice formula, Nestle Purina PetCare Company, St Louis, Missouri, USA) that 
had a crude fat content of 16% dry matter (as stated by the manufacturer).  Diet B was a 
low-fat  commercial  dog  food  (Royal  Canin  digestive  low  fat  Canine  Veterinary  Diet, 
Royal Canin, Aimargues, France) that had a crude fat content of 5%  dry matter as stated 
by  the  manufacturer.  Diet  C  was  composed  of  diet  A  with  supplemental  pancreatic 
enzymes (Creon 5000, Creon 10000 and Creon Forte, Solvay Pharmaceuticals, Pymble, 
NSW) containing lipase, 526 to 1,667 British Pharmacopoeia units/kg; amylase, 421 to 
1,200 British Pharmacopoeia units/kg; and protease, 31 to 67 European Pharmacopoeia 
units/kg.  Diet  D  was  composed  of  diet  B  with  supplemental  pancreatic  enzymes  (as 
described for diet C) and medium chain triglyceride (MCT) oil (SHS International Ltd, 
Liverpool, UK) containing 0.5 mL/kg; C8 and C10 fatty acids composition > 95%.  Food 
was withheld from the dogs for at least 12 hours prior to the feeding of each diet on the test 
dat.  For each dog, the amount fed of each diet was based on half the daily calculated 
maintenance energy requirement (resting energy requirement x 1.4). A blood sample was 
collected from each dog via jugular venipuncture before (0 hours [baseline]; 12.5mL) and 
at 5 to 10 minutes (2.5mL), 1 to 2 hours (3mL), and 6 hours (3mL) after feeding each 
experimental  diet.    Blood  samples  were  placed  on  ice  and  allowed  to  clot,  prior  to 
centrifugation; serum was separated promptly by use of a refrigerated centrifuge at 10
oC 
and stored at –18
oC.  Serum cTLI (commercial RIA, Diagnostic Products Corporation, Los 
Angeles, California, USA) and cPLI (ELISA) concentrations were measured at 0, 1 to 2, 
and  6  hours  after  feeding.  Both  cTLI  and  cPLI  were  measured  at  the  Gastrointestinal 
Laboratory, Department of Small Animal Medicine and Surgery, College of Veterinary 
Medicine, Texas A & M University, College Station, Texas. Serum gastrin concentration 
was measured at 0 hours, 5 to 10 minutes, and 1 to 2 hours after feeding.   188 
6.2.3 Data analysis 
The results were analysed by use of a repeated-measures general ANOVA (SPSS, 
version 14.0; SPSS Inc, Chicago, USA).  Differences in the dogs’ serum cTLI, cPLI, and 
gastrin concentrations among diets fed, among dogs, and over time were analysed with 
significance  set  at  a  value  of  P  ≤  0.05.    To  assess  variation  in  cTLI  and  cPLI 
concentrations from baseline (0 hours) at 1 to 2 and 6 hours after feeding, the percentage 
change  was  calculated.  To assess variation in  gastrin  concentrations  from  baseline (0 
hours) at 5 to 10 minutes and 1 to 2 hours after feeding, the actual change rather than 
percentage  change  was  calculated  to  allow  for  zero  values.  The  interassay  CV  was 
determined  for  serum  gastrin  concentrations  when  samples  were  assayed  on  different 
days.   
6.3 Results 
6.3.1 Dogs 
Ten healthy dogs were used in the study. Their ages ranged from 1 to 12 years 
(mean   SD age, 5.7   3.68 years) and weights ranged from 9.8 to 40.8 kg (mean weight, 
26.5    9.4  kg).  There  were  2  sexually  intact  males,  4  castrated  males,  and  4  spayed 
females. Among the dogs, there were 2 Labrador retrievers, 1 Gordon setter, 1 Miniature 
schnauzer, 1 Dalmatian, 1 Australian cattle dog, 1 Greyhound, and 3 mixed-breed dogs.   
6.3.2 Serum sample quality 
No samples in the present study were grossly lipaemic, haemolysed, or icteric. 
6.3.3 Gastrin assay validation 
On the basis of the data obtained by use of the enzyme-labeled immunometric 
assay  on  serum  samples  obtained  from  3  healthy  dogs,  the  mean  interassay  CV  was   189 
11.56%  and  the  mean  intra-assay  CV  was  11.41%.  Dilutional  parallelism  evaluations 
revealed acceptable linearity (Figure 6.1).   
 
Figure 6.1  Results  of  the  dilutional  parallelism  evaluations  of  an  enzyme-labeled 
immunometric  assay  for  measurement  of  serum  gastrin  concentration  in  dogs.  Serum 
samples were collected from 3 healthy dogs (designated as dogs A, B, and C). The assay 
was  performed  on  3  replicates  of  dog  A  serum,  6  replicates  of  dog  B  serum,  and  3 
replicates of dog B serum for each of the following dilutions: 1:2, 1:4, 1:8, 1:16, 1:32, 
1:64, and 1:128.  Serum from dog A (low gastrin concentration) was used as the diluent.  
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6.3.4 Serum cTLI concentration 
Among the 10 dogs during the 4 experimental periods, baseline cTLI concentration 
ranged from 4.4 to 128.5 μg/L (mean   SD, 13.6   19.5 μg/L). Mean serum concentrations 
of cTLI at 1 to 2 hours and at 6 hours after feeding were 12.6 and 12.3 μg/L, respectively, 
in dogs fed diet A; 11.9 and 11.2 μg/L, respectively, in dogs fed diet B; 12.6 and 11.3 
μg/L, respectively, in dogs fed diet C; and 12.8 and 11.4 μg/L, respectively, in dogs fed 
diet D. For each diet, the percentage change (from baseline) in serum cTLI concentration 
over time was calculated (Figure 6.2).  
 
 
 
Figure 6.2  Percentage change in mean serum cTLI concentrations in 10 healthy dogs 
before (0 hours [baseline]) and at 1 to 2 and 6 hours after consumption of 1 meal of each 
of 4 diets (1-week interval between diet treatments). Dogs were fed a maintenance 
commercial dog food that had a crude fat content of 16% (diet A [circles]); a low-fat 
commercial dog food that had a crude fat content of 5% (diet B [diamonds]); diet A with 
supplemental pancreatic enzymes
 (diet C [triangles]); and diet B with supplemental 
pancreatic enzymes and MCT oil (diet D [squares]). Food was withheld from the dogs for 
at least 12 hours prior to the feeding of each diet. Data are presented as mean   SD 
percentage change from baseline values.   191 
6.3.4 Serum cPLI concentration 
Among  the  10  dogs  during  the  4  experimental  periods,  the  baseline  cPLI 
concentration ranged from 5.3 to 169.6 μg/L (mean, 29.6   31.6 μg/L). The mean serum 
concentration of cPLI at 1 to 2 hours and at 6 hours after feeding were 24.3 and 24.2 μg/L, 
respectively, in dogs fed diet A; 28.5 and 24.2 μg/L, respectively, in dogs fed diet B; 33.6 
and 28.5 μg/L, respectively, in dogs fed diet C; and 59.2 and 42.6 μg/L, respectively, in 
dogs  fed  diet  D.  For  each  diet,  the  percentage  change  (from  baseline)  in  serum  cPLI 
concentration over time was calculated (Figure 6.3).             
 
 
Figure 6.3  Percentage change in mean serum cPLI concentrations in 10 healthy dogs 
before (0 hours [baseline]) and at 1 to 2 and 6 hours after consumption of 1 meal of each 
of 4 diets (1-week interval between diet treatments). Food was withheld from the dogs for 
at least 12 hours prior to the feeding of each diet. Data are presented as mean   SD 
percentage change from baseline values. Dogs were fed a maintenance commercial dog 
food that had a crude fat content of 16% (diet A [circles]); a low-fat commercial dog food 
that had a crude fat content of 5% (diet B [diamonds]); diet A with supplemental 
pancreatic enzymes
 (diet C [triangles]); and diet B with supplemental pancreatic enzymes 
and MCT oil (diet D [squares]). 
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6.3.5 Serum gastrin concentration 
Among  the  10  dogs  during  the  4  experimental  periods,  the  baseline  gastrin 
concentration ranged from < 5 to 16 pg/mL (mean, 2.2   4.3 pg/mL). The mean serum 
concentration of gastrin at 5 to 10 minutes and at 1 to 2 hours after feeding were 8.3 and 
11.0 pg/mL, respectively, in dogs fed diet A; 10.9 and 8.2 pg/mL, respectively, in dogs fed 
diet  B;  9.1  and  8.9  pg/mL,  respectively,  in  dogs  fed  diet  C;  8.0  and  12.7  pg/mL, 
respectively, in dogs fed diet D. For each diet, the actual change (from baseline) in serum 
gastrin concentration over time was calculated (Figure 6.4). 
 
 
 
Figure 6.4   Change in mean serum gastrin concentrations in 10 healthy dogs before  (0 
hours [baseline]) and at 5 to 10 minutes and 1 to 2 hours after consumption of 1 meal of 
each of 4 diets (1-week interval between diet treatments). Food was withheld from the dogs 
for at least 12 hours prior to the feeding of each diet. Data are presented as mean   SD 
actual change from baseline values. Dogs were fed a maintenance commercial dog food 
that had a crude fat content of 16% (diet A [circles]); a low-fat commercial dog food that 
had a crude fat content of 5% (diet B [diamonds]); diet A with supplemental pancreatic 
enzymes
 (diet C [triangles]); and diet B with supplemental pancreatic enzymes and MCT 
oil (diet D [squares]). 
 
6.3.6 Data comparisons 
In the study dogs, serum cPLI and cTLI concentrations did not differ significantly 
among diets fed, among dogs, or over time. Compared with the other diets, diet D was   193 
associated with a higher mean baseline serum cPLI concentration, but this difference was 
not significant (P = 0.2). Serum gastrin concentration at 0 hours was significantly different 
from values at the 2 later time points after feeding diet D. Serum gastrin concentration did 
not  differ  among  diets  fed;  diet  D  induced  the  least  amount  of  pancreatic  response, 
compared with the effects of the other diets, although this difference was not significant (P 
= 0.33). No significant deviation from this finding was apparent in data for any individual 
dog. 
6.4 Discussion 
Known triggers for pancreatic stimulation include gastric distension, dietary protein 
and  fatty  acid  intake,  emptying  of  gastric  contents  into  the  duodenum,  and  enteric 
neuropeptides (Williams, 1996). Results of the present study indicated no significant effect 
of the content of fat or the presence or absence of supplemental pancreatic enzymes and 
MCTs on the degree of pancreatic stimulation (assessed by measurement of serum cTLI, 
cPLI,  and  gastrin  concentrations)  in  healthy  dogs.    Serum  gastrin  concentration  was 
monitored to assess the immediate effects of gastric distension on pancreatic stimulation 
and  serum  cTLI  concentration  was  monitored  to  assess  overall  pancreatic  function. 
Assessment of serum cPLI concentration was also undertaken; this variable reflects the 
pancreatic response in relation to varying dietary fat content because co-lipase is activated 
and  converted  into  lipase  to  enable  fat  digestion,  and  because  cPLI  is  specific  to  the 
pancreas.   
The variables measured in our study are considered indirect indices of pancreatic 
stimulation  in  dogs.    Gastrin,  cTLI,  and  cPLI  were  chosen  as  indicators  because  they 
remain stable in serum samples and because high-specificity assays for measurement of 
serum concentrations are commercially available. To determine the degree of pancreatic   194 
response in healthy dogs in the study of this report, the percentage changes in serum cTLI 
and  cPLI  concentrations  and  the  actual  change  in  serum  gastrin  concentration  were 
assessed over time and among the 4 diets fed. It is possible that the measurements of these 
serum markers of pancreatic function were not sufficiently sensitive to accurately assess 
exocrine pancreatic stimulation and instead more direct intraduodenal markers should be 
measured.  However, the latter procedures are more technically difficult and invasive to 
perform. In our opinion, the variables measured in the present study are useful as indirect 
measures of pancreatic response. It was not possible to calculate the percentage change in 
serum  gastrin  concentration  from  baseline  values  for  all  dogs  at  all  time  points  after 
feeding of the diets because some concentrations were less than the detection limit of the 
assay. The assessment of serum gastrin was still considered appropriate because none of 
the concentrations were less than the detection limit of the assay during the validation 
process.  The fact that some of the study dogs had serum gastrin concentrations that were 
less than the detection limit of the assay at various time points during the 4 diet treatments 
is considered to reflect individual variation rather than inaccuracy of the test.   
Because of the short half-life of gastrin, serum concentrations were assessed at 5 to 
10  minutes  after  feeding  and  again  at  1  to  2  hours  after  feeding.    Mean  serum 
concentrations of gastrin at these 2 time points after feeding did not differ significantly, 
which likely represents ongoing secretion because of the persistence of food within the 
stomach 2 hours after feeding. There was no significant difference in the dogs’ serum 
gastrin concentration over time, among the 4 diets fed, or among dogs; thus, the preferred 
sample collection time point cannot be determined. 
The specificity of the gastrin assay used in the present study was assessed by the 
manufacturer.  The antibody in the assay reacts predominantly with G-17 and to lesser 
extents  with  G-34,  mini-gastrin,  and  cerulein  (DPC,  2005).  Cerulein  is  considered  an   195 
important pancreatic stimulant (DPC, 2005; Williams and Steiner, 2005). Haemolysis in 
serum samples does not interfere with the test (DPC, 2005).  The validation procedure 
performed  in  the  present  study  revealed  acceptable  intra-  and  inter-assay  CVs  for  an 
enzyme-based  assay;  therefore,  results  obtained  for  the  study  dogs  can  be  considered 
reliable.  Bilirubin concentrations > 85.5 µmol/L may interfere with the test and serum 
triglyceride concentrations > 11 mmol/L has been associated with degradation of values 
(DPC, 2005).  No samples in the present study were grossly lipaemic, haemolysed, or 
icteric.  
In  this  study,  indirect  indicators  of  pancreatic  adaptation  or  response  were 
measured in 10 healthy dogs that had no previous history of pancreatitis or any other 
intestinal illness.  It is unknown whether differences in diet composition, especially the 
percentage of crude fat, can markedly alter the degree of pancreatic stimulation or outcome 
in dogs with a history of naturally occurring pancreatitis.  Standard enteral diets contain 
long-chain triglycerides and consumption of such diets increases cholecystokinin (CCK) 
secretion and subsequently pancreatic stimulation in people (Shea et al., 2003). Enteral 
administration  of  medium-chain  triglycerides  is  thought  to  result  in  minimal  CCK 
secretion, thereby reducing pancreatic stimulation (Shea et al., 2003). Type of dietary fat 
may play a more important role than fat content per se, but whether this is of benefit in 
treatment of pancreatitis is not known. Although there is no evidence that restriction of 
dietary  fat  alters  pancreatic  stimulation,  restriction  of  dietary  fat  in  dogs  that  have  a 
confirmed history of pancreatitis is a current recommendation. Further studies would be 
required  to  adequately  challenge  the  dogma  of  feeding  low-fat  diets  to  all  dogs  with 
pancreatitis, rather than feeding such diets only to those with hyperlipidaemia after food 
has been withheld.     196 
Administration  of  supplemental  pancreatic  enzymes  has  been  applied  in  the 
management of people and dogs with exocrine pancreatic insufficiency that is secondary to 
chronic  pancreatitis  (Meier  and  Beglinger,  2006;  Watson,  2004).  The  provision  of 
pancreatic  enzymes  appears  to  decrease  postprandial  pain  in  humans  with  chronic 
pancreatitis  and  has  been  suggested  to  decrease  the  risk  of  reoccurrence  of  acute 
pancreatitis  via  a  negative  feedback  effect  on  pancreatic  enzyme  secretion  (Meier  and 
Beglinger, 2006).  The reduction in the signs of pain may also be due to other unknown 
mechanisms.  
6.5 Conclusion 
In the present study, diets C and D included supplemental pancreatic enzymes; the 
reduced  (albeit  not  significantly)  pancreatic  response  associated  with  diet  D  was  most 
likely attributable to the addition of MCTs.  The effects of dietary supplements containing 
pancreatic  enzymes  may  however  be  more  appreciable  in  dogs  with  acute  or  chronic 
pancreatitis rather than in normal dogs. Nevertheless, results of the present study indicated 
that the fat content of diets or the addition of MCT oil or pancreatic enzymes to diets fed to 
healthy dogs did not have any significant effect on serum concentrations of cTLI, cPLI, or 
gastrin. Although this may have implications for the treatment of pancreatitis (both acute 
and chronic) in dogs, it is uncertain how much of this conclusion can be extrapolated to 
dogs with acute pancreatitis. 
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Chapter 7: A pilot study to assess tolerability of early enteral nutrition 
via oesophagostomy tube feeding in dogs with severe acute pancreatitis  
The following is a modified version of the published paper: C.S. Mansfield, F. E. James, 
J.M. Steiner, J.S. Suchodolski, I.D. Robertson & G. Hosgood (2011) Journal of Veterinary 
Internal Medicine 25: 419-425.  
7.1 Introduction 
Acute pancreatitis has a high mortality rate in dogs, and surviving animals often 
require intensive treatment and hospitalisation (Simpson and Lamb, 1995; Watson, 2004; 
Williams and Steiner, 2005).  Apart from non-specific recommendations regarding 
correction of fluid, electrolyte and acid-base abnormalities there remains a paucity of 
information regarding specific management of acute pancreatitis in dogs. 
Nutritional management of acute pancreatitis in people is considered difficult due 
to the presence of substantial catabolism, pancreatic necrosis, increased metabolic demands 
and complications of ileus (Thomson, 2006).  Historically, the nutritional recommendation 
for management of acute pancreatitis in dogs has been ‘strict pancreatic rest’, in the belief 
that fasting results in no feedback that will further stimulate exocrine pancreatic secretion, 
thus protecting against auto-digestion to some extent (Simpson and Lamb, 1995).  
However, this theory has been questioned, because it has been extrapolated from studies of 
healthy people, and has not been proven in dogs.
  In fact, 3 experimental studies have 
suggested that there is minimal to no negative pancreatic feedback in dogs given nutrition 
in both the jejunum and duodenum (Imamura et al., 1993; Ragins et al., 1973; Sale et al., 
1977).  It also has been demonstrated in experimental models in rodents and in people with 
naturally-occurring disease that exocrine pancreatic secretion is in fact decreased during 
pancreatitis, and the decrease is most prominent in severe inflammation (Niederau et al., 
1990; O’Keefe et al., 2005).
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In people and in studies using animal (rodent and canine) experimental models, 
fasting leads to intestinal mucosal atrophy, increased rate of enterocyte apoptosis, 
decreased glutamine and arginine transport, changes in mucin composition of goblet and 
deep crypt cells and a breakdown in the intestinal barrier resulting in increased intestinal 
permeability (Deitch et al., 1987; Fukuyama et al., 2001; Hernandez et al., 1999; Sarac et 
al., 1994; Sharma and Schumacher, 1995).
  Additionally, the gut itself may either start or 
contribute to the systemic inflammatory response in acute pancreatitis (Flint and Windsor, 
2003).
  Intra-luminal nutrition is the most potent stimulator of intestinal mucosal 
regeneration due to stimulation of growth factors and mucosal blood flow (Flint and 
Windsor, 2003).  In addition, enteral nutrition may decrease splanchnic cytokine 
production, modulate the acute phase response, decrease catabolism and preserve protein 
(Ioannidis et al., 2008). 
Experimental models of pancreatitis in dogs have shown a benefit of early intra-
luminal nutrition compared to parenteral nutrition in decreasing bacterial translocation and 
down-regulating the severity of inflammation (Qin et al., 2002a; Qin et al., 2002b, 2003).
   
There also have been several clinical trials in people demonstrating benefit in early enteral 
nutrition compared to parenteral nutrition for treatment of acute pancreatitis, with fewer 
infectious complications, and in severe cases improved outcome and decreased length of 
hospitalisation (Eatock et al., 2005; Eckerwell et al., 2006; Koretz, 2009; Kumar et al., 
2006; Marik and Zaloga, 2004; McClave et al., 2006; Petrov et al., 2006; Petrov et al., 
2009; Powell et al., 2000). However, meta-analysis of these studies does not show a clear 
benefit of early enteral nutrition compared to parenteral nutrition, and there are no well-
constructed randomised controlled trials comparing enteral nutrition to nothing by mouth 
(Koretz, 2009; McClave et al., 2006).  More recent studies in people also suggest that   199 
gastric feeding (rather than jejunal) is well tolerated and safe, with no exacerbation of pain 
(Eatock et al., 2005; Eckerwell et al., 2006; Kumar et al., 2006).  
A previous study (as detailed in chapter 6) determined that there was no statistical 
difference in the indirectly measurable pancreatic response to diets of variable fat content 
in healthy dogs (James et al., 2009).
  This, along with the changing paradigm of feeding in 
people with severe acute pancreatitis, formed the background to this pilot study evaluating 
the tolerability of giving enteral nutrition proximal to the pylorus in dogs with severe 
pancreatitis.  
7.2 Materials & Methods 
7.2.1 Animal selection 
Ten dogs with a diagnosis of acute pancreatitis were recruited into the study within 
12-24 hours of admission to Murdoch University Veterinary Hospital.  The study was 
approved by the Murdoch University Animal Ethics Committee. Informed, signed owner 
consent was obtained.  
The diagnosis of acute pancreatitis was based on a combination of clinical signs 
(abdominal pain, vomiting), serum canine pancreatic lipase > 200 µg/L and, in all dogs, the 
presence of appropriate pancreatic changes on abdominal ultrasonography performed by a 
board-certified radiologist using a curvilinear 8 MHz or linear 15 MHz probe (Sequioa 
512, Acuson, Munich, Germany). These ultrasonographical changes included diffuse 
enlargement of the pancreas, hyperechoic mesentery surrounding the pancreas and variable 
pancreatic hypoechogenicity as previously published (Lamb and Simpson, 1995; Steiner, 
2003; Williams and Steiner, 2005).
  Dogs were excluded if other disease that could cause 
secondary pancreatic inflammation, such as septic peritonitis or pancreatic neoplasia, were 
evident during or after completion of the study, with a follow-up period of 2-4 years. Dogs   200 
had to weigh > 10 kg to comply with the volume of blood sampling required, and not have 
concurrent diabetic ketoacidosis.  Only dogs that showed substantial consequences of their 
disease (e.g. dehydration, pain, hypovolaemia, persistent vomiting. other systemic effects) 
necessitating hospitalisation and intravenous fluid therapy were recruited.
  
7.2.2 Initial patient assessment and treatment 
Historical and clinical information including signalment, potential inciting factors, 
previous medical history, physical examination findings, days of clinical illness preceding 
admission, days fasting and the clinical severity score as previously published were 
recorded for each dog on admission (Day 0) (Mansfield et al., 2008). After recruitment into 
the study, all dogs had baseline haematology, biochemistry (including glucose, cholesterol, 
lipase and amylase), electrolytes and urinalysis performed.  
All dogs received intravenous fluid therapy (using crystalloids with appropriate 
electrolyte supplementation) calculated to correct dehydration and ongoing losses on an 
individual basis.  Anti-emetic medication (metoclopramide; Metomide, Delvet Pty Ltd, 
Seven Hills, NSW at 1-2 mg/kg/day constant rate infusion) and analgesia (including 
fentanyl continuous rate infusion and patches, methadone, tramadol, lignocaine continuous 
rate infusion and morphine via epidural) also could be administered based on individual 
requirements.  These treatments were initiated before inclusion into the study for all dogs.  
Within the first 12 hours of admission to the study, a naso-oesophageal feeding tube was 
inserted and a low-rate (0.5 mL/kg/hour) infusion of a balanced electrolyte solution 
(Lectade, Jurox Pharmaceuticals, Rutherford NSW, Australia) was started in all dogs.  
Fresh frozen plasma (10 mL/kg/day) was administered to each dog for the first 2 days of 
the study.  Antibiotics (ampicillin; Ampicillin, Aspen Pharmcare Pty Ltd, St Leonard’s 
NSW at 25 mg/kg IV every 8 hours and metronidazole; Metronidazole, Baxter Healthcare,   201 
Toongabbie, NSW at 10 mg/kg IV every 12 hours) were to be given if dogs had a 
neutrophil count < 2.0 x 10
9/L or a left shift in combination with pyrexia (rectal 
temperature > 39° C), unless another specific indication was present.  Additional anti-
emetic (prochlorperazine; Stemetil, Aventis Pharma, Lane Cove, NSW) therapy could be 
administered if clinically indicated.  
7.2.3 Treatment groups 
Dogs were consecutively alternatively assigned to 1 of 2 treatment groups, 
parenteral nutrition (PN) or enteral nutrition via oesophageal tube feeding (EN) within the 
first 12-24 hours of admission, as described below.  The first 24 hours of the study protocol 
was designated Day 1, with continuation in the study until the end of Day 3.  After that 
time, treatment decisions including altering nutritional intervention were based entirely on 
individual dog requirements and not on the basis of the treatment assignment during the 
study.  
All dogs were anaesthetised using intravenous alfaxan (Alfaxan, Jurox 
Pharmaceuticals, Rutherford, NSW at 1-2 mg/kg) and inhalational isoflurane (Isoflurane, 
Veterinary Companies of Australia Pty Ltd, King’s Park, NSW) with full anaesthetic 
monitoring.  A brief endoscopic examination of the oesophagus was performed to 
subjectively assess the presence of moderate to severe oesophagitis, to account for 
oesophagitis as a confounding factor for causing regurgitation or lack of tolerability for EN 
in individual dogs.  This was done both at the time of the endoscopy and retrospectively 
with blinded review of the recordings.   
The dogs receiving PN had double-lumen jugular 16G catheters inserted under 
sterile conditions and the dogs then were recovered from anaesthesia.  Parenteral nutrition 
administration was started within 2 hours of anaesthetic recovery, at a rate of 50% resting   202 
energy requirements (RER) on Day 1 and 100% on Day 2.  For every 100 kcal of 
calculated RER, an additional 4 gms of protein (14 kcal) was added. This meant that 17.5% 
of the calories were supplied as lipid and 70.2% as 50% dextrose, along with 12.3% amino 
acid solution. Full asepsis was used when checking the jugular catheter site daily.  
The dogs receiving EN had large gauge (14-16F) single lumen feeding tubes 
inserted in the oesophagus and secured externally before recovery from anaesthesia.  Dogs 
were fed within 2 hours of recovery.  A total of 1/3 of their daily calculated calories (RER 
x 1.25) was fed, divided every 6 hours on day 1, 2/3 on day 2 and 100% on Day 3.  They 
were fed a low-fat commercial dog food (Digestive Low-Fat tinned diet, Royal Canin, 
Bristol, UK) with a fat content of 1.7% (1.9 g) per 100 kcal.  This diet was supplemented 
with commercial enteric-coated pancreatic enzymes (Creon, Solvay Pharmaceuticals, 
Pymble, NSW) at 5000 units/feed if body weight < 15 kg, 10,000 units/feed body weight 
15-30 kg or 25,000 units/feed if body weight > 30 kg.  Medium chain triglyceride (MCT) 
oil (MCT oil, SHS International Ltd, Liverpool, UK; with C8 and C10 fatty acids 
composition > 95%) also was supplemented at 1.0 mL/kg/day in divided doses, as 
established in a previous study that showed this combination trended towards a minimal 
pancreatic response (James et al., 2009). 
7.2.4 Monitoring 
Full daily clinical records were kept for each dog, including results of physical 
examination, clinical severity score as previously published, presence of any 
complications, vomiting or regurgitation events (these were not differentiated as they were 
not always observed), baseline laboratory data and body weight (Mansfield et al., 2008). 
Daily pain score was recorded from admission until Day 3, and used to modulate analgesic 
therapy. The pain score ranged from 0-10, adapted from previously published criteria, with   203 
a score of 2 indicating mild discomfort, 7 moderate to severe pain and 10 severe pain 
causing substantial alterations in mentation (Mathews, 2000).  
Blood was collected into plain and EDTA containers daily via cephalic or jugular 
venipuncture before the start of nutritional support at admission into the study (Day 1) until 
completion of study (Day 3) in all dogs and on Day 1 at 5 to 10 minutes after the first feed 
in the enteral nutrition dogs.  Blood was collected into chilled tubes, stored on ice to allow 
clotting and then centrifuged at 10°C at 5000 rpm for 5 minutes before harvesting sera or 
plasma and storing at -18°C.  
Serum samples were shipped on dry ice for measurement of canine trypsin-like 
immunoreactivity (cTLI), canine pancreatic-specific lipase (s-CPL) and C-reactive protein 
(CRP), which all were measured at the Gastrointestinal Laboratory, Texas A&M 
University using enzyme-based assays that previously have been validated in dogs 
(Kjelgaard-Hansen et al., 2003; Steiner et al., 2006). Reference intervals for these markers 
in dogs are 5.7-45.2 µg/L, 0-200 µg/L and 0-7.6 mg/L, respectively.  Frozen plasma and 
serum samples were transported for measurement of gastrin (Immunolite assay, DCP, Los 
Angeles)
 at a local laboratory.  A previous study had established a reference interval for 
gastrin in healthy dogs of < 5 to 16 pg/mL, and results < 4.77 pg/mL were recorded as 4.77 
(James et al., 2009).
    Additional aliquots of serum were shipped on dry ice for 
measurement of serum pancreatic elastase-1 (PE-1) at Schebo Biotech, Geissen, Germany.  
Gastrin, cTLI, and s-CPL, were measured at all time points in all dogs. CRP and elastase 
were measured at all time points, except the post-feed sample in dogs from the EN group. 
7.2.5 Statistical analyses 
Differences in clinical severity scores, oesophagitis, duration of clinical signs 
preceding hospitalisation, and blood marker concentrations (cTLI, s-CPL, gastrin, CRP,   204 
and PE-1) between the 2 treatment groups at admission were assessed by one-way 
ANOVA analysis.   
One-way ANOVA analysis was also used to compare the relative change in all 
marker concentrations from Day 1 to Day 3 between groups, and the duration of 
hospitalization between groups.  Change in clinical severity score from Day 0 to Day 3 was 
compared between the treatment groups by non-parametric Mann Whitney test, as the data 
was not homogenous.  The difference in marker concentrations at baseline (Day 1) and 5-
10 minutes post the first feeding for Group O was assessed using Fisher’s T-test.  
Differences were considered statistically significant if P was < 0.05. 
The number of vomiting or regurgitation episodes and the number of days each 
animal was hospitalised both were analysed by a Poisson model for an effect of treatment. 
Significance of the estimated beta coefficient was determined at P < 0.05. The beta 
estimate was exponentiated to determine the ratio of the incidence of events. The 
proportion of dogs surviving after each treatment was compared using Fisher’s exact test 
with significance determined at p<0.05 using a t2-sided probability. In the face of a non-
significant result, the sample size required to prove this difference with 95% confidence at 
a statistical power of 80% was determined.  PROC GENMOD and PROC FREQ were used 
for all analysis (SASv9.1, SAS Institute, Cary, North Carolina). 
7.3 Results 
There were 4 neutered females and 6 neutered males in the study.  The median age 
was 7 years, with a range of 2 to 11.  The median body weight was 26.1 kg, with a range of 
14.8-48.6 kg.  There were 3 cross breeds and 1 each of Siberian husky, Beagle, Bull terrier, 
Weimaraner, Golden retriever, Border collie and Rhodesian ridgeback (Table 7.1). All   205 
dogs that survived this episode (n=9) were still alive at 2-year follow-up, some up to 4 
years. No dog received PN after the initial 3-day period.  
 
Table 7.1 
Animal Data of study dogs. M = Male, F= Female, N= neutered.  
One dog had hyperlipidaemia on admission that persisted after recovery, and 
required ongoing management, and may have contributed to the development of acute 
pancreatitis.  This dog received EN.  No underlying cause was definitively identified in the 
other 9 dogs, but dietary indiscretion was suspected in 2.  No abnormalities in serum 
glucose concentration were present in any dog at any time point.  All dogs had serum 
canine pancreatic lipase > 300 µg/L, with 8 having concentration > 800 µg/L.  The median, 
mean and range for clinical severity score, duration of signs before admission into the 
study, serum CRP concentrations and concentrations for gastrin, cTLI, PE-1 and specCPL 
are presented in Table 7.2. There was no significant difference between treatment groups 
for any of these variables.   
All dogs in the EN group survived, whereas 1 dog in the PN group died. The 
proportion surviving was not different between treatments (P = 1.0).  Using this result of a 
binomial proportion of survival of 5/5 versus 4/5, the calculated sample size to conclude a 
difference with 95% confidence (at 80% power) would be 43 in each group. If the number 
  Dog #  Breed  Sex  Age (years)  Body weight (kg) 
O tube feeding  1  Siberian Husky  F (N)  7   25 
2  Beagle  F (N)  6  14.8 
3  Bull Terrier  F (N)  9  26.9 
4  Staffordhsire Bull Terrier X  M (N)  5  34.9 
5  Weimeraner  M (N)  10  34.8 
TPN  6  Standard Poodle  M (N)  4  20 
7  Golden Retriever  M(N)  7  48.6 
8  Border Collie  M (N)  8  24 
9  Rhodesian Ridgeback  M (N)  11  42.5 
10  Border Collie X  F (N)  2  25.4   206 
of controls (PN) versus treated (EN) was 2:1, the sample size required decreases to 35, 
with 70 controls.   
Adverse reactions or complications occurred in 3 dogs in the EN group, but were 
considered mild or short-term.  These included abdominal pain refractory to increasing 
analgesic modalities for the first 36 hours of the study (1 dog), urinary tract infection (1 
dog), pyoderma (1 dog) and oesophagostomy tube site infection (the same 3 dogs).  The 
tube site infections were considered mild except in the 1 dog that had pre-existing severe 
pyoderma. Discontinuation of tube feeding was not required in any dog.  The 3 dogs in this 
group with documented infection all received cephalexin.  The dog with refractory pain 
(pain scores were Day 0: 8, Day 1: 4, Day 2: 1) did not demonstrate any exacerbation of 
the pain after tube feeding, and the pain decreased substantially by Day 2. Analgesics used 
in this dog initially were buprenorphine, then methadone along with fentanyl continuous 
rate infusion, and then combined fentanyl and lignocaine continuous rate infusion. 
Analgesia was not necessary after Day 3.   In the PN group, jugular phlebitis occurred in 4 
dogs, with 1 severe enough to cause caval syndrome and require removal of the catheter on 
Day 3.  One dog had refractory abdominal pain and a pancreatic pseudocyst that developed 
after the treatment trial had been completed (Day 4) and required percutaneous ultrasound-
guided drainage.  The dog in this group that died developed extra-hepatic bile duct 
obstruction and pleural effusion.  One dog had no complications. The individual dog 
complications are detailed in Table 7.3.  
In the EN group, only one dog had three episodes of vomiting or regurgitation over 
7 days of hospitalisation, whereas in the PN group 3 dogs had 33 episodes (1 had 22 in 6 
days of hospitalisation, 1 had 9 in 10 days and 1 had 2 in 5 days).  There was a significant 
effect of treatment on the number of vomiting or regurgitation episodes (P < 0.001), with   207 
the ratio of the incidence of episodes for parenteral versus enteral nutrition estimated at 
11.0 (95% CI 3.4-35.8).  
The median duration of hospitalisation for the EN group was 5 days (range 4-7) and 
for the TPN group 6 days (range 5-10) (Table 7.3).  This was not statistically significant 
(P= 0.237).    208 
 
Table 7.2 
 
 
Statistical summaries for blood markers and clinical severity on admission to the study. EN= enteral nutrition as supplied by 
oesophagostomy feeding tube; PN= parenteral nutrition; Spec-CPL = canine pancreatic specific lipase; cTLI= canine tryspin-
like immunoreactivity; PE-1 = serum canine pancreatic elastase-1.
  Days of clinical 
signs 
before admission 
Clinical 
severity 
index 
Pain 
score 
C-reactive 
protein  
(mg/L) 
Spec-CPL
® 
(µg/L) 
cTLI 
(µg/L) 
Gastrin 
(pg/mL) 
PE-1 
(ng/mL) 
Treatment 
group 
EN  PN  EN  PN  EN  PN  EN  PN  EN  PN  EN  PN  EN  PN  EN  PN 
Minimum  1  1  1  1  5  3  45.3  35.3  316.0  960.0  9.9  12.8  4.77  4.77  0.9  2.7 
Maximum  4  5  6  4  8  6  173.8  330.4  1001.0  1001.0  27.8  33.0  14.1  7.53  21.8  31.7 
Mean  1.9  3  3.2  1.8  6.2  4.2  79.3  158.2  708.8  990.4  18.7  23.9  4.77  5.83  7.7  10.3 
Median  1.5  4  3  1  6  4  52.6  109.1  851.0  1001.0  16.2  24.0  4.77  4.77  3.5  4.8   209 
There were no differences in the change of any of the markers measured 
between the two treatment groups (Figure 7.1), although the change in CRP bordered 
on significant (P = 0.057).  The change in clinical severity score between admission 
(Day 0) and the end of the study (Day 3) was significantly different between the two 
treatment groups (an increase of 1.2 for the TPN group compared to a decrease of 3.2 
in the EN group) (Figure 7.2). Full laboratory results for all dogs are detailed in Table 
7.4.  
There was no difference in the measurement of any of the markers of pancreatic 
adaptation (cTLI, s-CPL, gastrin or haptoglobin) in the EN group at baseline (Day 1, 
Time 0) and 5-10 minutes after feeding, although s-CPL was almost significant (P = 
0.055), Figure 7.3.  
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Table 7.3  
 
Group  Dog 
# 
Outcome  Length of 
Hospital 
(days) 
Days clinical 
signs prior to 
admission 
CSS (Day 
O) 
CSS 
(Day 1) 
CSS 
(Day 2) 
CSS 
(Day 3) 
Complications  Vomiting
/reg 
episodes 
O score 
EN  1  Survived  4  1  3  3  0  0  Refractory 
pain/O site 
infection 
0  2 
2  Survived  4  1  1  1  0  0  UTI (pre-
existing)/O site 
infection 
0  0 
3  Survived  5  1.5  6  6  4  1  Pyoderma/ O 
site infection 
0  2 
4  Survived  7  4  4  4  0  0    3  0 
5  Survived  6  2  2  2  2  0    0  0 
TPN  6  Survived  6  1  2  2  1  0  Severe pain, 
pancreatic 
pseudocyst, 
jugular phlebitis 
22  1.5 
7  Survived  5  5  4  4  4  3  Jugular phlebitis  0  1 
8  Died  10  4  1  1  4  7  EHBDO, jugular 
phlebitis, pleural 
effusion 
9  1 
9  Survived  7  4  1  1  2  5  Caval syndrome 
due to jugular 
phlebitis 
0  0 
10  Survived  5  1  1  1  0  0  Nil  2  2 
Results of clinical severity scores (CSS), outcome, duration of hospitalisation and complications for each prospective study group (EN= 
enteral nutrition and TPN= total parenteral nutrition), with all dogs also receiving standard care, plasma and micro-enteral nutrition. 
O= oesophagus, EHBDO = extra-hepatic bile duct obstruction, UTI = urinary tract infection, O score = oesophagitis score.  
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Table 7.4        Table continued over page 
 
 
   
Treatment 
Group 
Dog #  Time sampling  cTLI  SpecCPL  CRP  Gastrin  Haptoglobin  Elastase 
EN                 
1 
 
 
Day 1, T=0  27.8  851  45.31   <4.77  2.42  0.86 
Day 1, T= 1-2 hr  10.7  450  NM  <4.77  2.17  NM 
Day 2, T=0  7.2  361  30.21  <4.77  2.23  0.48 
Day 3, T=0  5.7  251  24.79  9.2  2.22  1.34 
               
2  Day 1, T=0  23.5  1001  51.77  5.67  1.62  21.81 
Day 1, T= 1-2 hr  23.3  1001  NM  <4.77  1.67  NM 
Day 2, T=0  17.1  1001  49.68  5.1  1.95  20.18 
Day 3, T=0  13.1  1001  38.96  17.2  2.04  19.97 
               
3 
 
Day 1, T=0  9.9  316  73.1  14.1  2.10  2.94 
Day 1, T= 2 hr  6.6  302  NM  17.6  3.28  NM 
Day 2, T=0  6.6  167  149.04  13.3  2.71  12.56 
Day 3, T=0  6.9  95  95.93  12.4  1.74  27.75 
               
4 
 
Day 1, T=0  16.6  1001  173.82  <4.77  2.22  9.43 
Day 1, T= 1-2 hr  16.4  843   NM  <4.77  2.56  NM 
Day 2, T=0  8.7  414  72.62  <4.77  2.79  3.78 
Day 3, T=0  6.4  129  52.36  <4.77  2.06  1.96 
               
5  Day 1, T=0  16.2  375  52.61  <4.77  2.09  3.46 
Day 1, T= 1-2 hr  17.1  334  NM   <4.77  2.09  NM 
Day 2, T=0  10.7  181  195.74  <4.77  2.19  2.75 
Day 3, T=0  8.5  56  59.98  9.34  2.27  3.35   212 
 
 
Enzyme Concentrations for each dog in the prospective pilot study. EN = enteral nutrition as supplied by oesophasgostomy tube 
feeding; TPN = total parenteral nutrition; cTLI = canine trypsin-like immunoreactivity, SpecCPL = canine pancreatic specific 
lipase; CRP = C-reactive protein, NM = not measured.  
 
 
 
 
Treatment 
Group 
Dog #  Time sampling  cTLI  SpecCPL  CRP  Gastrin  Haptoglobin  Elastase 
TPN group                 
6  Day 1, T= 0  12.8  960  330.35  7.29  1.92  2.65 
Day 2, T=0  7.7  660  54.34  27.5  2.00  1.39 
Day 3, T=0  6.4  618  54.63  12.4  1.97  0.22 
 
7  Day 1, T= 0  33.8  989  46.4  7.53  2.36  4.83 
  Day 2, T=0  22.4  849  47.66  11.5  2.17  3.28 
  Day 3, T=0  10.3  474  49.35  5.62  2.11  5.09 
 
8  Day 1, T= 0  24  1001  109.05  <4.77  2.29  9.47 
  Day 2, T=0  14.3  1001  36.48  <4.77  1.58  10.19 
  Day 3, T=0  6.7  859  34.63  <4.77  1.24  6.8 
 
9  Day 1, T= 0  19.6  1001  35.29  <4.77  2.40  31.65 
  Day 2, T=0  14.9  1001  31.96  <4.77  2.29  49.44 
  Day 3, T=0  11.7  1001  27.48  <4.77  2.83  42.73 
 
10  Day 1, T= 0  30.4  1001  270.14  <4.77  1.44  2.89 
  Day 2, T=0  82.7  1001  302.55  10.2  2.68  3.05 
  Day 3, T=0  34.7  1001  283.17  14.3  2.81  2.84 
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Figure 7.1  
 
 
Median values of concentrations of specific canine pancreatic lipase (1a); C-reactive protein (1b), 
serum trypsin-like immunoreactivity (1c); Serum pancreatic elastase (1d); gastrin (1e) and 
haptoglobin (1f) on Days 1-3 of the study for the enteral nutrition (EN) group compared to the total 
parenteral nutrition group (TPN). There is no significant difference in changes in any of the 
measurements, although the change in specific canine pancreatic lipase approaches significance. 
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Figure 7.2  
 
 
Change in Clinical Severity score as represented by change in median between admission (Day 0) 
and completion of study (Day 3) between total parenteral nutrition (TPN) and enteral nutrition 
(EN). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3    215 
 
 
Change in serum markers canine pancreatic lipase (Spec cPL), trypsin like 
immunoreactivity (cTLI) and gastrin in dogs one hour after first feeding through an 
oesophagostomy tube. There is no statistical difference between the two readings for any 
markers, although Spec cPL approaches significance.    216 
7.4 Discussion 
This pilot study primarily aimed to demonstrate that early interventional nutrition 
was ethical, safe and well tolerated in dogs with severe pancreatitis. Additional aims were 
to refine the study design and calculate the numbers required to run a larger, prospective 
study. The number of dogs included in this pilot study is too small for meaningful analysis 
on the survival or rate of reduction in serum markers of general or pancreatic 
inflammation. Additionally, the development of inflammatory conditions as a result of the 
intervention (severe phlebitis in the PN group) may confound analysis of inflammatory 
markers. However, it is planned that in future larger studies analysis of these serum 
markers may help in determining the benefit of early enteral nutrition.  
This pilot study supports the notion that early enteral nutrition delivered proximal 
to the jejunum is well tolerated in dogs with severe pancreatitis. It may also be considered 
that PN could be detrimental in dogs with acute pancreatitis due to the high number of 
complications, but this may be an institutional bias as there were fewer complications in 
the EN group than the PN group.  The complications and adverse effects seen with PN 
were all related to catheter sepsis, and none with the composition of the infusion.  None of 
the PN group had hyperglycemia, hyperlipidaemia, re-feeding syndrome or hypervolaemia 
at any point, all of which have been associated with a poor outcome in critical care settings 
in both people and animals (Chan et al., 2002; Freeman et al., 1995; Thomson, 2006). 
 The 
1 dog that had pre-existing hyperlipidaemia was in the EN group. Because of this, it would 
seem logical to assume that any benefits seen with EN are due to direct nutritional delivery 
to the intestinal lumen rather than total caloric input alone. The additional resting energy 
requirement administered to the PN group (14%) and the EN group (25% by Day 3) is 
unlikely to have had detrimental effects, because RER is only an estimate of daily calorie   217 
requirements that may vary from measured direct calorimetric energy requirements as 
much as 25% in individual patients (Kleiber, 1961). 
One major argument against pre-pyloric (or gastric) feeding in pancreatitis is that it 
will be poorly tolerated due to decreased intestinal motility.  Certainly in our population of 
dogs this was not the case.  There were significantly more vomiting or regurgitation 
episodes in the PN group than in the EN group. This could be attributable to differences in 
patient selection, however case allocation was consecutive, there was no difference 
identified between groups at onset of the study and no animal was selected for the study on 
the basis of the prospective treatment group.  Additionally, all animals had decreased gut 
sounds on admission.  EN may improve gut health to a point that minimizes ileus and 
vomiting, although this could not be conclusively determined from this study.  Although 
pro-kinetic agents such as cisapride were allowed by the study protocol they were not 
needed in any animal.  Initially, all animals had metoclopramide constant rate infusion as 
part of their treatment, and there may have been a pro-kinetic benefit conferred from this 
treatment.  This pro-kinetic treatment was given to all dogs, and consequently is unlikely 
to have influenced the frequency of vomiting or regurgitation between groups.  There were 
similar degrees of oesophagitis visible grossly in both groups, but no statistical comparison 
was made due to the poor sensitivity of detecting oesophageal inflammation on visual 
assessment.   
Another argument against feeding proximal to the jejunum is the possible 
development of pancreatic pain.  There was no temporally associated abdominal pain 
observed when feeding was commenced in any of the EN dogs.  One dog in the EN group 
had substantial pain on admission that was initially refractory to increasing analgesia, but 
this declined rapidly after Day 2 while still receiving EN, and did not appear directly 
associated with feeding.  All analgesia could be discontinued in this dog by Day 4. Also,   218 
the dog that developed a pancreatic acute fluid collection (previously called a pseudocyst) 
was in the PN group. One possible hypothesis for acute fluid collection is increased and 
persistent pancreatic enzyme leakage, and so if stimulation of the pancreas in acute 
pancreatitis is increased with intra-luminal nutrition, development of acute fluid collections 
could be expected to be more likely in a dog given enteral nutrition.  
Another argument against pre-pyloric feeding is that it will increase pancreatic 
secretion by food stimulus within the duodenum.  None of the dogs in the EN group 
showed any adverse effects from feeding.  The need to avoid stimulus of the duodenum in 
acute pancreatitis does not appear to be upheld by this study.  
Currently, the recommendations of  many gastroenterology societies in human 
medicine is to supply enteral nutrition early in severe (but not mild) pancreatitis as there is 
a reduction in mortality and infectious complications (Heinrich et al., 2006; Johnson, 2005; 
Meier et al., 2006; Muddana et al., 2009; Petrov et al., 2008b) . There is still extensive 
debate about the advisability of these recommendations. 
It has been demonstrated in people and animal experimental models that there is 
significant third space loss with acute pancreatitis, and consequently splanchnic circulation 
decreases as part of circulatory shock (Flint and Windsor, 2003).
   The body adjusts for this 
loss by increasing the oxygen extraction from the systemic circulation, leading to regional 
ischaemia.  Intestinal ischaemia causes increased intestinal permeability and mucosal 
acidosis, which further increases the rate of apoptosis and decreases nutrient transport of 
epithelial cells, resulting in disruption of the lamina propria. Ischaemia also causes 
accumulation of hypoxanthine and depletion of ATP (Flint and Windsor, 2003).
   After 
fluid resuscitation (reperfusion is performed), xanthine oxidase is produced, which 
converts hypoxanthine to xanthine, with production of O2
-.  Free radicals are 
chemoattractants for neutrophils and other cytokines, which in turn amplify the   219 
inflammatory response.  Endothelial cells become stimulated by this, and express adhesion 
molecules that bind activated neutrophils, and thus further perpetuate the inflammatory 
process within the gut (Flint and Windsor, 2003).
  
In this study, we primarily wanted to evaluate 2 methods of interventional nutrition, 
and all dogs received a high level of baseline care.  This care included plasma transfusion 
and trickle esophageal electrolyte administration, so that any difference between the 2 
groups could be attributed to the interventional nutrition alone.  It is questionable whether 
plasma transfusion actually confers a positive benefit, as was recently proposed in 1 
retrospective study of dogs with pancreatitis (Weatherton and Streeter, 2009). However, a 
prospective comparison between animals with similar degrees of disease severity is needed 
before a definitive determination can be made about whether or not plasma administration 
provides any benefit in dogs with pancreatitis.   
A limitation of the current study was the fact that study observers were not blinded 
to the treatment groups, leading to the possibility that bias may have influenced results.  
Given that the 2 treatment modalities were so different, it was impossible to adequately 
blind the clinicians involved.  To overcome this in the future, it is suggested that treatment 
groups be randomly assigned and not known to the observer until the patient has been 
recruited into the study. This will remove the bias of sequential treatment group 
assignment, as a clinician may not actively recruit a dog into the study if he or she feels the 
treatment is not suitable for that animal.  
Relying on ultrasound examination for diagnosis may have meant that some dogs 
with pancreatitis that were presented to the center were not recruited for this study.  
However, this study was aimed at assessing efficacy of treatment in severely affected dogs, 
and false positive diagnoses were unlikely in this group.  All of the surviving 9 dogs were 
still alive 2- 4 years later, and the non-surviving dog had a full post-mortem examination   220 
that did not identify any changes unrelated to severe pancreatitis, and diseases such as 
pancreatic neoplasia or septic peritonitis seemed extremely unlikely.  
The diet chosen in this study was based on a previous study that assessed which 
dietary combination led to minimal pancreatic stimulation in healthy dogs (James et al., 
2009). 
 Extrapolation of this diet to dogs with pancreatic disease is not supported, nor 
indeed is it known if dietary modification is even necessary if there is minimal pancreatic 
stimulation during acute pancreatitis.  As there were no adverse effects associated with 
feeding, it can only be concluded that the diet used was not detrimental.  There may be 
additional or unknown benefits from adding supplements such as fiber, pro-biotics, omega-
3 fatty acids, or glutamine, as has been suggested in some studies in people (De Beaux et 
al., 1998; Karakan et al., 2007; Olah et al., 2002; Xu et al., 2006).  
Certainly, the optimal treatment of pancreatitis cannot rely on a single modality, 
nor does this pilot study suggest that early enteral nutrition necessarily is beneficial in 
severe pancreatitis.  Rather, this study is an initial step in trying to establish the best 
nutritional options for dogs with pancreatitis. It would seem logical from the data from 
humans and dogs to restrict the use of interventional enteral nutrition to dogs with severe 
disease, but the optimal timing and type of nutrition is yet to be established.  It was 
calculated that 35 to 43 dogs would need to be treated with EN in a prospective study to 
determine if there is a statistical difference in survival or days between PN and early EN.  
Future studies also should assess the number of days intensive management is required or 
the number of days until voluntary food intake occurs between the 2 groups.  
7.4 Conclusion 
The authors feel that due to the high number of technical complications and adverse 
catheter effects that parenteral nutrition should be reserved for those dogs that cannot   221 
support any form of enteral nutrition after a period of 4-5 days of anorexia.  Because 
oesophagostomy tube feeding is well tolerated, a study comparing this method to minimal 
enteral nutrition in severely affected animals should be undertaken, with similar numbers 
of dogs to be recruited as calculated for this study.  
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Chapter 8: Conclusion 
  Acute pancreatitis in dogs remains a challenging disease, with many still as yet 
answered questions regarding optimal diagnostic criteria and treatment options. A major 
part of this difficulty lies in the fact that pancreatitis has a spectrum of clinical 
presentations, various aetiologies and differing degrees of severity. The pathophysiology 
and current state of knowledge regarding this disease was explored in the first chapter of 
the thesis. In particular, the role of intra-acinar pH, inflammatory cascades and 
perpetuation of disease by the intestine were discussed. Each area of expanding knowledge 
regarding pathophysiology creates the potential for a new treatment strategy to be 
developed.  
Human medicine faces similar problems to canine medicine in regards to 
determination of optimal treatment. Although there has been a large increase in the amount 
of work published in the medical literature exploring the pathophysiology of pancreatitis in 
relation to potential treatments, these experiments are predominantly performed on rodent 
models. This in itself may be problematic, as the type of naturally occurring disease in 
dogs and people may differ substantially from the experimental models. Even 
extrapolating from people to dogs is flawed, as the pancreatic anatomy is slightly different, 
the physiological control of pancreatic secretion is different, the aetiology of the disease is 
different, and the complications that develop are different. Apart from surgical intervention 
for infected disease however, standard treatment of the severe acute form of the disease is 
very similar between people and dogs.  
Despite a plethora of new diagnostic tests and published studies, there remains a 
gap in the knowledge regarding the best way to diagnose acute pancreatitis in dogs. 
Currently, the gold standard is considered histological diagnosis. As this is seldom done in   223 
clinical practice, it means that establishment of true clinical utility of testing is 
problematic. Additionally, histological evidence of pancreatic inflammation may not 
always reflect clinically relevant pancreatitis. This in and of itself creates many difficulties 
in evaluating modalities such as ultrasound as commonly used in veterinary practice, and 
histology only obtained in very severely affected animals that have necropsy performed. In 
Chapter 2, the sensitivity and specificity of pancreatic-elastase-1 was determined in dogs 
with clinical presentations consistent with acute pancreatitis. Histopathology was not 
obtained in all dogs that had a diagnosis made by ultrasound, but was obtained in all dogs 
that were classified as not having pancreatitis. This study determined that pancreatic 
elastase-1 had an overall sensitivity of 61%, comparable to published sensitivities for other 
pancreatic markers such as lipase and pancreatic lipase. If only dogs with severe acute 
pancreatitis were evaluated, this sensitivity increased. Specificity was high at 92%. This 
study deliberately tried to replicate the clinical situation, where histology is not routinely 
performed in dogs with suspected acute pancreatitis. As such, this method of assessment is 
more clinically relevant than one based entirely on absence or presence of pancreatic 
inflammation.  
Along similar lines to other studies, in Chapter 3 we evaluated the specificity of 
canine pancreatic lipase in dogs that died or were euthanized for a variety of reasons. This 
study determined a specificity of 80% using the calculated diagnostic cut-off value, lower 
than other published reports for this test. This likely reflects the sick population of dogs 
assessed. It also likely results from an attempt to stratify the amount of pancreatic 
inflammation present in order to only assign a diagnosis of positive pancreatitis to dogs 
that had a minimum amount of histological pancreatitis present. Again, however this 
represented a sub-section of dogs that had severe disease, as evidenced by death or 
euthanasia. It also didn’t properly address the clinical utility of this assay, as there was no   224 
way to correlate to primary cause of death. Although not included in the body of this 
thesis, a study was performed that tried to address the clinical utility of a cage-side version 
of this test (appendix) in dogs presenting with clinical signs consistent with acute 
pancreatitis. This showed there was very poor correlation between the primary diagnosis 
and the pancreatic lipase result (either the quantified ELISA or semi-quantified SNAP 
test). This, along with the literature reviews highlights the difficulties in using histology to 
assign a primary diagnosis of acute pancreatitis, as the dog may present with another 
disease such as intestinal obstruction but have bystander pancreatic inflammation.   
The recent work aimed at understanding the pathophysiology of the disease in 
experimental models has been mirrored by an improved understanding of the systemic 
inflammatory response in naturally occurring critical illness. It is fairly well accepted that 
acute pancreatitis exerts its systemic effects by a complex and profound interaction of a 
variety of inflammatory pathways. This makes it likely that there may not be a single drug 
likely to counteract all aspects of this inflammation.  
The role of the gut in starting and perpetuating systemic inflammation is gaining 
wide acceptance in the medical community. That this occurs in dogs with acute pancreatitis 
is probable, although not proven. This thesis aimed to establish some guidance regarding 
treatment of this common and complicated condition. Development of a severity index was 
considered essential for this, as comparing treatments between dogs with differing degrees 
of severity would lead to considerable bias. The severity index (as presented in Chapter 4) 
was developed from clinical and laboratory data that could easily be obtained in general 
practice within 24 hours of admission. This severity index then could allow for 
stratification of disease, and recruitment only of severely affected animals into treatment 
trials. The biggest contributor to this severity was fasting for 3 or more days, and 
highlighted the need for studies of nutritional intervention. Further analysis of cases given   225 
plasma or a minimal form of enteral nutrition found no benefit in either of these 
modalities, as presented in Chapter 5. This conclusion is not robust due to the retrospective 
nature and small numbers of the study, but certainly raises some questions as to whether 
plasma, a costly and scarce resource, is truly of benefit in dogs with severe acute 
pancreatitis.  
In Chapter 6, the role of dietary fat in relationship to pancreatic secretion was 
explored. This study was done in healthy dogs, and measured various markers of 
pancreatic adaptation. There was no significant difference in the markers measured to 
various fat contents of the diet. This also brings into question whether feeding of a low-fat 
diet is essential in the management of acute pancreatitis in the dog. To answer the question 
of whether early enteral feeding would be well tolerated, or potentially be detrimental, this 
was assessed in a pilot study, as presented in Chapter 7. This found that oesophageal 
feeding was very well tolerated, and resulted in significantly less vomiting and/or 
regurgitation than total parenteral nutrition. There were not enough dogs in the study to 
determine a difference in mortality or outcome, but dogs fed via an oesophagostomy tube 
appeared to get better sooner, as indicated by reduction in the clinical severity index and 
other markers over 3 days. Whether this was due to a benefit derived from the enteral 
feeding, or a detriment derived from the intravenous feeding could not be determined. It 
was possible to calculate the number of dogs required in larger studies to determine a 
survival benefit between standard intestinal rest and tube feeding.  
In summary, these studies emphasise the difficulty in establishing clinical utility of 
diagnostic tests, when the gold standard (in this case pancreatic histopathology) is flawed, 
and difficult to do in general veterinary practice. Both pancreatic elastase and pancreatic 
lipase appear to have reasonably similar, and good, specificities. Pancreatic elastase has 
only been reviewed in this study, but this has higher sensitivity than pancreatic lipase when   226 
combing all previous reports. Additionally, it would appear that the clinical utility of these 
tests may be less as the pancreas may have microscopic inflammation in a variety of other 
abdominal diseases that require specific intervention.  It has also been established that 
large, multi-centre studies should be performed to determine how much of the potential 
treatment options (as determined in experimental rodent models and people) can be 
extrapolated to dogs. A starting point has now been made, in that a severity index has been 
developed and early feeding has been shown to be well tolerated. The author plans to 
initiate international, multi-centre randomised prospective trials evaluating multiple 
aspects of the management of this condition.  
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Appendix 
Clinical Utility of SNAP cPL™ in Dogs with Acute Abdominal Disease   
A version of this chapter has been submitted to Journal of Veterinary Emergency and 
Critical Care; authors M Haworth, G Hosgood and C Mansfield. The author of this thesis 
designed the study, participated in data collection and analysis, and contributed equally to 
the writing. This has been included as an appendix in this thesis in order to demonstrate 
the difficult translation from sensitivity of diagnostic testing to clinical utility, something 
not fully appreciated in the current published literature. It is not to be considered as part 
of the thesis.  
 
Introduction 
Acute pancreatitis is an important disease of dogs and the clinical signs are variable 
and non-specific, including abdominal pain, vomiting and diarrhoea (Williams and Steiner 
2005). These signs are indistinguishable from other diseases such as septic peritonitis or 
intestinal obstruction, which may require specific and timely treatment such as surgical 
intervention.  The list of potential aetiologies that can cause pancreatitis in dogs includes 
nutritional excesses, hyperlipoproteinaemia, drugs, toxins, hypercalcaemia, duct 
obstruction, duodenal/biliary reflux, pancreatic trauma, ischaemia/reperfusion and others 
(Charles, 2007; Williams, 1996). The pancreas may also be involved in other abdominal 
disease, particularly septic peritonitis, where the pancreatic inflammation is secondary to 
the primary problem. Therefore, sensitivities established for diagnostic tests based on 
histology alone may not be clinically reproducible.  
Accurate  ante-mortem  diagnosis  of  pancreatitis  is  challenging.  Histological 
examination of pancreatic tissue is considered the gold standard for diagnosis (Charles, 
2007; Watson et al., 2007). However, pancreatic biopsies are seldom obtained in critically 
ill dogs, and inflammation may be unevenly distributed throughout the pancreas (Newman 
et al., 2004). Multiple histological scoring systems have been developed, but it is unclear 
what relationship the histological activity has to clinical severity or presentation (Newman   259 
et  al.,  2006;  Watson  et  al.,  2007).    Abdominal  radiography  is  an  important  part  of 
investigation of acute abdominal disease, but the signs of pancreatitis are non-specific, and 
the modality is poorly sensitive (Hess et al., 1998; Schaer 1979). Abdominal ultrasound is 
used extensively in veterinary practice, with the primary lesion being peri-pancreatic fat 
necrosis seen in the acute necrotizing form (Hecht and Henry, 2007). Reported sensitivities 
for ultrasound are about 66-68%, but this is substantially greater in more severely affected 
dogs  (Hess  et  al.,  1998;  Mansfield  and  Jones,  2000;  Steiner  et  al.,  2008a).  Therefore, 
history,  clinical  signs,  laboratory  testing,  and  abdominal  imaging  are  used  to  make  a 
presumptive  diagnosis.  In  an  emergency  situation,  rapid  and  timely  diagnosis  is 
imperative.  
  An  ELISA  for  the  measurement  of  serum  canine  pancreatic  lipase 
immunoreactivity (cPLI) was developed in 2002; with cPLI shown to be located solely in 
the pancreas (Steiner et al., 2002; Steiner et al., 2003). It was subsequently adapted to a 
commercial  kit  (spec-cPL
®;  canine  pancreas-specific  lipase)  with  good  reproducibility 
(Huth et al., 2010). Sensitivity for cPLI and spec-cPL
® ranges from 21-88%, as reported in 
a total of 96 dogs in 3 studies (Steiner et al., 2001; Steiner et al., 2008a; Trivedi et al., 
2011). The sensitivity increases with increasing severity of pancreatic inflammation. The 
specificity for spec-cPL
® was reported to be high (86-95%) in two studies that assessed 
dogs at post-mortem (Neilson-Carley et al., 2011; Trivedi et al., 2011). The first mentioned 
of these studies assessed a substantial proportion of dogs that were young and healthy, and 
neither study evaluated the primary disease diagnosis. The specificity for dogs presenting 
with similar signs to pancreatitis is unknown.  
The quantitative SNAP
® cPL™ test has been has been developed as a cage-side 
semi-quantitative test utilizing the same ELISA technology as the spec cPL
® (Beall et al., 
2011).  A  negative  result  correlates  to  a  spec-cPL
®  concentration  <  200  µg/L;  an   260 
indeterminate result with  concentrations between 200-399 µg/L, and a positive result with 
concentration ≥ 400 µg/L, which is considered consistent with pancreatitis. The SNAP
® 
cPL™ test is reproducible and has good agreement with spec-cPL
® in validation studies 
(Beall et al., 2011).  
The primary objective of this study was to determine agreement of SNAP
® cPL™ 
and a diagnosis of primary pancreatitis in dogs presenting with acute abdominal disease, in 
order to determine the clinical utility in an emergency setting. A secondary objective of 
this study was to quantify the agreement between the spec-cPL
® and the SNAP
® cPL™ for 
paired serum samples taken from the same cohort of dogs.   
Materials and Methods 
 
Animal Selection and Investigations 
 
Client-owned dogs presenting to a first-opinion and referral emergency centre at a 
university teaching hospital between March 2009 and April 2010 were recruited.  Dogs 
were initially included if they had two or more of the following clinical signs: acute (< 2 
days) onset of abdominal pain, vomiting, abdominal distension or diarrhoea.  
Blood was collected via jugular, cephalic or saphenous venipuncture from dogs 
within 24 hours of admission.  If blood was collected specifically for the purposes of the 
study, signed owner consent was obtained.  The study was approved by the institutional 
Animal Ethics Committee, fulfilling NHMRC regulations. 
Diagnostics included a history, physical exam, haematology, serum biochemistry, 
and abdominal ultrasound by a specialist radiologist and other procedures as indicated for 
each individual dog to reach a definitive diagnosis. Dogs were diagnosed with pancreatitis 
if  they  had  ultrasonographical  or  histopathological  confirmation  of  pancreatic 
inflammation and/or necrosis with no other identifiable disease. Dogs that died had full 
post-mortem examination whenever possible, and the dogs surviving to discharge in this   261 
group  had  no  recurrence  of  clinical  signs  6  months  or  greater  on  follow  up,  making 
exocrine pancreatic neoplasia unlikely.  Supportive ultrasonographical evidence of acute 
pancreatitis  was  defined  as  enlarged,  hypoechoic  pancreatic  tissue  surrounded  by 
hyperechoic  peripancreatic  mesentery  or  fat.  These  dogs  may  have  also  displayed 
peritoneal effusion, extra-hepatic biliary obstruction, and thickening of the duodenal wall. 
Dogs  with  primary disease other than  acute pancreatitis  had definitive diagnosis  made 
either by histological examination or gross findings at surgical exploration.  
Laboratory testing 
 
The storage of the SNAP
® cPL™ kits, sample handling and testing procedure was 
as per the manufacturer’s instructions.  Two milliliters of patient blood was collected into 
plain  serum  tubes,  centrifuged  for  10  minutes,  and  allowed  to  equilibrate  to  room 
temperature for serum collection.  Testing using SNAP
® cPL™ was either performed at the 
time of collection and the remaining serum frozen at -20°C, or the serum sample was kept 
refrigerated for less than one week and then allowed to equilibrate to room temperature 
before being tested and then frozen.  All staff performing the test recorded a result of 1 
(test spot lighter than control) or 2 (test spot equal or darker than control) and were blinded 
to the actual meaning of this result.  A later batch analysis of spec-cPL
® concentration was 
performed on the frozen serum which had been stored up to 18 months. 
Data Analysis 
 
For analysis, dogs were allocated to one of two groups: 
  Group 1:  Dogs  with  confirmed pancreatitis  as  their primary disease (criteria as 
above)  
  Group 2: Dogs with confirmed disease other than acute pancreatitis as the primary 
cause of their clinical presentation. Microscopic pancreatic inflammation was only   262 
ruled  out  when  histological  examination  of  the  pancreas  was  obtained  at 
exploratory laparotomy or post mortem examination. If pancreatic neoplasia was 
present with no histological evidence of inflammatory infiltrates, it was included in 
this group. 
SNAP
® cPL™ was recorded as positive or negative.  A positive result was considered to 
have spec-cPL
® ≥ 200 µg/L, and a negative was considered < 200 µg/L. The reliable limits 
of detection of spec cPL
® are ≥ 36 µg/L and ≤ 954 µg/L (Huth et al., 2010). Concentrations 
≤ 30 µg/L were recorded as 30 µg/L. Concentrations ≥ 1000 µg/L were recorded as 1000 
µg/L.  The  agreement  between  positive  /  negative  SNAP
®  cPL™  tests  and  spec-cPL
®  
concentrations  of  greater  than  /  less  than  200  µg/L  respectively,  for  all  paired  serum 
samples,
  was made using McNemar’s test and quantified by the kappa (κ) coefficient 
PROC  FREQ  (SAS  v9.1,  SAS  Institute,  Cary,  NC)  .  The  kappa  (κ)  coefficient  range 
between  0  and  1  represents  no  agreement  other  than  chance  and  perfect  agreement 
respectively. Data were then categorized for dogs according to the diagnosis as above.  
Results 
Samples were collected from 64 client-owned dogs but 26 dogs were excluded as 
no definitive diagnosis could be made. The remaining 38 dogs ranged in age from 17 
weeks to 14.7 years (median 9.9 years, mean 9.4 years). There were 15 neutered females, 4 
entire females, 15 neutered males and 4 entire males.  Breeds included Labrador retriever 
(n=4), Siberian husky (n=3), Border collie (n=3), Jack Russell terrier (n=2), German 
shepherd (n=2), Rottweiler (n=2) and Australian cattle dog (n=2). The remaining 20 dogs 
were represented by a single or mixed-breeds.  
Spec-cPL
® was measured in 36 of the 38 dogs.  One dog diagnosed with 
pancreatitis and one without pancreatitis had insufficient serum available and so were not 
included in the agreement assessment. The spec-cPL
® concentrations was ≥ 200 µg/L in   263 
14/36 dogs and < 200 µg/L in 22/36 dogs.  SNAP
® cPL™ was performed in all 38 dogs. 
Overall, SNAP
® cPL™ was positive in 20 dogs and negative in 18 dogs. The agreement 
between a positive/negative SNAP
® cPL™ test and a spec-cPL
® concentration of ≥/ < 200 
µg/L, respectively, for all 36 dogs resulted in κ = 0.78 (95% CI 0.58-0.98).   
Eleven dogs were diagnosed with pancreatitis as their primary disease (Group 1), 
all by ultrasound with 1 also confirmed by histopathology performed after euthanasia. 
SNAP
® cPL™ was positive in 9 of these dogs and negative in 2.  All positive (9/9) SNAP
® 
cPL™ tests had spec-cPL
® concentrations ≥ 200 µg/L (range 320 to ≥ 1000 µg/L; median 
800 µg/L; mean 748 µg/L).  Both dogs from this group with negative SNAP
® cPL™ tests 
had spec-cPL
® concentrations ≤ 30 µg/L.  The agreement for a positive/negative SNAP
® 
cPL™ with spec-cPL
® concentrations in dogs with primary pancreatitis resulted in κ =1.0 
(or perfect agreement). 
Primary disease other than pancreatitis was diagnosed in 27 dogs (Group 2). 
Histology of the pancreas was performed in 5 of these cases that confirmed no evidence of 
pancreatic inflammation or necrosis.  The diagnoses included anaplastic, large, T-cell 
lymphoma of the liver (n=1); small intestinal infarction (n=1); erosive enterocolitis and 
pancreatic islet cell carcinoma (n=1); pancreatic islet cell carcinoma with hepatic 
metastasis (n=1); multicentric poorly differentiated carcinoma involving pancreas, liver, 
proximal duodenum, abdominal lymph nodes and lung (n=1). The other 22 dogs that did 
not have pancreatic histology may have had microscopic bystander pancreatic 
inflammation, but if present would have been considered inconsequential to the primary 
diagnosis. These diseases included small intestinal foreign bodies (n=7), haemoperitoneum 
due to splenic and/or concurrent hepatic masses (n= 3), pyometron (n=2), hepatic 
abscesses (n=2), emphysematous cholecystitis (n=2), a large abdominal mass that was 
unable to be associated with a definite organ by ultrasound with concurrent septic   264 
peritonitis (n=1), hepatic neoplasia of unidentified origin (n=1), septic peritonitis due to a 
ruptured jejunal mass (n=1), prostatic abscessation (n=1), pericardial effusion (n=1), and 
hepatic lymphoma (n=1). 
Eleven of these 27 dogs from group 2 had positive SNAP
® cPL™ whilst 16 were 
negative. This results in a misleading diagnosis from this test in 41% of this group. Of the 
10 dogs with a positive SNAP
® cPL™ that also had serum available, spec-cPL
® measured 
from < 30 to ≥ 1000 µg/L with a median of 477 µg/L and mean of 415 µg/L.  Therefore, 6 
dogs had spec-cPL
® consistent with pancreatitis (≥ 400 µg/L) and 4 had normal spec-cPL
® 
(< 200 µg/L).  The remaining 16 dogs with negative SNAP
® cPL™ had spec-cPL
® 
concentrations from < 30 to 121 µg/L (median: <30 ug/L; mean: 51 µg/L). 
The κ for agreement between a positive or negative SNAP
® cPL™ and a spec-cPL
® 
concentration
 of ≥ or < than 200 µg/L, respectively, for dogs in group 2 was 0.65 (95% CI: 
0.35-0.94).  The κ for agreement between a positive or negative SNAP
® cPL™ and a spec-
cPL
® concentration
 of ≥ or < 200 µg/L respectively for all dogs overall was 0.78 (95% CI: 
0.59-0.98).  When considering all dogs, the agreement of SNAP
® cPL™ with a diagnosis 
of primary pancreatitis resulted in a κ of 0.33 (95% CI 0.06-0.61). If dogs in group 1 
testing negative on SNAP
® cPL™ were moved to group 2 for analysis, agreement for 
diagnosis pancreatitis resulted in a κ of 0.44 (95% CI 0.20-0.67). 
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Table 1 
SNAP
® cPL™ 
positive  
SNAP® cPL™ 
negative  
Insufficient 
sample 
<30 
320  < 30 
504   
582   
612   
969   
≥ 1000   
≥ 1000   
≥ 1000   
Dogs presenting for acute abdomen with a diagnosis of primary pancreatitis grouped by 
SNAP
® cPL™ result with Spec-cPL
® results (µg/L); n = 11.   266 
 
 
Table 2  
SNAP
® cPL™ positive  SNAP
® cPL™ negative 
Diagnosis  Spec-cPL
® result (µg/L)  Diagnosis  Spec-cPL
® result (µg/L) 
SI foreign body  Insufficient sample  SI foreign body   < 30 
SI foreign body  < 30  SI foreign body  < 30 
Pyometron and sepsis  < 30  SI foreign body  < 30 
Hepatic T-cell lymphoma  68  Multicentric carcinoma   < 30 
SI foreign body and septic peritonitis  105  Pyometron  < 30 
Hepatic mass  404  Haemabdomen / splenic mass  < 30 
Haemabdomen / septic peritonitis  550  Haemabdomen / splenic mass  < 30 
Small intestinal infarction  568  Hepatic lymphoma  < 30 
Hepatic masses with septic peritonitis  672  Emphysematous cholecystitis  < 30 
Haemabdomen  with  splenic  and 
hepatic masses 
720  Emphysematous cholecystitis  < 30 
Hepatic abscess  ≥ 1000  Pericardial effusion  < 30 
    SI foreign body  78 
    Ulcerative enterocolitis  83 
    Prostatic abscess  86 
    Jejunal mass / septic peritonitis  121 
    Pancreatic and hepatic carcinoma 
with haemabdomen  
121 
Dogs presenting for acute abdomen where pancreatitis was not the primary cause grouped by SNAP® cPL™ result. Those in bold 
had pancreatic histology performed, and there was a confirmed absence of pancreatic inflammation. SI, Small Intestine  
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Discussion 
The  agreement  between  a  positive  or  negative  SNAP
®  cPL™  and  spec-cPL
® 
concentration ≥ or < than 200 µg/L respectively is good. This is not unexpected as the two 
tests are designed to measure pancreatic lipase and are based on the same technique, with 
previous studies showing good reproducibility (Beall et al., 2011).  Our results showed that 
if the SNAP
® cPL™ test was negative, spec-cPL
® concentration was correspondingly below 
the 200 µg/L cut-off value.  However, when the SNAP
® cPL™ test was positive, spec-cPL
® 
concentrations  were variable, with  results  at  both  the extremes of the detection limits. 
Further, the primary reason for presentation of many of these cases was not pancreatitis. 
SNAP
® cPL™ appears to perform well in dogs with primary pancreatitis. Previous 
studies assessing spec-cPL
® have shown a sensitivity of between 21-71% based on gross or 
histological evidence of pancreatitis (Steiner et al., 2008a; Trivedi et al., 2011).
 However, 
despite this initially good performance this study suggests that SNAP
® cPL™ should not be 
used as a single diagnostic test for primary pancreatitis. Failure to look beyond a positive 
result would have resulted in an erroneous and potentially fatal test result in approximately 
29% of dogs presenting with acute abdominal disease in this study.  
There  are  several  causes  for  the  positive  results  in  dogs  with  acute  abdominal 
disease other than pancreatitis.  It  is  unlikely that  other iso-forms  of lipase were being 
measured, as spec-cPL
® has been shown to detect only pancreatic lipase in dogs, and is not 
increased in dogs with exocrine pancreatic insufficiency (Steiner et al., 2002; Steiner et al., 
2006). Bystander pancreatic inflammation from local extension of peritoneal inflammation 
is another possible explanation.  Additionally, any condition that causes hypoperfusion of 
the  pancreas,  ischemia/reperfusion  of  the  splanchnic  circulation  may  also  cause 
pancreatitis, as the pancreas is exquisitely sensitive to disturbances of microcirculation 
(Charles, 2007; Cuthbertson and Christophi, 2006; Williams and Steiner 2005). There were  
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no dogs in this cohort that had suffered blunt force trauma, although this could also be a 
potential cause of pancreatitis in addition to other soft tissue trauma or injuries.   
Marked increases in total serum lipase activity have been reported in dogs with 
duodenal  foreign  bodies,  dogs  with  acute  gastroenteritis  and  dogs  with  renal  failure 
(Mansfield and Jones, 2000; Rallis et al., 1996; Strombeck et al., 1981). This phenomenon 
may be due to poor renal excretion of lipase, production of lipase by organs other than the 
pancreas or due to duodenal reflux causing pancreatitis. It is unknown whether these same 
possibilities apply to pancreatic-specific lipase. One study has shown that  spec-cPL
® is 
not increased in experimentally induced renal failure, but this has not verified in animals 
where there may be an acute decline in glomerular filtration, and there were no dogs in this 
cohort  with  substantial  azotaemia  or  anuria  (Steiner  et  al.,  2010).    Specificity  of 
pancreatitis has been reported to be high, but it cannot be determined from those studies if 
any dogs had septic peritonitis or intestinal foreign bodies (Neilson-Carley et al., 2011; 
Trivedi et al., 2011). As those studies were based on post-mortem analysis from referral 
centers, it is quite likely that dogs with intestinal foreign bodies weren’t assessed in them, 
as they would likely have been diagnosed and treated successfully.  
Four  dogs  in  this  study  had  positive  SNAP
®  cPL™  results  but  spec-cPL
® 
concentrations well below the lower cut-off value of 200 µg/L.   Instability of spec-cPL
® in 
serum is unlikely to be the cause of this anomaly, as spec-cPL
® has been shown to be 
stable  for  at  least  21  days  whether  frozen  at  –  20°C,  refrigerated,  or  stored  at  room 
temperature (Steiner et al., 2009). All samples from this study were either immediately 
frozen  or  refrigerated  for  less  than  a  week  and  then  frozen,  and  assayed  within 
manufacturer recommended limits of storage.  Haemolysis, icterus and lipaemia have been 
demonstrated to not interfere with the visual interpretation of SNAP
® cPL™, so is unlikely 
to be a factor (Beall et al., 2011). Operator error is unlikely to have been the cause of the  
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discrepant results in those 4, as all personnel had received training on how to perform the 
test.  It is possible a yet to be identified factor may have interfered with the test accuracy.    
One  limitation  of  this  study  is  the  use  of  ultrasound  alone  to  diagnose  acute 
pancreatitis.  The diagnosis of acute pancreatitis by ultrasound has been reported to have a 
sensitivity  ranging  from  66  to  68%,  although  these  cases  were  not  limited  to  acute 
presentations (Hess et al., 1998; Mansfield and Jones, 2000; Steiner et al., 2008a).  As 
well, diagnostic sensitivity is likely to be much higher now than the earlier studies due to 
improved equipment and operator expertise. In the more recent study, it is unclear whether 
there was other disease such as septic peritonitis, as only the pancreatic histology was 
reported (Steiner et al., 2008a). Regardless of the sensitivity of ultrasound, which will be 
extremely difficult to establish, the specificity of for diagnosis of acute pancreatitis and 
peri-pancreatic fat necrosis is well accepted (Hecht and Henry, 2007).   
 All dogs classified into group 1 were treated appropriately for pancreatitis, and had 
no recurrence of clinical signs within 6 months of discharge for all survivors, making 
concurrent pancreatic neoplasia unlikely. Of the 3 dogs that were euthanatized, 1 had a 
post-mortem performed that confirmed pancreatitis.  If any of the dogs in group 1 had 
another  clinically  relevant  disease  as  the  cause  for  presentation  that  was  not  primary 
pancreatitis, then dogs testing positive on SNAP
® cPL™ moving to group 2 would further 
deteriorate the overall agreement for pancreatitis.  It was also demonstrated that if dogs 
testing negative were moved from Group 1 to Group 2, the best κ was 0.44, which still 
represents poor agreement between SNAP
® cPL™ and a diagnosis of pancreatitis in the best 
case scenario.  
A further limitation of this study was the small number of dogs analysed.  Many 
dogs were excluded due to an absence of a final definitive diagnosis.  Therefore, bias 
towards severe disease may have arisen in this study, as dogs with milder presentation may  
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not  have  received  full  investigation.    Agreement  of  the  SNAP®  cPL™  in  determining 
primary pancreatitis may have been enhanced if these cases were included, but it is just as 
likely  that  as  many  dogs  with  mild  pancreatitis  as  those  with  non-pancreatic 
gastrointestinal disease did not reach a final diagnosis.  Despite this potential limitation, 
this study reflects the general population of cases in an emergency veterinary facility that is 
both general access and referral in nature. Additionally, dogs that present with the level of 
severity presented here are the very population of dogs in which the SNAP
® cPL™ test is 
likely to be used, and where rapid diagnostic accuracy is desired. 
It  has  been  suggested  that  the  highest  diagnostic  sensitivity  for  diagnosing 
pancreatitis may be the combination of spec-cPL
® or serum canine pancreatic-elastase-1 
and  abdominal  ultrasonography  by  an  experienced  operator  (Mansfield  et  al.,  2011b; 
Steiner  et  al,  2008a).  Certainly  this  study  also  supports  additional  testing  such  as 
abdominal imaging, along with stringent assessment of clinical and historical findings. The 
manufacturer  also  recommends  performing  a  quantitative  spec-cPL
®  assay  following 
SNAP
® cPL™.  Our study shows there is a good concordance between SNAP
® cPL™ and 
spec-cPL
®  concentration,  making  this  less  clinically  necessary  at  initial  presentation.  
Furthermore, measurement of spec-cPL
® and serum canine pancreatic-elastase-1 incurs a 
delay  in  results  and  many  dogs  with  acute  abdominal  disease  will  require  immediate 
surgical  intervention. There is  no data to  show that monitoring of pancreatic enzymes 
correlates to clinical improvement, or should be used to select treatment regimens.  
 
Conclusion  
This study indicates good agreement between SNAP
® cPL™ and spec-cPL
® concentration.  
SNAP
® cPL™ performs poorly for discriminating pancreatitis from other primary causes 
of acute abdominal disease in dogs.  Many of the dogs testing positive to SNAP
® cPL™  
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without primary pancreatitis required timely surgical intervention to maximize the chances 
of a positive outcome.  This is concerning as a possible temptation exists for clinicians to 
rely on the relatively inexpensive cage-side SNAP
® cPL™ when access to ultrasonography 
is  limited  or  financially  prohibitive  for  clients,  leading  to  a  false  sense  of  diagnostic 
security.  A positive SNAP
® cPL™ may indicate pancreatic inflammation is present, but 
cannot discriminate why it is present. Additional diagnostics, such as abdominal ultrasound 
or abdominal radiography are indicated to rule out these diseases. 